<SEC-DOCUMENT>0001178913-23-000334.txt : 20230131
<SEC-HEADER>0001178913-23-000334.hdr.sgml : 20230131
<ACCEPTANCE-DATETIME>20230131165029
ACCESSION NUMBER:		0001178913-23-000334
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20230131
DATE AS OF CHANGE:		20230131

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			COMPUGEN LTD
		CENTRAL INDEX KEY:			0001119774
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-240183
		FILM NUMBER:		23573158

	BUSINESS ADDRESS:	
		STREET 1:		26 HAROKMIM STREET
		STREET 2:		BUILDING D
		CITY:			HOLON
		STATE:			L3
		ZIP:			5885849
		BUSINESS PHONE:		011-972-3-765-8585

	MAIL ADDRESS:	
		STREET 1:		26 HAROKMIM STREET
		STREET 2:		BUILDING D
		CITY:			HOLON
		STATE:			L3
		ZIP:			5885849
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>zk2329099.htm
<DESCRIPTION>424B5
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Z-K GLOBAL
         Document created using Broadridge PROfile 22.12.1.5105
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div style="text-align: right; line-height: 1.25; font-weight: bold;">Filed Pursuant to Rule 424(b)(5)</div>
      <div style="text-align: right; line-height: 1.25; font-weight: bold;">Registration Statement No. 333-240183</div>
      <div style="line-height: 1.25; font-weight: bold;">PROSPECTUS SUPPLEMENT<br>
        (to Prospectus dated August 7, 2020)</div>
      <div style="text-align: center; line-height: 1.25;"><img width="267" height="85" src="image00001.jpg"></div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Up to $50,000,000</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Ordinary Shares</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">We have entered into a sales agreement (the &#8220;sales agreement&#8221;) with SVB Securities LLC (&#8220;SVB Securities&#8221;) dated January 31, 2023, relating to the sale of our ordinary shares, par value New Israeli
        Shekel (&#8220;NIS&#8221;) 0.01 per share (the &#8220;ordinary shares&#8221;). In accordance with the terms of the sales agreement, pursuant to this prospectus supplement, we may offer and sell our ordinary shares having an aggregate offering price of up to $50,000,000
        from time to time through SVB Securities, acting as our sales agent.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Our ordinary shares are traded on The Nasdaq Global Market and the Tel Aviv Stock Exchange (the &#8220;TASE&#8221;), under the symbol &#8220;CGEN.&#8221; The last reported sale price for our ordinary shares on The Nasdaq
        Global Market and on the TASE on January 30, 2023, was $0.8578 and NIS 2.96 per share ($0.8535 at a current exchange rate of NIS 1 to $3.468, in accordance with the NIS-$ exchange rate published by the Bank of Israel on January 30, 2023),
        respectively. The currency in which our shares are traded on the TASE is the NIS.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Sales of our ordinary shares, if any, under this prospectus supplement may be made by any method permitted that is deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) promulgated
        under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). SVB Securities is not required to sell any specific number or dollar amount of ordinary shares, but will act as our sales agent using commercially reasonable efforts consistent
        with its normal trading and sales practices on mutually agreed terms between SVB Securities and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">SVB Securities will be entitled to compensation under the terms of the sales agreement at a commission rate equal to 3.0% of the aggregate gross proceeds of any ordinary shares sold under the sales
        agreement. In connection with the sale of our ordinary shares on our behalf, SVB Securities will be deemed to be an &#8220;underwriter&#8221; within the meaning of the Securities Act and the compensation of SVB Securities will be deemed to be underwriting
        commissions or discounts. See &#8220;Plan of Distribution&#8221; beginning on page S-19 for additional information regarding the compensation to be paid to SVB Securities. We have also agreed to provide indemnification and contribution to SVB Securities
        against certain liabilities, including liabilities under the Securities Act and the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Investing in our ordinary shares involves a high degree of risk. Please read &#8220;Risk Factors&#8221; beginning on page S-5 of this prospectus supplement, on page 2 of the accompanying
        prospectus and in the documents incorporated by reference into this prospectus supplement.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">None of the Securities and Exchange Commission, the Israel Securities Authority or any state or other securities commission has approved or disapproved of these securities or
        passed on the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense under the laws of the United States and the laws of the State of Israel.</div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">SVB Securities</div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">The date of this prospectus supplement is January 31, 2023.</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">TABLE OF CONTENTS</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
      </div>
      <table cellspacing="0" cellpadding="2" border="0" id="zd656262b22604b1187f02f6ea8e75e63" style="font-family: 'Times New Roman',Times,serif; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0);">

          <tr>
            <td style="width: 94%; vertical-align: top;">&#160;</td>
            <td style="width: 6%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 94%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">PROSPECTUS SUPPLEMENT</div>
            </td>
            <td style="width: 6%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Page</div>
            </td>
          </tr>
          <tr>
            <td style="width: 94%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;"><a href="#AboutthisProspectusSupple1">About This Prospectus Supplement</a></div>
            </td>
            <td style="width: 6%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">S-i</div>
            </td>
          </tr>
          <tr>
            <td style="width: 94%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;"><a href="#CAUTIONARYNOTEREGARDINGFO1">Cautionary Note Regarding Forward-Looking Statements</a></div>
            </td>
            <td style="width: 6%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">S-ii</div>
            </td>
          </tr>
          <tr>
            <td style="width: 94%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;"><a href="#PROSPECTUSSUPPLEMENTSUMMA1">Prospectus Supplement Summary</a></div>
            </td>
            <td style="width: 6%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">S-1</div>
            </td>
          </tr>
          <tr>
            <td style="width: 94%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;"><a href="#RISKFACTORS1">Risk Factors</a></div>
            </td>
            <td style="width: 6%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">S-5</div>
            </td>
          </tr>
          <tr>
            <td style="width: 94%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;"><a href="#USEOFPROCEEDS1">Use of Proceeds</a></div>
            </td>
            <td style="width: 6%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">S-10</div>
            </td>
          </tr>
          <tr>
            <td style="width: 94%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;"><a href="#MATERIAL1">Material Tax Considerations</a></div>
            </td>
            <td style="width: 6%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">S-11</div>
            </td>
          </tr>
          <tr>
            <td style="width: 94%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;"><a href="#PLANOFDISTRIBUTION1">Plan of Distribution</a></div>
            </td>
            <td style="width: 6%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">S-19</div>
            </td>
          </tr>
          <tr>
            <td style="width: 94%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;"><a href="#LEGALMATTERS1">Legal Matters</a></div>
            </td>
            <td style="width: 6%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">S-20</div>
            </td>
          </tr>
          <tr>
            <td style="width: 94%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;"><a href="#EXPERTS1">Experts</a></div>
            </td>
            <td style="width: 6%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">
                <div style="line-height: 1.25;">S-20</div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 94%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;"><a href="#EXPENSES1">Expenses</a></div>
            </td>
            <td style="width: 6%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">
                <div style="line-height: 1.25;">S-20</div>
              </div>
            </td>
          </tr>
          <tr>
            <td style="width: 94%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;"><a href="#WHERE1">Where You Can Find More Information</a></div>
            </td>
            <td style="width: 6%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">S-21</div>
            </td>
          </tr>
          <tr>
            <td style="width: 94%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif;"><a href="#INCORPORATION1">Incorporation of Certain Documents by Reference</a></div>
            </td>
            <td style="width: 6%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif;">S-22</div>
            </td>
          </tr>
          <tr>
            <td style="width: 94%; vertical-align: top;">
              <div style="line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">PROSPECTUS</div>
            </td>
            <td style="width: 6%; vertical-align: top;">
              <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman', Times, serif; font-weight: bold;">Page</div>
            </td>
          </tr>

      </table>
      <div>
        <table cellspacing="0" cellpadding="2" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 93.99%; vertical-align: top; background-color: #FFFFFF;">
                <div style="line-height: 1.25;"><a href="#ABOUTTHISPROSPECTUS">ABOUT THIS PROSPECTUS</a></div>
              </td>
              <td style="width: 6.01%; vertical-align: top; background-color: #FFFFFF;">
                <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; text-align: center;">i</div>
              </td>
            </tr>
            <tr>
              <td style="width: 93.99%; vertical-align: top; background-color: #FFFFFF;">
                <div style="line-height: 1.25;"><a href="#PROSPECTUSSUMMARY">PROSPECTUS SUMMARY</a></div>
              </td>
              <td style="width: 6.01%; vertical-align: top; background-color: #FFFFFF;">
                <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; text-align: center;">1</div>
              </td>
            </tr>
            <tr>
              <td style="width: 93.99%; vertical-align: top; background-color: #FFFFFF;">
                <div style="line-height: 1.25;"><a href="#RISKFACTORS">RISK FACTORS</a></div>
              </td>
              <td style="width: 6.01%; vertical-align: top; background-color: #FFFFFF;">
                <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; text-align: center;">2</div>
              </td>
            </tr>
            <tr>
              <td style="width: 93.99%; vertical-align: top; background-color: #FFFFFF;">
                <div style="line-height: 1.25;"><a href="#NOTEREGARDINGFORWARD-LOOK">NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></div>
              </td>
              <td style="width: 6.01%; vertical-align: top; background-color: #FFFFFF;">
                <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; text-align: center;">3</div>
              </td>
            </tr>
            <tr>
              <td style="width: 93.99%; vertical-align: top; background-color: #FFFFFF;">
                <div style="line-height: 1.25;"><a href="#OFFERSTATISTICSANDEXPECTE">OFFER STATISTICS AND EXPECTED TIMETABLE</a></div>
              </td>
              <td style="width: 6.01%; vertical-align: top; background-color: #FFFFFF;">
                <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; text-align: center;">4</div>
              </td>
            </tr>
            <tr>
              <td style="width: 93.99%; vertical-align: top; background-color: #FFFFFF;">
                <div style="line-height: 1.25;"><a href="#CAPITALIZATION">CAPITALIZATION</a></div>
              </td>
              <td style="width: 6.01%; vertical-align: top; background-color: #FFFFFF;">
                <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; text-align: center;">5</div>
              </td>
            </tr>
            <tr>
              <td style="width: 93.99%; vertical-align: top; background-color: #FFFFFF;">
                <div style="line-height: 1.25;"><a href="#REASONSFORTHEOFFERANDUSEO">REASONS FOR THE OFFER AND USE OF PROCEEDS</a></div>
              </td>
              <td style="width: 6.01%; vertical-align: top; background-color: #FFFFFF;">
                <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; text-align: center;">6</div>
              </td>
            </tr>
            <tr>
              <td style="width: 93.99%; vertical-align: top; background-color: #FFFFFF;">
                <div style="line-height: 1.25;"><a href="#DESCRIPTIONOFSECURITIES">DESCRIPTION OF SECURITIES</a></div>
              </td>
              <td style="width: 6.01%; vertical-align: top; background-color: #FFFFFF;">
                <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; text-align: center;">7</div>
              </td>
            </tr>
            <tr>
              <td style="width: 93.99%; vertical-align: top; background-color: #FFFFFF;">
                <div style="line-height: 1.25;"><a href="#DESCRIPTIONOFORDINARYSHAR">DESCRIPTION OF ORDINARY SHARES</a></div>
              </td>
              <td style="width: 6.01%; vertical-align: top; background-color: #FFFFFF;">
                <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; text-align: center;">8</div>
              </td>
            </tr>
            <tr>
              <td style="width: 93.99%; vertical-align: top; background-color: #FFFFFF;">
                <div style="line-height: 1.25;"><a href="#DESCRIPTIONOFDEBTSECURITI">DESCRIPTION OF DEBT SECURITIES</a></div>
              </td>
              <td style="width: 6.01%; vertical-align: top; background-color: #FFFFFF;">
                <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; text-align: center;">14</div>
              </td>
            </tr>
            <tr>
              <td style="width: 93.99%; vertical-align: top; background-color: #FFFFFF;">
                <div style="line-height: 1.25;"><a href="#DESCRIPTIONOFRIGHTS">DESCRIPTION OF RIGHTS</a></div>
              </td>
              <td style="width: 6.01%; vertical-align: top; background-color: #FFFFFF;">
                <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; text-align: center;">19</div>
              </td>
            </tr>
            <tr>
              <td style="width: 93.99%; vertical-align: top; background-color: #FFFFFF;">
                <div style="line-height: 1.25;"><a href="#DESCRIPTIONOFWARRANTS">DESCRIPTION OF WARRANTS</a></div>
              </td>
              <td style="width: 6.01%; vertical-align: top; background-color: #FFFFFF;">
                <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; text-align: center;">20</div>
              </td>
            </tr>
            <tr>
              <td style="width: 93.99%; vertical-align: top; background-color: #FFFFFF;">
                <div style="line-height: 1.25;"><a href="#DESCRIPTIONOFUNITS">DESCRIPTION OF UNITS</a></div>
              </td>
              <td style="width: 6.01%; vertical-align: top; background-color: #FFFFFF;">
                <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; text-align: center;">23</div>
              </td>
            </tr>
            <tr>
              <td style="width: 93.99%; vertical-align: top; background-color: #FFFFFF;">
                <div style="line-height: 1.25;"><a href="#PLANOFDISTRIBUTION">PLAN OF DISTRIBUTION</a></div>
              </td>
              <td style="width: 6.01%; vertical-align: top; background-color: #FFFFFF;">
                <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; text-align: center;">24</div>
              </td>
            </tr>
            <tr>
              <td style="width: 93.99%; vertical-align: top; background-color: #FFFFFF;">
                <div style="line-height: 1.25;"><a href="#LEGALMATTERS">LEGAL MATTERS</a></div>
              </td>
              <td style="width: 6.01%; vertical-align: top; background-color: #FFFFFF;">
                <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; text-align: center;">26</div>
              </td>
            </tr>
            <tr>
              <td style="width: 93.99%; vertical-align: top; background-color: #FFFFFF;">
                <div style="line-height: 1.25;"><a href="#EXPERTS">EXPERTS</a></div>
              </td>
              <td style="width: 6.01%; vertical-align: top; background-color: #FFFFFF;">
                <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; text-align: center;">26</div>
              </td>
            </tr>
            <tr>
              <td style="width: 93.99%; vertical-align: top; background-color: #FFFFFF;">
                <div style="line-height: 1.25;"><a href="#EXPENSES">EXPENSES</a></div>
              </td>
              <td style="width: 6.01%; vertical-align: top; background-color: #FFFFFF;">
                <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; text-align: center;">26</div>
              </td>
            </tr>
            <tr>
              <td style="width: 93.99%; vertical-align: top; background-color: #FFFFFF;">
                <div style="line-height: 1.25;"><a href="#INCORPORATIONOFCERTAININF">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</a></div>
              </td>
              <td style="width: 6.01%; vertical-align: top; background-color: #FFFFFF;">
                <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; text-align: center;">26</div>
              </td>
            </tr>
            <tr>
              <td style="width: 93.99%; vertical-align: top; background-color: #FFFFFF;">
                <div style="line-height: 1.25;"><a href="#WHEREYOUCANFINDADDITIONAL">WHERE YOU CAN FIND ADDITIONAL INFORMATION</a></div>
              </td>
              <td style="width: 6.01%; vertical-align: top; background-color: #FFFFFF;">
                <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; text-align: center;">28</div>
              </td>
            </tr>
            <tr>
              <td style="width: 93.99%; vertical-align: top; background-color: #FFFFFF;">
                <div style="line-height: 1.25;"><a href="#ENFORCEABILITYOFCIVILLIAB">ENFORCEABILITY OF CIVIL LIABILITIES</a></div>
              </td>
              <td style="width: 6.01%; vertical-align: top; background-color: #FFFFFF;">
                <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; text-align: center;">28</div>
              </td>
            </tr>
            <tr>
              <td style="width: 93.99%; vertical-align: top; background-color: #FFFFFF;">
                <div style="line-height: 1.25;"><a href="#INDEMNIFICATIONFORSECURIT">INDEMNIFICATION FOR SECURITIES ACT LIABILITIES</a></div>
              </td>
              <td style="width: 6.01%; vertical-align: top; background-color: #FFFFFF;">
                <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; text-align: center;">29</div>
              </td>
            </tr>

        </table>
      </div>
    </div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <!--PROfilePageNumberReset%LCR%1%S - %%-->
    <div><br>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="AboutthisProspectusSupple1"><!--Anchor--></a>About this Prospectus Supplement</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">On July 30, 2020, we filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) a registration statement on Form F-3 (File No. 333-240183) utilizing a shelf registration process relating to the
        securities described in this prospectus supplement, which registration statement was declared effective on August 7, 2020. Under this shelf registration process, we may, from time to time, sell up to $350,000,000 of our ordinary shares and other
        securities, of which this offering is a part.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">This document is in two parts. The first part is this prospectus supplement, which describes the specific terms of this offering and also adds to and updates information contained in the
        accompanying prospectus and the documents incorporated by reference into this prospectus supplement and the accompanying prospectus. The second part, the accompanying prospectus, gives more general information, some of which may not apply to this
        offering. Generally, when we refer to this prospectus, we are referring to the combined document consisting of this prospectus supplement and the accompanying prospectus.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">In this prospectus supplement, as permitted by law, we &#8220;incorporate by reference&#8221; information from other documents that we file with the SEC. This means that we can disclose important information
        to you by referring to those documents. The information incorporated by reference is considered to be a part of this prospectus supplement and the accompanying prospectus and should be read with the same care. When we make future filings with the
        SEC to update the information contained in documents that have been incorporated by reference, the information included or incorporated by reference in this prospectus supplement is considered to be automatically updated and superseded. If the
        description of the offering varies between this prospectus supplement and the accompanying prospectus, you should rely on the information contained in this prospectus supplement. However, if any statement in this prospectus supplement or the
        accompanying prospectus is inconsistent with a statement in another document having a later date (including a document incorporated by reference in the accompanying prospectus), the statement in the document having the later date modifies or
        supersedes the earlier statement.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">You should rely only on the information contained in or incorporated by reference&#160;in this prospectus supplement, the accompanying prospectus, or any free writing prospectus that we may authorize
        for use in connection with the offering. We have not, and SVB Securities has not, authorized any other person to provide you with information&#160;different from that contained in this prospectus supplement, the accompanying prospectus or any free
        writing prospectus we have authorized for use in connection with this offering. If anyone provides you with different or inconsistent information, you should not rely on it. We and SVB Securities take no responsibility for, and can provide no
        assurance as to the reliability of, any other information that others may give you. We are not, and SVB Securities is not, making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. The distribution of
        this prospectus supplement and the offering of the ordinary shares in certain jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus supplement must inform themselves about, and observe
        any restrictions relating to, the offering of the ordinary shares and the distribution of this prospectus supplement outside the United States. This prospectus supplement does not constitute, and may not be used in connection with, an offer to
        sell, or a solicitation of an offer to buy, any securities offered by this prospectus supplement by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation. You should assume that the information
        appearing in this prospectus supplement is accurate as of the date on the front cover of this prospectus supplement only&#160;and that any information we have incorporated by reference is accurate only as of the date of the document incorporated by
        reference, regardless of the time of delivery of this prospectus, or any sale of our ordinary shares. Our business, financial condition, results of operations and prospects may have changed since that date.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference in the prospectus
        supplement or the accompanying prospectus were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a
        representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately
        representing the current state of our affairs.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Unless the context indicates otherwise, references in this prospectus to &#8220;NIS&#8221; are to the legal currency of Israel, and &#8220;U.S. dollars,&#8221; &#8220;$&#8221; or &#8220;dollars&#8221; are to United States dollars.&#160;References in
        this prospectus supplement to &#8220;Compugen,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Compugen Ltd. and our wholly owned subsidiary Compugen USA, Inc., except where the context otherwise requires or as otherwise indicated.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">S - i</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="CAUTIONARYNOTEREGARDINGFO1"><!--Anchor--></a>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">We have included or incorporated by reference into this prospectus supplement, the accompanying prospectus, the documents incorporated by reference herein, therein and in any free writing
        prospectus that we have authorized for use in connection with this offering, statements that may constitute &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act, Section 21E of the Exchange Act and the safe-harbor
        provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on our current beliefs, expectations and assumptions at the time made. Forward-looking statements can be identified by the use of words
        such as &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;should,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;will,&#8221; &#8220;may,&#8221; &#8220;expect,&#8221; &#8220;estimate,&#8221; &#8220;project,&#8221; &#8220;positioned,&#8221; &#8220;strategy,&#8221; and similar expressions that are intended to identify forward-looking statements, although not all
        forward-looking statements contain these identifying words. These forward-looking statements involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future
        results, performance or achievements expressed or implied by such forward-looking statements. Our actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including
        those discussed in this prospectus supplement, the accompanying prospectus, the documents incorporated by reference herein, therein and in any free writing prospectus that we have authorized for use in connection with this offering. While we
        believe that we have a reasonable basis for each forward-looking statement contained in this prospectus supplement, the accompanying prospectus, the documents incorporated by reference herein and in any free writing prospectus that we have
        authorized for use in connection with this offering, we caution you that these statements are based on a combination of facts and factors known by us at the time they are made and our projections of the future, about which we cannot be certain.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">In addition, you should refer to the information contained under the heading &#8220;Risk Factors&#8221; in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference
        herein and therein for a discussion of other important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of these and other factors, we cannot assure you
        that the forward-looking statements in this prospectus supplement, the accompanying prospectus, the documents incorporated by reference herein, therein or in any free writing prospectus that we have authorized for use in connection with this
        offering will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these
        statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. You should not place undue reliance on these forward-looking statements, which apply only as
        of the date they are made. You should read this prospectus supplement, the accompanying prospectus, the documents incorporated by reference herein, therein or and in any free writing prospectus that we have authorized for use in connection with
        this offering completely and with the understanding that our actual future results may be materially different from what we expect.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, unless required by law. You are advised, however,
        to consult any further disclosures we make on related subjects in the reports we file with the SEC.</div>
      <div style="text-align: center; margin-right: 5.25pt; margin-left: 5.25pt; line-height: 1.25; font-weight: bold;"> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">S - ii</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%1%S - %%-->
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <div style="border: #000000 2px solid; padding: 5px; width: 99%;">
          <div>
            <div style="text-align: center; margin-right: 5.25pt; margin-left: 5.25pt; line-height: 1.25; font-weight: bold;"> <br>
            </div>
            <div style="text-align: center; margin-right: 5.25pt; margin-left: 5.25pt; line-height: 1.25; font-weight: bold;"><a name="PROSPECTUSSUPPLEMENTSUMMA1"><!--Anchor--></a>PROSPECTUS SUPPLEMENT SUMMARY</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="margin-right: 5.25pt; line-height: 1.25; font-style: italic; text-align: justify;">This summary highlights selected material information contained elsewhere or incorporated by reference in this prospectus supplement and the
              accompanying prospectus. This summary does not contain all the information that you should consider before investing in our securities. You should read this summary together with the entire prospectus supplement and the accompanying
              prospectus carefully, including the &#8220;Risk Factors&#8221; sections contained in this prospectus supplement, the accompanying prospectus and the documents that are incorporated herein and therein by reference, including any financial statements in
              such documents and the notes to those financial statements, and in any free writing prospectus that we have authorized for use in connection with this offering, before making an investment decision. This prospectus supplement may add to,
              update or change information contained in or incorporated by reference in the accompanying prospectus.</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="line-height: 1.25; font-weight: bold;">Overview</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="line-height: 1.25; text-align: justify;">We are a clinical-stage therapeutic discovery and development company utilizing our broadly applicable predictive computational discovery capabilities to identify novel drug targets and new
              biological pathways to develop therapeutics in the field of cancer immunotherapy. Our innovative immuno-oncology pipeline consists of four clinical stage programs, targeting immune checkpoints we discovered computationally, COM701, COM902,
              AZD2936 and bapotulimab (formerly known as BAY1905254). Our lead product candidate, COM701, a potential first-in-class anti-PVRIG antibody, has been evaluated in Phase 1 clinical trials, for the treatment of solid tumors as a monotherapy and
              in combination with nivolumab &#177; Bristol Myers Squibb investigational anti-TIGIT, BMS-986207. Following the termination of our collaboration with Bristol Myers Squibb Company, these combination studies are being wound down while the monitoring
              of patients on study treatment is still ongoing. COM902, a potential best-in-class therapeutic antibody targeting TIGIT, has been evaluated in Phase 1 clinical trials as a monotherapy and in combination with COM701. As part of our data-driven
              focus on two specific tumor types for the further clinical evaluation of COM701 and COM902, we are working to initiate a clinical trial in metastatic microsatellite stable colorectal cancer with a triple treatment combination of COM701,
              COM902 and pembrolizumab and a study in platinum resistant ovarian cancer patients. AZD2936 is a novel anti PD-1/TIGIT bispecific antibody where the TIGIT-specific component is derived from our COM902 antibody. AZD2936 is being developed by
              AstraZeneca PLC (&#8220;AstraZeneca&#8221;) pursuant to an exclusive license agreement between us and AstraZeneca and is in Phase 2 clinical trial in patients with advanced or metastatic non-small cell lung cancer. Bapotulimab, an antibody targeting
              ILDR2, licensed to Bayer Pharma AG (&#8220;Bayer&#8221;) under a research and discovery collaboration and license agreement, is also in a Phase 1 clinical trial in immuno-oncology treatment na&#239;ve head and neck squamous cell carcinoma patients. This
              research and discovery collaboration and license agreement will expire on February 27, 2023, and we plan to pursue our right to receive an exclusive license under Bayer&#8217;s intellectual property as required to allow us to continue the
              development and commercialization of bapotulimab, to the extent we choose to do so. Our therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance. The most
              advanced early-stage program, COM503, a potential first-in-class, high affinity antibody targeting cytokine biology to enhance anti-tumor immunity in a differentiated manner, entered pre-IND enabling studies. Our business model is to
              selectively enter into collaborations for our novel targets and related drug product candidates at various stages of research and development under various revenue-sharing arrangements. Integrating cutting edge computational capabilities with
              ground-breaking immuno-oncology research and drug development expertise has enabled the advancement of three drug targets from computer prediction through successful preclinical studies to the clinic and as a result, we believe that we are
              uniquely positioned to discover and develop potential new, first-in-class treatment options for cancer patients.</div>
            &#160;</div>
        </div>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;" class="BRPFPageNumber">S - 1</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;">
        <div style="border: #000000 2px solid; padding: 5px; width: 99%;">
          <div>
            <div style="line-height: 1.25; font-weight: bold;"> <br>
            </div>
            <div style="line-height: 1.25; font-weight: bold;">Our Strategy</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="line-height: 1.25; text-align: justify;">We aim to transform patient lives by developing first-in-class therapeutics in the field of cancer immunotherapy based on our computational target discovery capabilities. Our pipeline
              strategy for the development of potentially first-in-class cancer immunotherapies is differentiated in the competitive landscape of immuno-oncology in the following manner:</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 18pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top;">&#8226;</td>
                  <td style="width: auto; vertical-align: top;">
                    <div style="text-align: justify;">It is based on the discovery of novel targets and biological pathways discovered by our predictive computational discovery capabilities with the potential to address the unmet need of patients
                      non-responsive to current cancer immunotherapies;</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 18pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top;">&#8226;</td>
                  <td style="width: auto; vertical-align: top;">
                    <div style="text-align: justify;">We integrate our cutting-edge computational capabilities with our ground-breaking immuno-oncology research and drug development expertise to inform our drug development process; and</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 18pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top;">&#8226;</td>
                  <td style="width: auto; vertical-align: top;">
                    <div style="text-align: justify;">We use the same integrated capabilities to identify drug combinations and design biomarker strategy for future patient selection.</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="line-height: 1.25; text-align: justify;">We believe this uniquely positions us in the discovery and the development of first-in-class drugs for cancer immunotherapy.</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="line-height: 1.25;">In our clinical therapeutic pipeline, our most advanced programs are:</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 18pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top;">&#8226;</td>
                  <td style="width: auto; vertical-align: top;">
                    <div style="text-align: justify;"><font style="font-weight: bold;">COM701 </font>is our lead immuno-oncology pipeline program. COM701 is a humanized antibody that binds with high affinity to PVRIG, a novel immune checkpoint target
                      candidate discovered by us that blocks the interaction with its ligand, PVRL2. Our data suggests that the PVRIG pathway is parallel and complementary to TIGIT, an immune checkpoint discovered computationally by us in 2009. These two
                      pathways intersect with DNAM-1, a costimulatory receptor on T cells and NK cells. The PD-1 pathway also intersects with DNAM-1. In certain tumors, the blockade of both TIGIT and PVRIG may be required to stimulate an antitumor immune
                      response, with or without additional PD-1 pathway blockade. Phase 1 trials for COM701 were initiated in September 2018.</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 18pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top;">&#8226;</td>
                  <td style="width: auto; vertical-align: top;">
                    <div style="text-align: justify;"><font style="font-weight: bold;">COM902</font> is a high affinity, fully human antibody developed by us, targeting TIGIT, an immune checkpoint. COM902 blocks the interaction of TIGIT with PVR, its
                      ligand. Our preclinical data suggests that in certain tumor indications the blockage of both TIGIT and PVRIG, two coinhibitory arms of the DNAM-1 axis, may be required to stimulate an anti-tumor immune response with or without the
                      blockade of the PD-1 pathway. Phase 1 trials for COM902 were initiated in March 2020.</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 18pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top;">&#8226;</td>
                  <td style="width: auto; vertical-align: top;">
                    <div style="text-align: justify;"><font style="font-weight: bold;">AZD2936</font> is a novel PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from COM902 and is being developed pursuant to an exclusive license
                      agreement with AstraZeneca. AstraZeneca initiated its Phase 2 trial in patients with advanced or metastatic non-small cell lung cancer in September 2022.</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 18pt;"><br>
                  </td>
                  <td style="width: 18pt; vertical-align: top;">&#8226;</td>
                  <td style="width: auto; vertical-align: top;">
                    <div style="text-align: justify;"><font style="font-weight: bold;">Bapotulimab</font> (formerly known as BAY1905254) is a new immune checkpoint identified by us targeting ILDR2, that is being developed by Bayer pursuant to a research
                      and discovery collaboration and license agreement signed in 2013. The research and discovery collaboration and license agreement will expire on February 27, 2023, and we plan to pursue our right to receive an exclusive license under
                      Bayer&#8217;s intellectual property as required to allow us to continue the development and commercialization of bapotulimab, to the extent we choose to do so.</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
          </div>
        </div>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;" class="BRPFPageNumber">S - 2</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">
        <div style="border: #000000 2px solid; padding: 5px; width: 99%;">
          <div>
            <div style="line-height: 1.25; font-weight: bold;"> <br>
            </div>
            <div style="line-height: 1.25; font-weight: bold;">Corporate Information</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="text-align: justify; line-height: 1.25;">Our legal and commercial name is Compugen Ltd. We were incorporated on February 10, 1993, as an Israeli corporation and operate under the Israeli Companies Law, 5759-1999, as amended together
              with all regulations promulgated thereunder (the &#8220;Companies Law&#8221;). Compugen USA, Inc., our wholly owned subsidiary, was incorporated in Delaware in March 1997, is qualified to do business in California, with an office located at 225 Bush
              Street, Suite 348, 395 Oyster Point Blvd., Suite 307 South San Francisco, CA 94104.</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="text-align: justify; line-height: 1.25;">Our principal executive offices are located at 26 Harokmim Street, Holon 5885849, Israel. Our telephone number is +972-3-765-8585 and our website is www.cgen.com. The information on, or
              accessible through, our website or any other website referenced herein is not incorporated by reference into this prospectus supplement, is not considered a part of this prospectus supplement and should not be relied upon with respect to this
              offering.</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="line-height: 1.25; font-weight: bold;">Israel Innovation Authority</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="line-height: 1.25; text-align: justify;">The government of Israel encourages research and development projects in Israel through the Israel Innovation Authority (the &#8220;IIA&#8221;), pursuant to and subject to the provisions of the Israeli
              Law for the Encouragement of Industrial Research and Development of 1984 and regulations promulgated thereunder (together, the &#8220;R&amp;D Law&#8221;). Under the R&amp;D Law, research and development projects which are approved by the Research
              Committee of the IIA are eligible for grants, in exchange for payment of royalties from revenues generated by the products (and related services) developed within the framework of such approved project (&#8220;Financed Know-How&#8221;) and subject to
              compliance with certain requirements and restrictions under the R&amp;D Law, which must generally continue to be complied with even following full repayment of all IIA grants.</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="line-height: 1.25; text-align: justify;">We received grants from the IIA for several projects and may receive additional grants in the future. Under the terms of the grants received, we are required to pay royalties ranging between
              3% to 5% of the revenues we generate from our products which incorporate technologies which were financed by such grants, until 100% of the dollar value of the grant is repaid (plus LIBOR interest applicable to grants received on or after
              January 1, 1999). As of December 31, 2022, we received grants from the IIA in the aggregate principal amount of approximately $7.3 million. Our contingent obligation for royalties, net of royalties already paid or accrued in the sum of
              approximately $2.0 million, along with the accumulated LIBOR interest to date of approximately $4.3 million, totaled approximately $9.6 million as of December 31, 2022. In addition to the obligation to pay royalties to the IIA, the R&amp;D
              Law requires that products which incorporate Financed Know-How be manufactured in Israel and prohibits the transfer of the&#160;Financed Know-How and any right derived therefrom to third parties, unless otherwise approved in advance by the IIA.
              Such prior consent may be given by the IIA subject to payment of increased royalties.</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="line-height: 1.25; text-align: justify;">In addition, we participated in four MAGNET Consortium programs - Drugs and Diagnostic Kits, or DAAT Consortium, Tevel Biotechnology Consortium, Pharmalogica Consortium and Rimonim Consortium
              &#8211; for which we received from the IIA a total amount of approximately $2.1 million, and in two MAGNETON programs, for which we received from the IIA approximately $0.5 million. These grants do not bear any royalty obligations, but as the
              R&amp;D Law applies to these programs, the restrictions on transfer of know-how or manufacturing outside of Israel, as detailed above, do apply.</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="line-height: 1.25; text-align: justify;">For a description of our obligations in connection with the grants from the IIA under the R&amp;D Law, see Item 5C &#8220;Operating and Financial Review and Prospects&#8212; Research and Development,
              Patents and Licenses&#8212; Research and Development Grants&#8212; The Israel Innovation Authority&#8221; in our Annual Report on Form 20-F for the fiscal year ended December 31, 2021, which is incorporated herein by reference.</div>
            &#160;</div>
        </div>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;" class="BRPFPageNumber">S - 3</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;">
        <div style="border: #000000 2px solid; padding: 5px; width: 99%;">
          <div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="text-align: center; line-height: 1.25; font-weight: bold;">THE OFFERING</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 35.58%; vertical-align: top;">
                    <div style="line-height: 1.25; font-weight: bold;">Ordinary shares offered by us:</div>
                  </td>
                  <td style="width: 64.42%; vertical-align: top;">
                    <div style="line-height: 1.25;">Ordinary shares having an aggregate offering price of up to $50 million.</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 35.58%; vertical-align: top;">&#160;</td>
                  <td style="width: 64.42%; vertical-align: top;">&#160;</td>
                </tr>
                <tr>
                  <td style="width: 35.58%; vertical-align: top;">
                    <div style="line-height: 1.25; font-weight: bold;">Ordinary shares to be outstanding after this offering:</div>
                  </td>
                  <td style="width: 64.42%; vertical-align: top;">
                    <div style="line-height: 1.25; text-align: justify;">Up to 144,913,288 ordinary shares, assuming sales of 58,288,645 ordinary shares in this offering at an offering price of $0.8578 per share, which was the last reported sale price of
                      our ordinary shares on The Nasdaq Global Market on January 30, 2023. The actual number of ordinary shares issued will vary depending on the sales price under this offering.</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 35.58%; vertical-align: top;">&#160;</td>
                  <td style="width: 64.42%; vertical-align: top;">&#160;</td>
                </tr>
                <tr>
                  <td style="width: 35.58%; vertical-align: top;">
                    <div style="line-height: 1.25; font-weight: bold;">Plan of Distribution:</div>
                  </td>
                  <td style="width: 64.42%; vertical-align: top;">
                    <div style="line-height: 1.25; text-align: justify;">&#8220;At the market offering&#8221; that may be made from time to time through our sales agent, SVB Securities. See &#8220;Plan of Distribution&#8221; on page S-19 of this prospectus supplement.</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 35.58%; vertical-align: top;">&#160;</td>
                  <td style="width: 64.42%; vertical-align: top;">&#160;</td>
                </tr>
                <tr>
                  <td style="width: 35.58%; vertical-align: top;">
                    <div style="line-height: 1.25; font-weight: bold;">Use of Proceeds:</div>
                  </td>
                  <td style="width: 64.42%; vertical-align: top;">
                    <div style="line-height: 1.25; text-align: justify;">We currently intend to use the net proceeds from this offering for pipeline development, general corporate purposes and working capital. See &#8220;Use of Proceeds&#8221; on page S-10 of this
                      prospectus supplement.</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 35.58%; vertical-align: top;">&#160;</td>
                  <td style="width: 64.42%; vertical-align: top;">&#160;</td>
                </tr>
                <tr>
                  <td style="width: 35.58%; vertical-align: top;">
                    <div style="line-height: 1.25; font-weight: bold;">Risk Factors:</div>
                  </td>
                  <td style="width: 64.42%; vertical-align: top;">
                    <div style="line-height: 1.25; text-align: justify;">Investing in our ordinary shares involves significant risks. See the information under the heading &#8220;Risk Factors&#8221; beginning on page S-5 of this prospectus supplement, on page 2 of the
                      accompanying prospectus and in the documents incorporated by reference into this prospectus supplement for a discussion of factors you should carefully consider before deciding to invest in our ordinary shares.</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 35.58%; vertical-align: top;">&#160;</td>
                  <td style="width: 64.42%; vertical-align: top;">&#160;</td>
                </tr>
                <tr>
                  <td style="width: 35.58%; vertical-align: top;">
                    <div style="line-height: 1.25; font-weight: bold;">Trading markets:</div>
                  </td>
                  <td style="width: 64.42%; vertical-align: top;">
                    <div style="line-height: 1.25; text-align: justify;">Our ordinary shares are traded on The Nasdaq Global Market and on the TASE under the symbol &#8220;CGEN.&#8221;</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <div style="line-height: 1.25; text-align: justify;">The number of ordinary shares to be outstanding immediately after this offering as shown above is based on 86,624,643 ordinary shares outstanding as of September 30, 2022 and excludes the
              following as of that date:</div>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 7.69%; vertical-align: middle;">&#160;</td>
                  <td style="width: 3.85%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#8226;</div>
                  </td>
                  <td style="width: 88.46%; vertical-align: top;">
                    <div style="text-align: justify; line-height: 1.25;">7,859,856&#160;ordinary shares issuable upon the exercise of outstanding options to purchase ordinary shares, having a weighted average exercise price of $5.81 per share;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 7.69%; vertical-align: middle;">&#160;</td>
                  <td style="width: 3.85%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#8226;</div>
                  </td>
                  <td style="width: 88.46%; vertical-align: top;">
                    <div style="text-align: justify; line-height: 1.25;">297,469 ordinary shares issuable upon the exercise of outstanding warrants to purchase ordinary shares, with an exercise price of $4.74 per share;</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 7.69%; vertical-align: middle;">&#160;</td>
                  <td style="width: 3.85%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#8226;</div>
                  </td>
                  <td style="width: 88.46%; vertical-align: top;">
                    <div style="line-height: 1.25; text-align: justify;">an aggregate of 2,216,190 ordinary shares issuable and reserved for future grants under the Compugen 2010 Share Incentive Plan, as amended; and</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 7.69%; vertical-align: middle;">&#160;</td>
                  <td style="width: 3.85%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#8226;</div>
                  </td>
                  <td style="width: 88.46%; vertical-align: top;">
                    <div style="line-height: 1.25; text-align: justify;">an aggregate of 324,146 ordinary shares issuable and reserved for future grants under the Compugen 2021 Employee Share Purchase Plan.</div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;"><br style="line-height: 1.25;">
            </div>
          </div>
        </div>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;" class="BRPFPageNumber">S - 4</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="RISKFACTORS1"><!--Anchor--></a>RISK FACTORS</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-style: italic; text-align: justify;">An investment in our ordinary shares involves a high degree of risk. Before deciding whether to invest in our ordinary shares, you should consider carefully the risks described
        below as well as those discussed under the section captioned &#8220;Item 3. Key Information. Risk Factors&#8221; contained in our Annual Report on Form 20-F for the year ended December 31, 2021, as amended, filed with the SEC on February 28, 2022, which is
        incorporated by reference in the prospectus supplement and the accompanying prospectus, in their entirety, together with other information in this prospectus supplement, the accompanying prospectus, the information and documents incorporated by
        reference herein and therein, and in any free writing prospectus that we have authorized for use in connection with this offering. The risks and uncertainties previously described and discussed below are not the only ones we face. Additional risks
        and uncertainties not presently known to us, or that we currently see as immaterial, may also harm our business. If any of these risks actually occurs, our business, financial condition, results of operation or cash flow could be adversely
        affected. This could cause the trading price of our ordinary shares to decline, resulting in a loss of all or part of your investment.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-weight: bold;">Risks Related to our Ordinary Shares and this Offering</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-style: italic; font-weight: bold; text-align: justify;">Our management and board of directors will have broad discretion in the use of the net proceeds we receive in this offering and might not apply the proceeds
        in ways that increase the value of your investment.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; text-align: justify;">Our management and board of directors will have broad discretion over the use of our net proceeds from this offering, and you will be relying on their judgment regarding the application of these
        proceeds, which can be different from that contemplated as of the date of this prospectus supplement. Our management and board of directors might not apply our net proceeds in ways that ultimately increase the value of your investment and we might
        not be able to yield a significant return, if any, on any investment of these net proceeds. Our failure to apply these funds effectively could have a material adverse effect on our business, delay the development of our products and cause the price
        of our ordinary shares to decline.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-style: italic; font-weight: bold; text-align: justify;">The shares offered hereby will be sold in &#8220;at the market offerings&#8221; and investors who buy shares at different times will likely pay different prices.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; text-align: justify;">Investors who purchase shares in this offering at different times will likely pay different prices, and accordingly may experience different levels of dilution and different outcomes in their
        investment results. We will have discretion, subject to market demand, to vary the timing, prices and number of shares sold in this offering, and it is not possible to predict the number of shares that will ultimately be issued and sold or the
        prices that will be paid by investors. Investors may experience a decline in the value of the shares they purchase in this offering as a result of sales made at prices lower than the prices they paid.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-style: italic; font-weight: bold; text-align: justify;">Investors in this offering may experience immediate and substantial dilution.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; text-align: justify;">The public offering price of the ordinary shares offered pursuant to this prospectus supplement may be higher than the net tangible book value per ordinary shares. Therefore, if you purchase
        ordinary shares in this offering at a price that is higher than the net tangible book value per share of our ordinary shares, you will incur immediate and substantial dilution in the net tangible book value per share from the price per share that
        you pay. <br>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="line-height: 1.25; font-style: italic; font-weight: bold;">You may experience future dilution as a result of future equity offerings.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="line-height: 1.25; text-align: justify;">We may in the future offer additional ordinary shares or other securities convertible into or exchangeable for our ordinary shares at prices that may not be the same as the price per share in
          this offering. We may sell shares or other securities in any other offering at a price per share that is less than the price per share paid by investors in this offering, and investors purchasing shares or other securities in the future could
          have rights superior to existing shareholders. The price per share at which we sell additional ordinary shares, or securities convertible or exchangeable into ordinary shares, in future transactions may be higher or lower than the price per share
          paid by investors in this offering.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;" class="BRPFPageNumber">S - 5</font></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25; text-align: justify;">In addition, we have issued warrants and options to purchase our ordinary shares, and this may result in the issuance of a substantial number of additional ordinary shares upon their exercise,
          which shares are eligible for, or may become eligible for, unrestricted resale. If the holders of outstanding options or warrants to acquire ordinary shares exercise those options or warrants at prices below the public offering price, you will
          incur further dilution. We may issue additional securities convertible into or exchangeable for our ordinary shares in the future. Any sales of such shares in the public market or otherwise could reduce the prevailing market price of our ordinary
          shares, as well as make future sales of ordinary shares by us less attractive or not feasible, thus limiting our capital resources.</div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25; font-style: italic; font-weight: bold;">We may not be able to meet the continued listing standards of The Nasdaq Stock Market LLC, or Nasdaq, which require a minimum closing bid price of $1.00 per share, which could
          result in our delisting and negatively impact the price of our ordinary shares and our ability to access the capital markets.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="line-height: 1.25; text-align: justify;">Our ordinary shares are listed on The Nasdaq Global Market.&#160;The Nasdaq Stock Market LLC (&#8220;Nasdaq&#8221;) provides various continued listing requirements that a company must meet in order for its shares
          to continue trading on the exchange. Among these requirements is the requirement that our shares trade at a minimum bid price of $1.00 per share.&#160;On October 31, 2022, we received a written notice from the Listing Qualifications Department of
          Nasdaq, notifying us that our ordinary shares failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by Nasdaq Listing Rule 5450(a)(1) (the &#8220;Minimum Bid Price Requirement&#8221;).</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25; text-align: justify;">Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), we have a compliance period of 180 calendar days from the date of the notification letter from Nasdaq, or until May 1, 2023, to regain compliance
          with the Minimum Bid Price Requirement. If at any time before May 1, 2023, the closing bid price of our ordinary shares is at least $1.00 for a minimum of 10 consecutive business days, we will be deemed to have regained compliance with the
          Minimum Bid Price Requirement, following which, Nasdaq will provide a written confirmation of compliance and the matter will be closed. In the event that we do not regain compliance by May 1, 2023, we may transfer the listing and trading of our
          ordinary shares to The Nasdaq Capital Market, provided that we meet the applicable standards for initial listing of our ordinary shares on the Nasdaq Capital Market (other than the Minimum Bid Price Requirement) and may be eligible for an
          additional 180 calendar day grace period by providing a written notice of our intention to cure the deficiency during this second compliance period by effecting a reverse share split, if necessary. If we do not regain compliance with the Minimum
          Bid Price Requirement by May 1, 2023, and we are ineligible for an additional grace period, Nasdaq will provide written notice that the ordinary shares are subject to delisting from The Nasdaq Global Market. In that event, we may appeal the
          determination to a Nasdaq hearings panel.</div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25; text-align: justify;">There is no assurance that our share price will trade&#160;at or above a minimum bid price of $1.00 per share and if we fail to meet minimum listing requirements,&#160;there can be no assurance that we
          will be able to regain compliance with the Minimum Bid Price Requirement or will otherwise be in compliance with other Nasdaq listing criteria. Any such delisting could adversely affect our ability to obtain financing for the continuation of our
          operations and could result in the loss of confidence by investors, collaborators and employees.</div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Our ordinary shares are traded on more than one market and this may result in price variations.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; text-align: justify;">In addition to being traded on The Nasdaq Global Market, our ordinary shares are also traded on the TASE. Trading in our ordinary shares on these markets take place in different currencies (U.S.
        dollars on Nasdaq and NIS on the TASE), and at different times (resulting from different time zones, trading days and public holidays in the United States and Israel). The trading prices of our ordinary shares on these two markets may differ due to
        these and other factors. Any decrease in the price of our ordinary shares on one market could cause a decrease in the trading price of our ordinary shares on the other market.</div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;" class="BRPFPageNumber">S - 6</font></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="line-height: 1.25; font-style: italic; font-weight: bold; text-align: justify;">Because we do not intend to declare cash dividends on our ordinary shares in the foreseeable future, shareholders must rely on appreciation of the value of
          our ordinary shares for any return on their investment and may not receive any funds without selling their ordinary shares.</div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
      <div style="line-height: 1.25; text-align: justify;">We have never declared or paid cash dividends on our ordinary shares and do not anticipate declaring or paying any cash dividends in the foreseeable future. In addition, the terms of any future
        debt agreements may preclude us from paying dividends. As a result, we expect that only appreciation of the price of our ordinary shares, if any, will provide a return to investors in this offering for the foreseeable future. In addition, because
        we do not pay cash dividends, if our shareholders want to receive funds in respect of our ordinary shares, they must sell their ordinary shares to do so.</div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="line-height: 1.25; font-style: italic; font-weight: bold; text-align: justify;">Unfavorable global or domestic political or economic conditions could adversely affect our business, financial condition or results of operations.</div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
      <div style="line-height: 1.25; text-align: justify;">The global economy continues to experience significant volatility, and the economic environment may continue to be, or become, less favorable than that of past years. Higher costs for goods and
        services, inflation, deflation, the imposition of tariffs or other measures that create barriers to or increase the costs associated with international trade, overall economic slowdown or recession and other economic factors in Israel, the U.S. or
        in any other markets in which we operate could adversely affect our operations and operating results. Among other matters, the continued risk of a debt default by one or more European countries, related financial restructuring efforts in Europe,
        and/or evolving deficit and spending reduction programs instituted by the U.S. and other governments could negatively impact the global economy and/or pharmaceutical industry.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; text-align: justify;">In addition, recent political and civil actions in Israel during the month of January 2023, resulting from, among other things, proposed changes to certain Israeli constitutional legislation, may
        have an adverse effect on the Israeli social, economic and political landscape and in turn, on us. However, it is difficult to predict at this time what the effect of such actions will be, if any. Furthermore, although to date we have not been
        directly impacted by the current military conflict between Russia and Ukraine, this conflict, or any expansion thereof, could disrupt or otherwise adversely impact our operations and those of third parties upon which we rely. Related sanctions,
        export controls or other actions have been or may in the future be initiated by nations including the United States, the European Union or Russia (e.g., potential cyberattacks, disruption of energy flows, etc.), which could adversely affect our
        business and/or our supply chain, our CROs, CMOs and other third parties with whom we conduct business. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market
        conditions could adversely impact our business.&#160;</div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="line-height: 1.25; font-style: italic; font-weight: bold; text-align: justify;">Our shareholders&#8217; rights and responsibilities are governed by Israeli law which differs in some material respects from the rights and responsibilities of
          shareholders of U.S. companies.</div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
      <div style="line-height: 1.25; text-align: justify;">Because we are incorporated under Israeli law, the rights and responsibilities of our shareholders are governed by our Articles of Association, as amended from time to time, or Articles, and
        Israeli law. These rights and responsibilities differ in some respects from the rights and responsibilities of shareholders in U.S.-based corporations. In particular, a shareholder of an Israeli company has a duty to act in good faith and in a
        customary manner in exercising its rights and performing its obligations towards the company and other shareholders and to refrain from abusing its power in the company, including, among other things, in voting at the general meeting of
        shareholders on certain matters, such as an amendment to a company&#8217;s articles of association, an increase of a company&#8217;s authorized share capital, a merger of a company and approval of interested party transactions that require shareholder
        approval. A shareholder also has a general duty to refrain from discriminating against other shareholders. In addition, a controlling shareholder or a shareholder who knows that it possesses the power to determine the outcome of a shareholders&#8217;
        vote or to appoint or prevent the appointment of an office holder in a company or has another power with respect to a company, has a duty to act in fairness towards such company. Israeli law does not define the substance of this duty of fairness
        and there is limited case law available to assist in understanding the nature of this duty or the implications of these provisions. These provisions may be interpreted to impose additional obligations and liabilities on our shareholders that are
        not typically imposed on shareholders of U.S. corporations.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;" class="BRPFPageNumber">S - 7</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">If we are a passive foreign investment company, or PFIC,&#160;our U.S. shareholders may be subject to adverse U.S. federal income tax consequences. Based on our
          analysis of our estimated income, estimated assets, activities and market capitalization, we believe that we were a PFIC for the taxable year ended December 31, 2022.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;">&#160;</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">For U.S. federal income tax purposes, we generally will be classified as a PFIC for any taxable year in which, after the application of certain look-through rules with respect to our
          subsidiaries, either: (i) 75% or more of our gross income is passive income or (ii) at least 50% of the average value (determined on the basis of a weighted quarterly average) of our total assets for the taxable year produce or are held for the
          production of passive income. For purposes of these tests, passive income includes, among other things, dividends, interest, and gains from the sale or exchange of investment property and certain rents and royalties (excluding rents and royalties
          that are received from unrelated parties in connection with the active conduct of a trade or business). Assets that produce or are held for the production of passive income may include cash, even if held as working capital or raised in a public
          offering, marketable securities, and other assets that may produce passive income. Generally, in determining whether a non-U.S. corporation is a PFIC, a non-U.S. corporation that directly or indirectly owns at least 25% by value of the shares of
          another corporation is treated as holding and receiving directly its proportionate share of assets and income of such corporation.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;">&#160;</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">Based on our analysis of our estimated income, estimated assets, activities and market capitalization, we believe that we were a PFIC for the taxable year ended December 31, 2022. However, the
          determination of whether or not we are a PFIC is a fact-intensive determination made on an annual basis and because the applicable law is subject to varying interpretations, we cannot provide any assurance regarding our PFIC status and our U.S.
          counsel expresses no opinion with respect to our PFIC status for any taxable year. If we are classified as a PFIC for any taxable year during which a U.S. shareholder holds our ordinary shares, U.S. investors could be subject to adverse tax
          consequences regardless of whether we continue to qualify as a PFIC, including the treatment of gains realized on the sale of our ordinary shares as ordinary income, rather than as capital gain, the loss of the preferential rate applicable to
          dividends received on our ordinary shares by individuals who are U.S. holders (as defined in &#8220;<font style="font-style: italic;">Material Tax Considerations &#8211; Certain Material U.S. Federal Income Tax Considerations to U.S. Holders</font>&#8221; below),
          the addition of interest charges on certain taxes treated as deferred taxes, and additional reporting requirements. A U.S. shareholder of a PFIC generally may mitigate these adverse U.S. federal income tax consequences by making a &#8220;qualified
          electing fund&#8221; election, or QEF, or, in some circumstances, a &#8220;mark to market&#8221; election. We may provide the information necessary for U.S. holders to make QEF elections if we were treated as a PFIC for any taxable year, although, there is no
          assurance that we will do so. There is no assurance that we will have timely knowledge of our status as a PFIC in the future. Accordingly, U.S. holders may be unable to make a timely QEF election with respect to our ordinary shares.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;">&#160;</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">For further discussion of the PFIC rules and the adverse U.S. federal income tax consequences in the event we are classified as a PFIC, as well as certain elections that may be available to U.S.
          holders, see &#8220;<font style="font-style: italic;">Material Tax Considerations &#8211; Certain Material U.S. Federal Income Tax Considerations to U.S. Holders</font>.&#8221;</div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">If we are a controlled foreign corporation, there could be materially adverse U.S. federal income tax consequences to certain U.S. Holders of our ordinary
          shares.</div>
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">Each &#8220;Ten Percent Shareholder&#8221; (as defined below) in a non-U.S. corporation that is classified as a controlled foreign corporation, or a &#8220;CFC&#8221;, for U.S. federal income tax purposes generally is
          required to include in income for U.S. federal tax purposes such Ten Percent Shareholder&#8217;s pro rata share of the CFC&#8217;s &#8220;Subpart F income&#8221; (as defined below), global intangible low taxed income, and investment of earnings in U.S. property,
          regardless of whether we make any distributions. Subpart F income generally includes dividends, interest, rents, royalties, gains from the sale of securities and income from certain transactions with related parties. In addition, a Ten Percent
          Shareholder that realizes gain from the sale or exchange of shares in a CFC may be required to classify a portion of such gain as dividend income rather than capital gain. An individual that is a Ten Percent Shareholder with respect to a CFC
          generally would not be allowed certain tax deductions or foreign tax credits that would be allowed to a Ten Percent Shareholder that is a U.S. corporation. We cannot provide any assurance that we will assist investors in determining whether we or
          any of our future non-U.S. subsidiaries are treated as a CFC or furnish to any U.S. holder the information required to comply with the reporting and tax-paying obligations discussed above. Failure to comply with these reporting obligations may
          subject a Ten Percent Shareholder to significant monetary penalties and may prevent the statute of limitations with respect to such Ten Percent Shareholder&#8217;s U.S. federal income tax return for the year for which reporting was due from starting.</div>
        <div style="text-align: justify; line-height: 1.25;"> <br>
        </div>
        <div style="text-align: justify; line-height: 1.25;">
          <div style="line-height: 1.25;">A non-U.S. corporation generally will be classified as a CFC for U.S. federal income tax purposes if Ten Percent Shareholders own, directly or indirectly, more than 50% of either the total combined voting power of
            all classes of stock of such corporation entitled to vote or of the total value of the stock of such corporation. A &#8220;Ten Percent Shareholder&#8221; is a United States person (as defined by the Internal Revenue Code of 1986, as amended, or, the
            &#8220;Code&#8221;) who owns (directly or indirectly) 10% or more of the total combined voting power of all classes of stock entitled to vote or 10% or more of the total value of all classes of stock of such corporation.</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="line-height: 1.25;">The determination of CFC status is complex and includes attribution rules, the application of which is not entirely certain. In addition, changes to the attribution rules relating to the determination of CFC status
            may make it difficult to determine our CFC status for any taxable year. Because our group includes at least one U.S. subsidiary (Compugen USA, Inc.), those changes to the attribution rules may cause any non-U.S. subsidiaries that we form or
            acquire in the future to be treated as controlled foreign corporations.</div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="line-height: 1.25;">Each U.S. holder (as defined in &#8220;<font style="font-style: italic;">Material Tax Considerations &#8211; Certain Material U.S. Federal Income Tax Considerations to U.S. Holders</font>&#8221; below) should consult its own tax
            advisors with respect to the potential adverse U.S. tax consequences of becoming a Ten Percent Shareholder in a CFC. If we are classified as both a CFC and a PFIC (as defined above), we generally will not be treated as a PFIC with respect to
            those U.S. holders that meet the definition of a Ten Percent Shareholder during the period in which we are a CFC.</div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;" class="BRPFPageNumber">S - 8</font></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
        <div style="text-align: justify; line-height: 1.25;">
          <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif; font-weight: bold;">Risks Related to Our Intellectual Property</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif; font-style: italic; font-weight: bold;">If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent
            protection, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="margin-right: 1pt; line-height: 1.25; font-family: 'Times New Roman', serif; font-size: 8pt;"><font style="font-family: 'Times New Roman',serif; font-size: 10pt; color: rgb(0, 0, 0);">We have applied for patents covering proteins,
              therapeutic and diagnostic product candidates and their method of use, and the success of our business depends, to a large extent, on our ability to obtain and maintain such patents and any additional patents covering our future product
              candidates. We design our patent strategy to fit the business competitive landscape and continual legislative changes. In addition, we periodically analyze and examine our patent portfolio to align it with our pipeline strategy and business
              needs.</font><font style="font-size: 10pt;"> We have issued patents and pending patent applications that are related to our product candidates in the U.S., Europe, and other territories. <font style="font-family: 'Times New Roman',serif; color: rgb(0, 0, 0);">We plan to continue to apply for patent protection for our therapeutic and diagnostic inventions, but we cannot be sure that any of our patent applications will be accepted, or that they will be accepted to the extent
                that we seek or that they will not be challenged. Additionally, we file for patent protection in selected countries and not in all countries of the world. Therefore, we are exposed to competition in those countries in which we have no
                patent protection. Also, due to our early-stage pipeline and various business considerations, we may be required to seek patent protection at a very early-stage. This may cause us to file with insufficient supportive data, possibly making
                it difficult to obtain patents in jurisdictions that do not accept post filing evidence to support the claims, and thus enabling others to compete with us. This may also cause issuance of a patent at an earlier stage creating a shorter
                commercialization period under patent protection, possibly enabling others to compete with us. Delays in filing patents may preclude us from obtaining protection on some or all of our product candidates due to others filing ahead of us.
                Patent applications filed before us, but yet unpublished, may cause us to spend significant resources in areas that due to these previously filed patents or applications we are not able to obtain patent protection or are only able to obtain
                a narrower scope of protection than contemplated.</font></font></div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="margin-right: 1pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif;">Because the patent position of biopharmaceutical companies involves complex legal and factual questions, we cannot predict the validity,
            scope or enforceability of patents with certainty. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability and our patents may be subject to a third party pre issuance submission of prior art to the
            patent authorities or become involved in opposition, derivation, revocation, reexamination, post-grant and <font style="font-style: italic;">inter partes</font> review, or other similar proceedings challenging our patent rights in the United
            States and other jurisdictions which may result in such patents being narrowed, invalidated, or held unenforceable, and thus could limit our ability to stop competitors from marketing related products or limit the length of the term of patent
            protection that we may have for our product candidates. Such proceedings also may result in substantial cost and require our pending patent applications, and those we may file in the future may not result in patents being issued. Furthermore,
            even if our patents do issue, and even if they are unchallenged, our patents may not adequately protect all our intellectual property or prevent others from designing their products in a way to avoid being covered by our claims. If the breadth
            or strength of protection provided by the patents we hold is threatened, this could dissuade companies from collaborating with us to develop, and could threaten our ability to commercialize product candidates and expose us to unexpected
            competition that could have a material adverse impact on our business. For example, in October 2020, two parties, one being GlaxoSmithKline (following an assignment), filed oppositions in the European Patent Office (&#8220;EPO&#8221;) requesting revocation
            of our granted European patent relating to anti-PVRIG antibodies. Following our response, a preliminary non-binding opinion of the European opposition division was received in October 2022, with a summons to attend oral proceedings in July
            2023. The opposition division preliminary non-binding opinion accepts some of our arguments filed in our response in March 2021, and acknowledges that the formal requirements of the priority claim of the patent that is the subject matter of the
            opposition are being successfully met. Nevertheless, the preliminary non-binding opinion states that the requirements of novelty and inventive step for the said patent are not met, mainly because the oppositions division believes that our
            priority documents do not contain sufficient data that plausibly link anti-PVRIG antibodies to activation of T cells and/or NK cells, and to the treatment of cancer. Based on similar considerations the division considers the claimed
            subject-matter insufficiently disclosed in the patent.&#160; We plan to timely respond the preliminary non-binding opinion. In January 2023, another opposition was filed by GlaxoSmithKline, requesting revocation of our granted European patent
            relating to method of screening for inhibitors of the binding association of PVRIG polypeptide with PVRL2. We plan to timely respond to this opposition.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="margin-right: 1pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif;">Furthermore, changes in either the patent laws or interpretation of the patent laws in the United States or other jurisdictions could
            weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future and increase the uncertainties and costs surrounding the prosecution of patent applications, and the enforcement or
            defense of our issued patents. Such changes could diminish the value of our patents and applications, thereby impairing our ability to protect our product candidates, and could have a material adverse effect on our business, financial
            condition, results of operations and prospects. For example, the U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of
            patent owners in certain situations. In October 2017, in <font style="font-style: italic;">Amgen v. Sanofi</font>, the Federal Circuit overturned the &#8220;newly characterized antigen&#8221; test, which permitted patentees to claim a genus of antibodies
            by describing the structure of a corresponding antigen, on the grounds that it failed to satisfy the requirements found in Section 112 of the Patent Act, 35 U.S.C. &#167; 112. In doing so, the Federal Circuit called into question the validity of
            numerous existing patents. In November 2022, the Supreme Court granted certiorari in <font style="font-style: italic;">Amgen v. Sanofi</font>, agreeing to review the Federal Circuit&#8217;s &#8220;full scope of the claimed embodiments&#8221; test for
            enablement. Nonetheless, in the current IP environment in the U.S., we may not be able to obtain or defend broad patent protection on our antibody inventions.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="margin-right: 1pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif;">Moreover, because of the extensive time required for development, testing and regulatory review of a potential product, it is possible
            that, before any particular product candidate can be commercialized, any related patent may expire or remain in force for only a short period following commercialization, thereby reducing any advantage of the patent protection.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="margin-right: 1pt; line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif;">The process of obtaining patents for inventions that cover our products is uncertain for a number of reasons, including but not limited
            to:</div>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z54c8b65ca4f94b30b260bf91e48aeb63">

              <tr>
                <td style="width: 13pt;"><br>
                </td>
                <td style="width: 13pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',serif;">the patenting of inventions involves complex legal issues relating to intellectual property laws, prosecution and enforcement of patent claims across a number or
                    patent jurisdictions, many of which have not yet been settled;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z40409a1fdcd34e12ae2d7a153aa706bb">

              <tr>
                <td style="width: 13pt;"><br>
                </td>
                <td style="width: 13pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',serif;">legislative and judicial changes, or changes in the examination guidelines of governmental patent offices may negatively affect our ability to obtain patent claims to
                    certain biological molecules- and/or use of certain therapeutic targets;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z804fb9e2998c4368aacd2806dfcb6ce2">

              <tr>
                <td style="width: 13pt;"><br>
                </td>
                <td style="width: 13pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',serif;">if we are not the first to file a patent application on one of our inventions, we may not be able to obtain a patent on our invention, and may not be able to protect
                    one or more of our therapeutic product candidates;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z55c971af1e804e85ad72e58e10cc1890">

              <tr>
                <td style="width: 13pt;"><br>
                </td>
                <td style="width: 13pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',serif;">competition from other biotechnology and pharmaceutical companies who have already sought patent protection relating to proteins and protein based products, as well
                    as therapeutic antibodies or other modulators specifically binding these proteins, and their utility based discoveries that we may intend to develop and commercialize; such prior patents may negatively affect our ability to obtain
                    patent claims on antibodies or certain proteins or other biologic modulators, or may hinder our ability to obtain sufficiently broad patent claims for our inventions, and/or may limit our freedom to operate;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8c3c87c4caeb41869b90db832cfce47a">

              <tr>
                <td style="width: 13pt;"><br>
                </td>
                <td style="width: 13pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',serif;">publication of data on gene products or proteins by non-commercial and commercial entities may hinder our ability to obtain sufficiently broad patent claims for our
                    inventions;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z8f3a845e8efc404bb9e599547d2776f1">

              <tr>
                <td style="width: 13pt;"><br>
                </td>
                <td style="width: 13pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',serif;">even if we succeed in obtaining patent protection, such protection may not be sufficient to prevent third parties from circumventing our patent claims;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2d148ba2a6df4003b8f0eddc25d19108">

              <tr>
                <td style="width: 13pt;"><br>
                </td>
                <td style="width: 13pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',serif;">even if we succeed in obtaining patent protection, we may face freedom to operate issues;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="za0a3c987e571423fae0db46a2af13e7c">

              <tr>
                <td style="width: 13pt;"><br>
                </td>
                <td style="width: 13pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',serif;">even if we succeed in obtaining patent claims protecting our inventions and product candidates, our patents could be subject to challenge and litigation by our
                    competitors, and may be partially or wholly invalidated as a result of such legal/judicial challenges and in connection with such challenges;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z2703539696284f5cb22651a76bfca7d5">

              <tr>
                <td style="width: 13pt;"><br>
                </td>
                <td style="width: 13pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',serif;">significant costs that may need to be incurred in registering and filing patents;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zd47dc694474c44c78b223ca209430699">

              <tr>
                <td style="width: 13pt;"><br>
                </td>
                <td style="width: 13pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',serif;">insufficient data to support our claims and/or may support others in strengthening their patents;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z0c30953139d9475bb5a47d40228fcd6d">

              <tr>
                <td style="width: 13pt;"><br>
                </td>
                <td style="width: 13pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',serif;">seeking patent protection at an early stage may prevent us from providing comprehensive data supporting the patent claims and may prevent allowance of certain patent
                    claims or limit the scope of patent claim coverage;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z3a08617b313a41abadea097720e92cbf">

              <tr>
                <td style="width: 13pt;"><br>
                </td>
                <td style="width: 13pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',serif;">we may not be able to supply sufficient data to support our claims, within the legally prescribed time following our initial filing in order to support our patent
                    claims and this may harm our ability to get appropriate patent protection or protection at all;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z269d9624aefb4bf3a8c2f2771713d2bc">

              <tr>
                <td style="width: 13pt;"><br>
                </td>
                <td style="width: 13pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',serif;">our claims may be too broad and not have sufficient enablement, in which case such claims might be rejected by patent offices or invalidated in court; and</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="zbbe9d7e540254d75a773a7d03fb6fd69">

              <tr>
                <td style="width: 13pt;"><br>
                </td>
                <td style="width: 13pt; vertical-align: top; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif;">&#8226;</td>
                <td style="width: auto; vertical-align: top; text-align: justify;">
                  <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman',serif;">we might fail to demonstrate a unique technical feature for our antibodies as compared to existing prior art, in which case our claims might be rejected by the
                    respective patent office, requiring superiority over prior art.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25; color: rgb(0, 0, 0); font-family: 'Times New Roman',serif;">If we do not succeed in obtaining patent protection for our inventions (should it be discoveries, drug targets candidates and product candidates) to the
            fullest extent for which we seek protection, or if we fail to select the best inventions to seek such protection, our business and financial results could be materially harmed.</div>
          <div style="line-height: 1.25;">&#160;</div>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;" class="BRPFPageNumber">S - 9</font></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="USEOFPROCEEDS1"><!--Anchor--></a>USE OF PROCEEDS</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; text-align: justify;">We currently intend to use the net proceeds from this offering for our pipeline development, general corporate purposes and working capital. We have not determined the amount of net proceeds to be
        used specifically for the foregoing purposes. As a result, our management will have broad discretion in the allocation of the net proceeds from this offering. Pending use of the net proceeds, we currently intend to invest any proceeds in a variety
        of capital preservation instruments, including short-term, investment-grade and/or interest-bearing instruments.</div>
      <div style="text-align: center; line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;" class="BRPFPageNumber">S - 10</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="MATERIAL1"><!--Anchor--></a>MATERIAL TAX CONSIDERATIONS</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">The following summarizes material Israeli and U.S. federal tax consequences concerning the acquisition, ownership and disposition of our ordinary shares by purchasers or holders of our ordinary
        shares. Because parts of this discussion are based on new or existing tax or other legislation that has not been subject to judicial or administrative interpretation, there can be no assurance that the views expressed herein will be accepted by the
        tax or other authorities in question. The discussion is subject to change, including due to amendments under Israeli law or changes to the applicable judicial or administrative interpretations of Israeli law, which change could affect the tax
        consequences described below, possibly with retroactive effect. The summary below does not address all of the tax consequences that may be relevant to all purchasers or holders of our ordinary shares in light of each purchaser&#8217;s or holder&#8217;s
        particular circumstances and specific tax treatment. For example, the summary below does not address the tax treatment of residents of Israel and traders in securities who are subject to specific tax regimes. As individual circumstances may differ,
        holders of our ordinary shares should consult their own tax advisors as to U.S., Israeli or other tax consequences of the purchase, ownership and disposition of our ordinary shares. This discussion is not intended, nor should it be construed, as
        legal or professional tax advice and it is not exhaustive of all possible tax considerations. Each person should consult his, her or its own tax or legal advisor.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">Israeli Taxation</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Taxation of Capital Gains Applicable to Non-Israeli Shareholders</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Israeli law generally imposes a capital gains tax on the sale of securities of an Israeli resident company traded on the TASE, on an authorized stock exchange outside Israel or on a regulated
        market (which includes a system through which securities are traded pursuant to rules prescribed by the competent authority in the relevant jurisdiction), which includes Nasdaq, in or outside Israel (a &#8220;Recognized Exchange&#8221;). Pursuant to the
        Israeli Income Tax Ordinance (New Version) 5721-1961 (the &#8220;Ordinance&#8221;), the capital gains tax rate applicable to individuals upon the sale of such securities is such individual&#8217;s marginal tax rate but not more than 25%, or 30% with respect to an
        individual who meets the definition of a &#8216;Substantial Shareholder&#8217; on the date of the sale of the securities or at any time during the 12 months preceding such date. A &#8216;Substantial Shareholder&#8217; is defined as a person who, either alone or together
        with any other person, holds, directly or indirectly, at least 10% of any of the means of control of a company (which includes, among other things, the right to receive profits of the company, voting rights, the right to receive the company&#8217;s
        liquidation proceeds and the right to appoint a director).</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">With respect to corporate investors, capital gain tax equal to the corporate tax rate (23% in 2023 and thereafter) will be imposed on the sale of our traded shares.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">However, if our ordinary shares are traded on a Recognized Exchange, gains on the sale of our ordinary shares held by non-Israeli tax resident investors will generally be, subject to certain
        conditions, exempt from Israeli capital gains tax so long as the gains were not derived from a permanent establishment that the non-Israeli tax resident investor maintains in Israel. Furthermore, non-Israeli &#8220;Body of Persons&#8221; (as defined in the
        Ordinance, and includes corporate entities, partnerships, and other entities) will not be entitled to such exemption if Israeli residents, whether directly or indirectly, (i) holds more than 25% of the means of control in such non-Israeli
        corporation or (ii) are the beneficiaries of or are entitled to 25% or more of the revenues or profits of such corporation.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Notwithstanding the foregoing, dealers in securities in Israel are taxed at regular tax rates applicable to business income.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">In addition, persons paying consideration for shares, including purchasers of shares, Israeli securities dealers effecting a transaction, or a financial institution through which securities being
        sold are held, are required, subject to any applicable exemptions and the demonstration by the selling shareholder of its non-Israeli residency and other requirements, to withhold tax upon the sale of publicly traded securities at a rate of 25% for
        individuals and at the corporate tax rate (23% in 2023 and thereafter) for corporations.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;" class="BRPFPageNumber">S - 11</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25;">The sale of shares may also be exempt from Israeli capital gain tax under the provisions of an applicable tax treaty. For example, the Convention Between the Government of the United States and the
        Government of the State of Israel With Respect to Taxes of Income, as amended (the &#8220;U.S.-Israel Tax Treaty&#8221;), exempts U.S. residents for the purposes of the treaty (who are entitled to claim the benefits of the U.S.-Israel Tax Treaty) from Israeli
        capital gain tax in connection with such sale, provided (i) the U.S. resident owned, directly or indirectly, less than 10% of the Israeli resident company&#8217;s voting power at any time within the 12-month period preceding such sale; (ii) the seller,
        being an individual, is present in Israel for a period or periods of less than 183 days during the taxable year; and (iii) the capital gain from the sale was not derived through a permanent establishment of the U.S. resident in Israel. Under the
        U.S.-Israel Tax Treaty, U.S. residents for the purposes of the treaty may be permitted to claim a credit for such taxes against U.S. federal income tax imposed on the sale, under the circumstances and subject to the limitations specified in the
        U.S.-Israel Tax Treaty and U.S. tax legislation, as discussed below under &#8220;<font style="font-style: italic;">Certain Material U.S. Federal Income Tax Considerations to U.S. Holders &#8211; Distributions</font>.&#8221;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Income Taxes on Dividend Distribution to Non-Israeli Shareholders</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;"> <br>
      </div>
      <div style="text-align: justify; line-height: 1.25;">In principle, non-Israeli residents (whether individuals or corporations) are generally subject to Israeli income tax on the receipt of dividends paid by Israeli publicly traded companies at the
        rate of 25%, if the shares are registered with a nominee company (as such term is used in the Israeli Securities Law, 5728-1968). If the shares are not registered with a nominee company, the rate of 25% will apply to non-Israeli residents
        shareholders who are not considered Substantial Shareholders, as defined above, and who were not considered Substantial Shareholders at any time during the 12 months preceding the date of the distribution, and the rate of 30% will apply to
        dividends paid to Substantial Shareholders and to persons who were Substantial Shareholders at any time during the 12 months preceding the date of the distribution. Notwithstanding the above, a lower tax rate may be provided under an applicable tax
        treaty between Israel and the shareholder&#8217;s country of residence (subject to the receipt in advance of a valid tax certificate from the Israel Tax Authority allowing for a reduced tax rate). The distribution of dividends to non-Israeli residents
        (either individuals or corporations) from income derived from a company&#8217;s Approved Enterprises or Benefiting Enterprises during the applicable benefits period or from Preferred Enterprises is subject to withholding tax at a rate of 20%, unless a
        lower tax rate is provided under an applicable tax treaty (subject to the receipt in advance of a valid tax certificate from the Israel Tax Authority allowing for a 20% withholding tax rate or a lower tax rate, provided by an applicable tax
        treaty).</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">A non-resident of Israel who has received dividend income derived from or accrued in Israel, from which the full amount of tax was withheld, is generally exempt from the duty to file tax returns in
        Israel with respect to such income, provided that: (i) such income was not derived from a business conducted in Israel by the taxpayer; and (ii) the taxpayer has no other taxable sources of income in Israel with respect to which a tax return is
        required to be filed; and (iii) the taxpayer is not liable for Excess Tax (as described below).</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25;">Residents of the United States generally will have withholding tax in Israel deducted at source. They may be entitled to a credit or deduction for U.S. federal income tax purposes for all or part of the amount of the
        taxes withheld, subject to detailed rules contained in U.S. tax legislation, as discussed below under &#8220;<font style="font-style: italic;">Certain Material U.S. Federal Income Tax Considerations to U.S. Holders &#8211; Distributions</font>.&#8221;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Under the U.S.-Israel Tax Treaty, the maximum Israeli withholding tax rate on dividends paid to a holder of our ordinary shares who is a U.S. resident for the purposes of the U.S.-Israel Tax
        Treaty, is generally 25%. The U.S.-Israel Tax Treaty provides that a 15% or a 12.5% Israeli dividend withholding tax will apply to dividends paid to a U.S. corporation owning 10% or more of an Israeli company&#8217;s voting shares during, in general, the
        current and preceding tax year of the Israeli company. The 15% rate applies to dividends distributed from income derived from an Approved Enterprise, or a Benefiting Enterprise, in each case within the applicable period or, from a Preferred
        Enterprise, and the lower 12.5% rate applies to dividends distributed from income derived from other sources. However, these provisions do not apply if the company has certain amounts of passive income. The aforementioned rates under the
        U.S.-Israel Treaty will not apply if the dividend income was derived through a permanent establishment of the U.S. resident in Israel.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;" class="BRPFPageNumber">S - 12</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Excess Tax</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Furthermore, an additional tax liability at the rate of 3% is applicable on the annual taxable income, including, but not limited to, income derived from dividends, interest and capital gains, of
        individuals who are subject to tax in Israel (whether such individual is an Israeli resident or non-Israeli resident) exceeding a certain threshold (NIS 698,280 in 2023), which amount is linked to the Israeli consumer price index.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Estate and Gift Tax</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Israeli law currently does not impose estate or gift taxes.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-weight: bold;">Certain Material U.S. Federal Income Tax Considerations to U.S. Holders</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-style: italic; font-weight: bold;">General</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; text-align: justify;">The following is a summary of certain material U.S. federal income tax considerations generally applicable to the acquisition, ownership and disposition of our ordinary shares by U.S. holders (as
        defined below) that hold our ordinary shares as &#8220;capital assets&#8221; (generally, property held for investment) under the Code. For this purpose, a &#8220;U.S. holder&#8221; is a holder who for U.S. federal income tax purposes is a beneficial owner of ordinary
        shares acquired in this offering and who is: (a) a citizen or individual resident of the United States; (b) a corporation (or other entity taxable as a corporation for U.S. federal income tax purposes) created or organized in or under the laws of
        the United States, any state thereof or the District of Columbia; (c) an estate the income of which is subject to U.S. federal income tax regardless of its source; or (d) a trust that is subject to the primary supervision of a court over its
        administration and one or more U.S. persons control all substantial decisions, or a trust that has validly elected to be treated as a domestic trust under applicable Treasury Regulations. This summary does not address any tax consequences to
        persons other than U.S. holders.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">The statements in this summary are based on the current U.S. federal income tax laws as contained in the Code, Treasury Regulations, and relevant judicial decisions and administrative guidance, all
        as of the date hereof, and such authorities may be replaced, revoked or modified, possibly with retroactive effect, so as to result in U.S. federal income tax consequences different from those discussed below. No ruling has been sought from the
        Internal Revenue Service (the &#8220;IRS&#8221;), with respect to any U.S. federal income tax consequences described below, and there can be no assurance that the IRS or a court will not take a contrary position.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; text-align: justify;">The following summary does not address all aspects of U.S. federal income tax consequences to certain types of U.S. holders that are subject to special treatment, such as banks; insurance
        companies; tax-exempt organizations; financial institutions; broker-dealers; dealers in securities or currencies; corporations that accumulate income to avoid U.S. federal income tax; traders in securities that elect to use the mark-to-market
        method of accounting for their securities; partnerships or other pass-through entities (or arrangements treated as a partnership) for U.S. federal tax purposes; S corporations; regulated investment companies; real estate investment trusts;
        expatriates; persons owning, directly, constructively or by attribution, 10% or more, by voting power or value, of our ordinary shares; persons whose &#8220;functional currency&#8221; is not the U.S. dollar; persons who hold ordinary shares as part of a
        hedging, constructive sale or conversion, straddle, or other risk-reducing transaction; former U.S. citizens or long term residents of the United States; corporations that accumulate income to avoid U.S. federal income tax; persons who hold our
        ordinary shares in connection with a trade or business, permanent establishment or fixed base outside the United States; or persons that received an interest in our ordinary shares through the exercise of an option or otherwise in exchange for
        services.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;" class="BRPFPageNumber">S - 13</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25; text-align: justify;">This summary is a general summary and does not address all aspects of U.S. federal income taxation that may be relevant to particular U.S. holders based on their particular investment or tax
        circumstances.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; text-align: justify;">This summary relates only to U.S. federal income taxes and does not address any other taxes, including but not limited to, state, local, or non-U.S. taxes and does not describe all of the U.S.
        federal income tax consequences that may be relevant, including the special tax accounting rules under Section 451(b) of the Code, the U.S. federal non-income tax considerations, including estate or gift tax considerations, the Medicare
        contribution and the alternative minimum tax.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; text-align: justify;">If a partnership (including an entity or arrangement classified as a partnership for U.S. federal income tax purposes) holds our ordinary shares, the tax treatment of a partner (including a person
        classified as a partner for U.S. federal income tax purposes) will generally depend upon the status of the partner and the activities of the partnership. A partner of a partnership holding our ordinary shares should consult its tax advisors.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">This summary is not a substitute for careful tax planning. Prospective investors are urged to consult their own tax advisors regarding the specific U.S. federal, state, foreign
        and other tax consequences to them, in light of their own particular circumstances, of the purchase, ownership and disposition of our ordinary shares and the effect of potential changes in applicable tax laws.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; font-weight: bold;">Passive Foreign Investment Company Rules</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; text-align: justify;">In general, a corporation organized outside the United States will be classified as a passive foreign investment company, or PFIC, for U.S. federal income tax purposes for any taxable year in
        which, after the application of certain look-through rules with respect to income and assets of its subsidiaries, either:</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="z5cf567d545604e2d9eab0411f9370619" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 3%; vertical-align: middle;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="line-height: 1.25;">&#8226;</div>
            </td>
            <td style="width: 94%; vertical-align: top;">
              <div style="line-height: 1.25; text-align: justify;">at least 75% of its gross income is passive income, or</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: middle;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">&#160;</td>
            <td style="width: 94%; vertical-align: top;">&#160;</td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: middle;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="line-height: 1.25;">&#8226;</div>
            </td>
            <td style="width: 94%; vertical-align: top;">
              <div style="line-height: 1.25; text-align: justify;">at least 50% of the value (determined on the basis of a quarterly weighted average) of its total assets for the taxable year is attributable to assets that produce or are held for the
                production of passive income.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">For this purpose, passive income generally includes, among other things, dividends, interest, royalties and rents (other than royalties and rents derived in the active conduct of a trade or
        business and not derived from a related person). Assets that produce or are held for the production of passive income may include cash (unless held in a non-interest bearing account for short term working capital needs), marketable securities and
        other assets that may produce passive income. The 50% passive asset test described above is generally based on the fair market value of each asset, with the value of goodwill and going concern value determined in large part by reference to the
        market value of our ordinary shares, which may be volatile. Generally, in determining whether a non-U.S. corporation is a PFIC, a proportionate share of the income and assets of each corporation in which it owns, directly or indirectly, at least a
        25% interest (by value) is taken into account. Whether we are a PFIC for any taxable year will depend on the composition of our income and the composition and value of our assets (which, may be determined in large part by reference to the market
        price of the ordinary shares, which is likely to continue to fluctuate) in each year, and because this is a factual determination made annually after the end of each taxable year, there can be no assurance that we will not be considered a PFIC in
        any taxable year.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Based on the composition of our income, and the composition and value of our assets, in 2022, we believe that we were a PFIC for the taxable year ended December 31, 2022. However, the determination
        of whether or not we are a PFIC is a fact-intensive determination made on an annual basis and because the applicable law is subject to varying interpretations we cannot provide any assurance regarding our PFIC status and our U.S. counsel expresses
        no opinion with respect to our PFIC status for any taxable year. In particular, our status as a PFIC in current or any future tax year is uncertain because, among other things, (i) we currently own a substantial amount of passive assets, including
        cash, (ii) we may not receive milestone payments under any of our collaboration agreements, in which case, our income may be exclusively passive and (iii) the valuation of our assets that generate non-passive income for PFIC purposes, including our
        intangible assets, is uncertain and may be determined in substantial part by our market capitalization, which may vary substantially over time. Furthermore, there can be no assurance that the IRS will agree with our conclusion or that the IRS would
        not successfully challenge our position. No ruling from the IRS concerning our status as a PFIC has been obtained or is currently planned to be requested. Accordingly, we cannot provide any assurances regarding our PFIC status for the current or
        future taxable years.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;" class="BRPFPageNumber">S - 14</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25;">If we are classified as a PFIC in any taxable year during a U.S. holder&#8217;s holding period of our ordinary shares, such U.S. holder could be liable for additional taxes and interest charges upon (1)
        a distribution paid during a taxable year that is greater than 125% of the average annual distributions paid in the three preceding taxable years, or, if shorter, the U.S. holder&#8217;s holding period for the ordinary shares, and (2) any gain recognized
        on a sale, exchange or other taxable disposition, including a pledge, of the ordinary shares, whether or not we continue to be a PFIC. In these circumstances, the tax will be determined by allocating such distribution or gain ratably over the U.S.
        holder&#8217;s holding period for the ordinary shares. The amount allocated to the current taxable year (i.e., the year in which the distribution occurs, or the gain is recognized) and any year prior to the first taxable year in which we are a PFIC will
        be taxed as ordinary income earned in the current taxable year. The amount allocated to other taxable years will be taxed at the highest marginal rates in effect for individuals or corporations, as applicable, to ordinary income for each such
        taxable year, and an interest charge, generally applicable to underpayments of tax, will be added to the tax. In addition, non-corporate U.S. Holders will not be eligible for reduced rates of taxation on any dividends received from us, if we are a
        PFIC in the taxable year in which such dividends are paid or in the preceding taxable year.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">If we are a PFIC for any year during which a U.S. holder holds the ordinary shares, we must generally continue to be treated as a PFIC by that holder for all succeeding years during which the U.S.
        holder holds the ordinary shares, unless we cease to meet the requirements for PFIC status and the U.S. holder makes a &#8220;deemed sale&#8221; election with respect to the ordinary shares. If such election is made, the U.S. holder will be deemed to have sold
        the ordinary shares it holds at their fair market value on the last day of the last taxable year in which we qualified as a PFIC, and any gain from such deemed sale would be subject to the consequences described above. After the deemed sale
        election, the U.S. holder&#8217;s ordinary shares with respect to which the deemed sale election was made will not be treated as shares in a PFIC unless we subsequently again become a PFIC.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">If a U.S. holder has made a qualified electing fund (&#8220;QEF&#8221;) election covering all taxable years during which the holder holds ordinary shares and in which we are a PFIC, distributions and gains
        will not be taxed as described above. Instead, a U.S. holder that makes a QEF election is required for each taxable year to include in income (i) the holder&#8217;s pro rata share of the PFIC&#8217;s ordinary earnings as ordinary income or (ii) the holder&#8217;s
        pro rata share of the QEF net capital gain as capital gain, regardless of whether such earnings or gain have in fact been distributed, for each taxable year that the entity is classified as a PFIC. If a U.S. holder makes a QEF election with respect
        to us, any distributions paid by us out of our earnings and profits that were previously included in the U.S. holder&#8217;s income under the QEF election would not be taxable to the holder. A U.S. holder will increase its tax basis in its ordinary
        shares by an amount equal to any income included under the QEF election and will decrease its tax basis by any amount distributed on the ordinary shares that is not included in the holder&#8217;s income. If a U.S. holder has made a QEF election with
        respect to its ordinary shares, any gain or loss recognized by the U.S. holder on a sale or other disposition of such ordinary shares will constitute capital gain or loss. In addition, if a U.S. holder makes a timely QEF election, our ordinary
        shares will not be considered shares in a PFIC in years in which we are not a PFIC, even if the U.S. holder had held ordinary shares in prior years in which we were a PFIC.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">U.S. holders should consult their tax advisors regarding making QEF elections in their particular circumstances. If a U.S. holder does not make and maintain a QEF election for the U.S. holder&#8217;s
        entire holding period for our ordinary shares by making the election for the first year in which the U.S. holder owns our ordinary shares, the U.S. holder will be subject to the adverse PFIC rules discussed above unless the U.S. holder can properly
        make a &#8220;purging election&#8221; with respect to our ordinary shares in connection with the U.S. holder&#8217;s QEF election. A purging election may require the U.S. holder to recognize taxable gain on the U.S. holder&#8217;s ordinary shares.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;" class="BRPFPageNumber">S - 15</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25;">In order to comply with the requirements of a QEF election, a U.S. holder must receive certain information from us. The QEF election is made on a shareholder-by-shareholder basis and can be revoked
        only with the consent of the IRS. A shareholder makes a QEF election by attaching a completed IRS Form 8621, including the information provided in the PFIC annual information statement, to a timely filed U.S. federal income tax return and by filing
        a copy of the form with the IRS. We may provide the information necessary for U.S. holders to make QEF elections if we were treated as a PFIC for any taxable year, although, there is no assurance that we will do so. There is no assurance that we
        will have timely knowledge of our status as a PFIC in the future. Accordingly, U.S. holders may be unable to make a timely QEF election with respect to our ordinary shares.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">U.S. holders should consult their tax advisors to determine whether any of these above elections would be available and if so, what the consequences of the alternative treatments would be in their
        particular circumstances.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">The tax consequences that would apply if we are a PFIC would also be different from those described above if a timely and valid &#8220;mark-to-market&#8221; election is made by a U.S. holder for the ordinary
        shares held by such U.S. holder. An electing U.S. holder would generally take into account as ordinary income or loss each year an amount equal to the difference between the U.S. holder&#8217;s adjusted tax basis in such ordinary shares and their fair
        market value; however, losses would be allowed only to the extent of the excess of amounts previously included in income over ordinary losses deducted in prior years as a result of the mark-to-market election. Any gain from a sale, exchange or
        other taxable disposition of the ordinary shares in any taxable year in which we are a PFIC would be treated as ordinary income and any loss from such sale, exchange or other taxable disposition would be treated first as ordinary loss (to the
        extent of any net mark-to-market gains previously included in income) and thereafter as capital loss. The adjusted tax basis of a U.S. holder&#8217;s ordinary shares is increased by the amount included in gross income under the mark-to-market regime, or
        is decreased by the amount of the deduction allowed under the regime. If a U.S. holder makes a mark-to-market election it will be effective for the taxable year for which the election is made and all subsequent taxable years unless the shares are
        no longer regularly traded on a qualified exchange or the IRS consents to the revocation of the election.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">A mark-to-market election is available to a U.S. holder only for &#8220;marketable stock.&#8221; Generally, stock will be considered marketable stock if it is &#8220;regularly traded&#8221; on a &#8220;qualified exchange&#8221;
        within the meaning of applicable Treasury Regulations. A class of stock is regularly traded during any calendar year during which such class of stock is traded, other than in <font style="font-style: italic;">de minimis</font> quantities, on at
        least 15 days during each calendar quarter. The ordinary shares will be marketable stock as long as they remain listed on a qualified exchange, such as Nasdaq, and are regularly traded. However, we can provide no assurances that our ordinary shares
        will continue to be listed on a qualified exchange or will be regularly traded. A mark-to-market election will not apply to the ordinary shares for any taxable year during which we are not a PFIC but will remain in effect with respect to any
        subsequent taxable year in which we become a PFIC. U.S. holders are urged to consult their tax advisor about the availability of the mark-to-market election, and whether making the election would be advisable in such holder&#8217;s particular
        circumstances.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">If we are a PFIC and, at any time, have a non-U.S. subsidiary that is classified as a PFIC (a &#8220;lower-tier&#8221; PFIC), U.S. holders of our ordinary shares generally would be deemed to own, and also
        would be subject to the PFIC rules with respect to, their indirect ownership interests in that lower-tier PFIC. If we are a PFIC and a U.S. holder of our ordinary shares does not make a QEF election in respect of a lower-tier PFIC, the U.S. holder
        could incur liability for the deferred tax and interest charge described above if either (1) we receive a distribution from, or dispose of all or part of our interest in, the lower-tier PFIC or (2) the U.S. holder disposes of all or part of its
        ordinary shares. We may provide the information necessary for U.S. holders to make QEF elections with respect to any lower-tier PFIC, although there is no assurance that we will do so. A mark-to-market election under the PFIC rules with respect to
        our ordinary shares would not apply to a lower-tier PFIC, and a U.S. holder would not be able to make such a mark-to-market election in respect of its indirect ownership interest in that lower-tier PFIC. Consequently, U.S. holders of our ordinary
        shares could be subject to the PFIC rules with respect to income of the lower-tier PFIC the value of which already had been taken into account indirectly via mark-to-market adjustments. U.S. holders are urged to consult their own tax advisors
        regarding the issues raised by lower-tier PFICs.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;" class="BRPFPageNumber">S - 16</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: justify; line-height: 1.25;">Each U.S. holder who is a shareholder of a PFIC must file an annual information report on IRS Form 8621 containing such information as the U.S. Treasury Department may require. The failure to file
        IRS Form 8621 could result in the imposition of penalties and the extension of the statute of limitations with respect to U.S. federal income tax.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-weight: bold;">THE RULES DEALING WITH PFICS AND WITH THE QEF AND MARK-TO-MARKET ELECTIONS ARE VERY COMPLEX AND ARE AFFECTED BY VARIOUS FACTORS IN ADDITION TO THOSE DESCRIBED ABOVE, INCLUDING
        OUR OWNERSHIP OF ANY NON-U.S. SUBSIDIARIES. AS A RESULT, U.S. HOLDERS OF ORDINARY SHARES ARE STRONGLY ENCOURAGED TO CONSULT THEIR TAX ADVISORS ABOUT THE PFIC RULES IN CONNECTION WITH THEIR PURCHASING, HOLDING OR DISPOSING OF ORDINARY SHARES.</div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
        <div style="text-align: justify; line-height: 1.25;"><font style="font-weight: bold; font-style: italic;">U.S. Federal Income Tax Consequences If We Are Not a PFIC</font>.</div>
      </div>
      <div style="line-height: 1.25;">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="line-height: 1.25;">
        <div style="text-align: justify; line-height: 1.25;">The description of the U.S. federal income tax consequences of the receipt of distributions and the sale or other taxable exchange of our ordinary shares, described in the following two sections
          &#8220;- <font style="font-style: italic;">Distributions</font>&#8221; and &#8220;<font style="font-style: italic;">- Disposition of Ordinary Shares</font>,&#8221; apply only if we are not a PFIC in the relevant year and our ordinary shares are not subject to the rules
          described above under &#8220;-<font style="font-style: italic;">Passive Foreign Investment Company Rules</font>&#8221; because we were a PFIC with respect to a U.S. holder and its ordinary shares in a prior year.</div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Distributions</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Subject to the discussion under &#8220;<font style="font-style: italic;">- Passive Foreign Investment Company Rules</font>&#8221; above, the gross amount of any distributions with respect to our ordinary
        shares (including any amounts withheld to reflect Israeli withholding taxes) will be taxable as dividends, to the extent paid out of our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Such
        income (including any withheld taxes) will be includable in a U.S. holder&#8217;s gross income as ordinary income on the day actually or constructively received. Distributions in excess of earnings and profits will be non-taxable to the U.S. holder to
        the extent of, and will be applied against and reduce (but not below zero), the U.S. holder&#8217;s adjusted tax basis in the ordinary shares. Distributions in excess of earnings and profits and such adjusted tax basis will generally be taxable to the
        U.S. holder as described below under &#8220;<font style="font-style: italic;">- Disposition of Ordinary Shares</font>.&#8221; However, since we do not calculate our earnings and profits under U.S. federal income tax principles, it is expected that any
        distribution will be reported as a dividend, even if that distribution would otherwise be treated as a non-taxable return of capital or as capital gain under the rules described above. The amount of any dividend paid by us will be treated as
        foreign-source dividend income to U.S. holders, and the dividends received deduction will not be available to a U.S. holder that is taxed as a corporation as a result.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">With respect to non-corporate U.S. holders, certain dividends received from a &#8220;qualified foreign corporation&#8221; that is not a PFIC may be subject to reduced rates of taxation. A qualified foreign
        corporation includes a foreign corporation that is eligible for the benefits of a comprehensive income tax treaty with the United States which the United States Treasury Department determines to be satisfactory for these purposes and which includes
        an exchange of information provision. The United States Treasury Department has determined that the US-Israel Tax Treaty meets these requirements. A foreign corporation is also treated as a qualified foreign corporation with respect to dividends
        paid by that corporation on shares that are readily tradable on an established securities market in the United States. As discussed under &#8220;- <font style="font-style: italic;">Passive Foreign Investment Company Rules</font>&#8221; above, there can be no
        assurance that our ordinary shares will be considered readily tradable on an established securities market in any year. If we are a qualified foreign corporation, and we are not classified as a PFIC for the taxable year in which a dividend is paid
        or in the preceding taxable year (as discussed above under &#8220;<font style="font-style: italic;">- Passive Foreign Investment Company Rules</font>&#8221;), dividend income will generally qualify as &#8220;qualified dividend income&#8221; in the hands of individual U.S.
        holders, which is generally taxed at the lower applicable long term capital gains rates, provided certain holding period and other requirements for treatment of such dividends as &#8220;qualified dividend income&#8221; are satisfied. U.S. holders should
        consult their own tax advisors regarding the availability of the lower rate for dividends paid with respect to our ordinary shares.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;" class="BRPFPageNumber">S - 17</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25; text-align: justify;">Although, to the extent we pay dividends in the future, we intend to pay dividends to U.S. holders in U.S. dollars, the amount of any dividend paid in Israeli currency will equal its U.S. dollar
        value for U.S. federal income tax purposes, calculated by reference to the exchange rate in effect on the date the dividend is received by the U.S. holder, regardless of whether the Israeli currency is converted into U.S. dollars. If the Israeli
        currency received as a dividend are converted into United States dollars on the date they are received, the U.S. holder generally will not be required to recognize foreign currency gain or loss in respect of the dividend income. If the Israeli
        currency is not converted into U.S. dollars on the date of receipt, the U.S. holder will have a basis in the Israeli currency equal to its U.S. dollar value on the date of receipt. Any subsequent gain or loss upon the conversion or other
        disposition of the Israeli currency will be treated as ordinary income or loss, and generally will, for U.S. federal income tax purposes, be treated as income or loss from U.S. sources.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Certain U.S. holders generally may be eligible, subject to a number of complex limitations, to claim Israeli taxes withheld from distributions and paid over to the Israeli taxing authorities either
        as a deduction from gross income or as a credit against U.S. federal income tax liability. To the extent a refund of the tax withheld is available to a U.S. holder under Israeli law or under the Treaty, the amount of tax withheld that is refundable
        will not be eligible for credit against a U.S. holder&#8217;s United States federal income tax liability. The foreign tax credit is subject to numerous complex limitations that must be determined and applied on an individual basis. U.S. holders should
        consult their own tax advisors regarding the foreign tax credit rules.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Disposition of Ordinary Shares</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">In general, subject to the discussion under &#8220;- <font style="font-style: italic;">Passive Foreign Investment Company Rules</font>&#8221;, above, a U.S. holder will recognize U.S.-source capital gain or
        loss upon a taxable disposition of an ordinary share equal to the difference between the sum of the fair market value of any property and the amount of cash received in such disposition (including the amount of any foreign taxes withheld therefrom)
        and the U.S. holder&#8217;s adjusted tax basis in such share. A U.S. holder&#8217;s adjusted tax basis generally will equal the U.S. holder&#8217;s acquisition cost less any distributions treated as a return of capital as described under &#8220;- <font style="font-style: italic;">Distributions</font>&#8221; above. Such capital gain or loss will be long-term capital gain or loss if a U.S. holder&#8217;s holding period in the ordinary share is more than one year at the time of the taxable disposition. Under current law,
        subject to certain exceptions (including but not limited to those described under &#8220;<font style="font-style: italic;">- Passive Foreign Investment Company Rules</font> &#8221; above), long-term capital gain realized by a non-corporate U.S. holder
        generally will be eligible for reduced rates of tax. The deduction of capital losses may be subject to limitation. Because gain from the sale or other taxable disposition of an ordinary share will generally be treated as U.S.-source income and,
        subject to certain exceptions, Treasury Regulations generally preclude U.S. taxpayers from claiming a foreign tax credit with respect to any non-U.S. tax imposed on gains from dispositions of shares held as capital assets unless the tax is
        creditable under an applicable income tax treaty, your ability to claim a foreign tax credit with respect to Israeli tax imposed on any such sale or other taxable disposition, if any, may be significantly limited. U.S. holders should consult their
        own tax advisors regarding the foreign tax credit rules with respect to any foreign taxes withheld from a taxable disposition of ordinary shares, as well as regarding any foreign currency gain or loss in connection with such a disposition.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-style: italic; font-weight: bold;">Backup Withholding and Information Reporting</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">In general, information reporting will apply to dividends in respect of our ordinary shares and the proceeds from the sale or exchange of our ordinary shares that are paid to a U.S. holder within
        the United States (and in certain cases, outside the United States), unless such holder is an exempt recipient. A backup withholding tax generally applies to such payments if the U.S. holder fails to provide a taxpayer identification number and a
        duly executed IRS Form W-9 or certification of other exempt status unless the U.S. holder otherwise establishes that it is exempt from such rules.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Any amounts withheld under the backup withholding rules will be allowed as a refund or a credit against a U.S. holder&#8217;s U.S. federal income tax liability provided the required information is
        furnished to the IRS in a timely manner.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Individuals who own &#8220;specified foreign financial assets&#8221; with an aggregate value in excess of $50,000 may be required to file an information report on IRS Form 8938, &#8220;Statement of Specified Foreign
        Financial Assets,&#8221; with respect to such assets with their tax returns. &#8220;Specified foreign financial assets&#8221; include any financial accounts maintained by foreign financial institutions, as well as any of the following, but only if they are not held
        in accounts maintained by financial institutions: (i) stocks and securities issued by non-U.S. persons; (ii) financial instruments and contracts held for investment that have non-U.S. issuers or counterparties; and (iii) interests in foreign
        entities. U.S. holders that are individuals are urged to consult their tax advisors regarding the application of these rules to their ownership of our ordinary shares.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;" class="BRPFPageNumber">S - 18</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="PLANOFDISTRIBUTION1"><!--Anchor--></a>PLAN OF DISTRIBUTION</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">We have entered into the sales agreement with SVB Securities, under which we may issue and sell our ordinary shares from time to time through SVB
        Securities as our sales agent. Pursuant to this prospectus supplement and accompanying prospectus, we may sell ordinary shares having an aggregate gross sales price of up to $50 million. Sales of our ordinary shares, if any, will be made by any
        method that is deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) under the Securities Act, including sales made directly on or through the Nasdaq Global Market, on or through any other existing trading market for the ordinary
        shares.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">SVB Securities will offer our ordinary shares subject to the terms and conditions of the sales agreement on a daily basis or as otherwise agreed upon by
        us and SVB Securities. We will designate the maximum number or amount of ordinary shares to be sold through SVB Securities on a daily basis or otherwise determine such maximum number or amount together with SVB Securities. Subject to the terms and
        conditions of the sales agreement, SVB Securities will use commercially reasonable efforts consistent with its normal trading and sales practices to sell on our behalf all of the ordinary shares requested to be sold by us. We may instruct SVB
        Securities not to sell ordinary shares if the sales cannot be effected at or above a minimum price designated by us in any such instruction. SVB Securities or we may suspend the offering of our ordinary shares being made through SVB Securities
        under the sales agreement upon proper notice to the other party. SVB Securities and we each have the right, by giving written notice as specified in the sales agreement, to terminate the sales agreement in each party&#8217;s sole discretion at any time.
        The offering of our ordinary shares pursuant to the sales agreement will otherwise terminate upon the termination of the sales agreement as provided therein.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">The compensation payable to SVB Securities as sales agent will be an amount equal to 3.0% of the gross proceeds of any ordinary shares sold through it
        pursuant to the sales agreement. We have also agreed to reimburse SVB Securities up to $75,000 for its actual outside legal expenses incurred in connection with the filing of this prospectus supplement and to pay SVB Securities up to $25,000
        periodically thereafter for its legal expenses incurred in connection with its ongoing due diligence for this offering. In accordance with Financial Industry Regulatory Authority, Inc. (&#8220;FINRA&#8221;) Rule 5110, these reimbursed fees and expenses are
        deemed sales compensation to SVB Securities in connection with this offering. We estimate that the total expenses of the offering payable by us, excluding commissions payable to SVB Securities under the sales agreement, will be approximately
        $265,000.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">The remaining sales proceeds, after deducting any expenses payable by us and any transaction fees imposed by any governmental, regulatory or
        self-regulatory organization in connection with the sales of our ordinary shares, will equal our net proceeds for the sale of such ordinary shares. SVB Securities will provide written confirmation to us no later than the next succeeding trading day
        on The Nasdaq Global Market after each day on which ordinary shares are sold through it as sales agent under the sales agreement. Each confirmation will include the number or amount of shares sold through it as sales agent on that day, the
        volume-weighted average price of the shares sold, and the net proceeds to us from such sales.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">We will report at least quarterly the number of ordinary shares sold through SVB Securities under the sales agreement, the net proceeds to us and the
        compensation paid by us to SVB Securities in connection with the sales of ordinary shares during the relevant period. Settlement for sales of ordinary shares will occur, unless the parties agree otherwise, on the second trading day following the
        date on which any sales were made in return for payment of the net proceeds to us. There is no arrangement for funds to be received in an escrow, trust or similar arrangement.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">In connection with the sale of the ordinary shares on our behalf pursuant to the sales agreement, SVB Securities will be deemed to be an &#8220;underwriter&#8221;
        within the meaning of the securities act and the compensation paid to SVB Securities will be deemed to be underwriting commissions or discounts. We have agreed in the sales agreement to provide indemnification and contribution to SVB Securities
        with respect to certain liabilities, including liabilities under the Securities Act or the Exchange Act. As sales agent, SVB Securities will not engage in any transactions that stabilize our ordinary shares.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Our ordinary shares are listed on the Nasdaq Global Market and the TASE and trade under the symbol &#8220;CGEN.&#8221; The transfer agent for our ordinary shares is
        American Stock Transfer &amp; Trust Company, LLC. SVB Securities' address is 1301 Avenue of the Americas, 12<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> Floor, New York, New York, 10019.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: justify; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">SVB Securities and/or its affiliates have provided, and may in the future provide, various investment banking and other financial services for us for
        which services they have received, and may in the future receive, customary fees.</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;" class="BRPFPageNumber">S - 19</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="LEGALMATTERS1"><!--Anchor--></a>LEGAL MATTERS</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Certain legal matters of U.S. securities law relating to this offering will be passed upon for us by Cooley LLP, New York, New York. The validity of the ordinary shares and certain other legal
        matters as to Israeli law will be passed upon for us by Shibolet &amp; Co., Law Firm, Tel Aviv, Israel. SVB Securities LLC is being represented in connection with this offering by Covington &amp; Burling LLP, New York, New York, with respect to
        U.S. federal law, and Gornitzky &amp; Co., Tel Aviv, Israel, with respect to Israeli law.</div>
      <div style="text-align: justify; line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="EXPERTS1"><!--Anchor--></a>EXPERTS</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">The consolidated financial statements of Compugen Ltd. appearing in the Annual Report on Form 20-F as amended for the year ended December 31, 2021 and the effectiveness of Compugen Ltd. internal
        control over financial reporting as of December 31, 2021, as filed with the SEC on February 28, 2022 (and as amended on February 28, 2022), have been audited by Kost Forer Gabbay &amp; Kasierer, a Member of Ernst &amp; Young Global, independent
        registered public accounting firm, as set forth in their report thereon, included therein, and incorporated herein by reference. Such consolidated financial statements and the assessment of the effectiveness of internal control over financial
        reporting as of the respective dates are incorporated herein by reference in reliance upon such reports given on the authority of such firm as experts in accounting and auditing.&#160;The address of Kost Forer Gabbay &amp; Kasierer is 144 Menachem Begin
        Road, Building A, Tel-Aviv, Israel 6492102.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="EXPENSES1"><!--Anchor--></a>EXPENSES</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; text-align: justify;">The following table sets forth the expenses of this offering payable by us, excluding commissions and reimbursement of expenses, in connection with the offering of our ordinary shares registered
        under the registration statement of which this prospectus forms&#160;a parts. All amounts are estimated except for the FINRA filing fee.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" border="0" align="center" style="width: 90%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;" id="z870ced0e937f4331b51cad2067f10970" class="cfttable">

          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 88%; background-color: rgb(204, 238, 255);">
              <div style="line-height: 1.25;">FINRA filing fee</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftcurrcell">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">53,000</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 88%;">
              <div style="line-height: 1.25;">Printer fees and expenses</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">3,000</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 88%;">
              <div style="line-height: 1.25;">Legal fees and expenses</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">155,000</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 88%;">
              <div style="line-height: 1.25;">Accounting fees and expenses</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">50,000</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 88%; padding-bottom: 2px;">
              <div style="line-height: 1.25;">Miscellaneous</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1" class="cftcurrcell">&#160;</td>
            <td valign="bottom" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">4,000</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>
          <tr>
            <td valign="bottom" style="vertical-align: bottom; width: 88%; padding-bottom: 4px;">
              <div style="line-height: 1.25;">Total</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftguttercell">&#160;</td>
            <td valign="bottom" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftcurrcell">
              <div style="line-height: 1.25;">$</div>
            </td>
            <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1" class="cftnumcell">
              <div style="line-height: 1.25;">265,000</div>
            </td>
            <td valign="bottom" nowrap="nowrap" style="vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1" class="cftfncell">&#160;</td>
          </tr>

      </table>
      <div style="text-align: center; line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;" class="BRPFPageNumber">S - 20</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="WHERE1"><!--Anchor--></a>WHERE YOU CAN FIND MORE INFORMATION</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">We have filed with the SEC a registration statement on Form F-3 under the Securities Act with respect to the securities offered by this prospectus supplement and the accompanying prospectus. This
        prospectus supplement and the accompanying prospectus do not contain all the information contained in the registration statement, including its exhibits and schedules. You should refer to the registration statement, including its exhibits and
        schedules, for additional information. Whenever we make reference in this prospectus to any of our contracts, agreements or other documents, the references are not necessarily complete and you should refer to the exhibits attached to the
        registration statement for copies of the actual contract, agreement or other document.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">We are subject to the informational requirements of the Exchange Act applicable to foreign private issuers. We, as a &#8220;foreign private issuer,&#8221; are exempt from the rules under the Exchange Act
        prescribing certain disclosure and procedural requirements for proxy solicitations, and our officers, directors and principal shareholders are exempt from the reporting and &#8220;short-swing&#8221; profit recovery provisions contained in Section 16 of the
        Exchange Act, with respect to their purchases and sales of ordinary shares. In addition, we are not required to file annual, quarterly and current reports and financial statements with the SEC as frequently or as promptly as other companies not
        deemed to be a &#8220;foreign private issuer&#8221; whose securities are registered under the Exchange Act.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">You can review the registration statement, including the related exhibits and schedules, as well as any document we file or furnish with the SEC without charge by accessing the SEC&#8217;s website at <font style="font-style: italic;">www.sec.gov</font>.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">We also maintain a website at <font style="font-style: italic;">www.cgen.com</font>, through which you can access certain SEC filings. The information on, or accessible through, our website is not
        incorporated by reference into this prospectus supplement, is not considered a part of this prospectus supplement and should not be relied upon with respect to this offering.</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-family: 'Times New Roman',Times,serif; font-weight: normal; font-style: normal;" class="BRPFPageNumber">S - 21</font></div>
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="INCORPORATION1"><!--Anchor--></a>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">The SEC allows us to &#8220;incorporate by reference&#8221; into this prospectus supplement and the accompanying prospectus the information we file with it, which means that we can disclose important
        information to you by referring you to those documents. Each document incorporated by reference is current only as of the date of such document, and the incorporation by reference of such documents shall not create any implication that there has
        been no change in our affairs since the date thereof or that the information contained therein is current as of any time subsequent to its date. The information incorporated by reference is considered to be part of this prospectus supplement and
        information we file later with the SEC will automatically update and supersede this information. The documents we are incorporating by reference as of their respective dates of filing are:</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="z5f0ce895a1d04a5584a188d077623e2d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 3%; vertical-align: middle;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">&#8226;</div>
            </td>
            <td style="width: 94%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">our Annual Report on <a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891322000846/0001178913-22-000846-index.htm">Form 20-F</a> for the year ended December 31, 2021, filed
                on February 28, 2022, as amended by Amendment No. 1 on <a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891322000863/0001178913-22-000863-index.htm">Form 20-F/A</a> filed on February 28, 2022;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: middle;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">&#8226;</div>
            </td>
            <td style="width: 94%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">our Reports on Form 6-K filed on <a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891322000785/0001178913-22-000785-index.htm">February 24, 2022</a>, <a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891322001844/0001178913-22-001844-index.htm">May 10, 2022</a>, <a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891322001975/0001178913-22-001975-index.htm">May
                  16, 2022</a>, <a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891322002918/0001178913-22-002918-index.htm">August 4, 2022</a>, <a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891322002921/zk2228247.htm">August


                  4, 2022</a>, <a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891322002923/zk2228249.htm">August 4, 2022</a>, <a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891322002923/zk2228249.htm">August 4, 2022</a>, <a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891322003385/0001178913-22-003385-index.htm">September 12, 2022</a>, <a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891322003433/zk2228477.htm">September 15,
                  2022</a>, <a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891322003493/0001178913-22-003493-index.htm"> September 22, 2022</a>, <a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891322003789/0001178913-22-003789-index.htm">November 2, 2022</a>, <a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891322003836/0001178913-22-003836-index.htm">November


                  7, 2022</a>, <a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891322003975/0001178913-22-003975-index.htm">November 14, 2022</a>, <a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891322004056/0001178913-22-004056-index.htm">November 16, 2022</a>, <a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891322004216/0001178913-22-004216-index.htm">December


                  1, 2022</a>, <a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891322004226/zk2228843.htm">December 2, 2022</a> and <a href="https://www.sec.gov/Archives/edgar/data/1119774/000117891322004276/0001178913-22-004276-index.htm">December


                  6, 2022</a>; and</div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: middle;">&#160;</td>
            <td style="width: 3%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">&#8226;</div>
            </td>
            <td style="width: 94%; vertical-align: top;">
              <div style="text-align: justify; line-height: 1.25;">the description of our ordinary shares contained in our Form 8-A filed on August 2, 2000 (File No. 000-30902), including any amendments or reports filed for the purpose of updating the
                description.</div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">All subsequent annual reports on Form 20-F and all subsequent reports on Form 6-K filed by us, that are identified by us as being incorporated by reference into the registration statement of which
        this prospectus forms a part, shall be deemed to be incorporated by reference into this prospectus supplement and deemed to be a part hereof after the date of this prospectus supplement but before the termination of the offering under this
        prospectus supplement. Unless expressly incorporated by reference, nothing in this prospectus supplement and the accompanying prospectus shall be deemed to incorporate by reference information furnished to, but not filed with, the SEC.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">Any statement contained in a document incorporated by reference herein shall be deemed to be modified or superseded for all purposes to the extent that a statement contained in this prospectus
        supplement, or in any other subsequently filed document which is also incorporated or deemed to be incorporated by reference, modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified
        or superseded, to constitute a part of this prospectus supplement.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="line-height: 1.25; text-align: justify;">You can obtain any of the filings incorporated by reference in this prospectus through us or from the SEC through the SEC&#8217;s website at&#160;<font style="font-style: italic;">www.sec.gov</font>. Our
        filings with the SEC, including our annual reports on Form 20-F and reports on Form 6-K and exhibits incorporated in and amendments to those reports, are also available free of charge on our website (<font style="font-style: italic;">www.cgen.com</font>)
        as soon as reasonably practicable after they are filed with, or furnished to, the SEC. The reference to our website is an inactive textual reference only, and information contained therein or connected thereto is not incorporated into this
        prospectus or the registration statement of which it forms a part.&#160;A copy of this prospectus supplement and the accompanying prospectus are available on the Israel Securities Authority&#8217;s magna website, <font style="font-style: italic;">www.magna.isa.gov.il</font>.
        You may request, orally or in writing, a copy of these documents,&#160;including a copy of the information incorporated by reference into this prospectus supplement and accompanying prospectus, which will be provided to you at no cost, by contacting:</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Eran Ben Dor<br>
        General Counsel<br>
        Compugen Ltd.<br>
        26 Harokmim Street<br>
        Holon 5885849, Israel<br>
        Phone: +972-3-765-8585<br>
        Fax: +972-3-765-8555<br>
        <div><br>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageNumberArea"><font style="font-weight: normal; font-style: normal;" class="BRPFPageNumber">S - 22</font></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin-top: 4px; margin-bottom: 4px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"></div>
        </div>
      </div>
      <div style="line-height: 1.25;">
        <div>
          <div style="line-height: 1.25; font-weight: bold;">PROSPECTUS</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: center; line-height: 1.25;"><img width="238" height="75" src="image0.jpg"></div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: center; margin-right: 0.2pt; line-height: 1.25; font-weight: bold;">$350,000,000<br>
            Ordinary Shares<br>
            Debt Securities<br>
            Rights<br>
            Warrants<br>
            Units</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">We may offer and sell from time to time in one or more offerings our ordinary shares, debt securities, rights, warrants and units comprising any combination of these securities having an
            aggregate offering price up to $350,000,000.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">Each time we sell securities pursuant to this prospectus, we will provide in a supplement to this prospectus the price and any other material terms of any such offering and the securities
            offered. Any prospectus supplement may also add, update or change information contained in the prospectus. You should read this prospectus and any applicable prospectus supplement, as well as the documents incorporated by reference or deemed
            incorporated by reference into this prospectus, carefully before you invest in any securities.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">Our ordinary shares are traded on The Nasdaq Global Market and on the Tel Aviv Stock Exchange under the symbol &#8220;CGEN.&#8221; The closing sale price of our ordinary shares on The Nasdaq Global Market
            and on the Tel Aviv Stock Exchange on July 27, 2020, was $14.82 and $14.43 per share, respectively. The currency in which our stock is traded on the Tel Aviv Stock Exchange is the New Israeli Shekel, or NIS. The above closing price on the Tel
            Aviv Stock Exchange represents a conversion from NIS to dollar amounts in accordance with the dollar - NIS conversion rate as of July 27, 2020, as reported by the Bank of Israel.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25; font-weight: bold;">An investment in our securities involves a high degree of risk. See the section entitled &#8220;Risk Factors&#8221; on page 2 of this prospectus and under similar headings in any amendment
            or supplement to this prospectus or in any filing with the Securities and Exchange Commission that is incorporated by reference herein.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25; font-weight: bold;">Neither the Securities and Exchange Commission nor any state or other securities commission has approved or disapproved of these securities or determined if this prospectus is
            truthful or complete. Any representation to the contrary is a criminal offense.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">This prospectus may not be used to consummate sales of securities unless it is accompanied by a prospectus supplement.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: center; margin-right: 36pt; line-height: 1.25;">The date of this prospectus is&#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160; &#160;&#160; , 2020</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">TABLE OF CONTENTS</div>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z98769d749a99422384371f20ce97719d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 93.99%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;"><a href="#ABOUTTHISPROSPECTUS">ABOUT THIS PROSPECTUS</a></div>
                </td>
                <td style="width: 6.01%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">i</div>
                </td>
              </tr>
              <tr>
                <td style="width: 93.99%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;"><a href="#PROSPECTUSSUMMARY">PROSPECTUS SUMMARY</a></div>
                </td>
                <td style="width: 6.01%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">1</div>
                </td>
              </tr>
              <tr>
                <td style="width: 93.99%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;"><a href="#RISKFACTORS">RISK FACTORS</a></div>
                </td>
                <td style="width: 6.01%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">2</div>
                </td>
              </tr>
              <tr>
                <td style="width: 93.99%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;"><a href="#NOTEREGARDINGFORWARD-LOOK">NOTE REGARDING FORWARD-LOOKING STATEMENTS</a></div>
                </td>
                <td style="width: 6.01%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">3</div>
                </td>
              </tr>
              <tr>
                <td style="width: 93.99%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;"><a href="#OFFERSTATISTICSANDEXPECTE">OFFER STATISTICS AND EXPECTED TIMETABLE</a></div>
                </td>
                <td style="width: 6.01%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">4</div>
                </td>
              </tr>
              <tr>
                <td style="width: 93.99%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;"><a href="#CAPITALIZATION">CAPITALIZATION</a></div>
                </td>
                <td style="width: 6.01%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">5</div>
                </td>
              </tr>
              <tr>
                <td style="width: 93.99%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;"><a href="#REASONSFORTHEOFFERANDUSEO">REASONS FOR THE OFFER AND USE OF PROCEEDS</a></div>
                </td>
                <td style="width: 6.01%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">6</div>
                </td>
              </tr>
              <tr>
                <td style="width: 93.99%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;"><a href="#DESCRIPTIONOFSECURITIES">DESCRIPTION OF SECURITIES</a></div>
                </td>
                <td style="width: 6.01%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">7</div>
                </td>
              </tr>
              <tr>
                <td style="width: 93.99%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;"><a href="#DESCRIPTIONOFORDINARYSHAR">DESCRIPTION OF ORDINARY SHARES</a></div>
                </td>
                <td style="width: 6.01%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">8</div>
                </td>
              </tr>
              <tr>
                <td style="width: 93.99%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;"><a href="#DESCRIPTIONOFDEBTSECURITI">DESCRIPTION OF DEBT SECURITIES</a></div>
                </td>
                <td style="width: 6.01%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">14</div>
                </td>
              </tr>
              <tr>
                <td style="width: 93.99%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;"><a href="#DESCRIPTIONOFRIGHTS">DESCRIPTION OF RIGHTS</a></div>
                </td>
                <td style="width: 6.01%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">19</div>
                </td>
              </tr>
              <tr>
                <td style="width: 93.99%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;"><a href="#DESCRIPTIONOFWARRANTS">DESCRIPTION OF WARRANTS</a></div>
                </td>
                <td style="width: 6.01%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">20</div>
                </td>
              </tr>
              <tr>
                <td style="width: 93.99%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;"><a href="#DESCRIPTIONOFUNITS">DESCRIPTION OF UNITS</a></div>
                </td>
                <td style="width: 6.01%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">23</div>
                </td>
              </tr>
              <tr>
                <td style="width: 93.99%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;"><a href="#PLANOFDISTRIBUTION">PLAN OF DISTRIBUTION</a></div>
                </td>
                <td style="width: 6.01%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">24</div>
                </td>
              </tr>
              <tr>
                <td style="width: 93.99%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;"><a href="#LEGALMATTERS">LEGAL MATTERS</a></div>
                </td>
                <td style="width: 6.01%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">26</div>
                </td>
              </tr>
              <tr>
                <td style="width: 93.99%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;"><a href="#EXPERTS">EXPERTS</a></div>
                </td>
                <td style="width: 6.01%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">26</div>
                </td>
              </tr>
              <tr>
                <td style="width: 93.99%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;"><a href="#EXPENSES">EXPENSES</a></div>
                </td>
                <td style="width: 6.01%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">26</div>
                </td>
              </tr>
              <tr>
                <td style="width: 93.99%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;"><a href="#INCORPORATIONOFCERTAININF">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</a></div>
                </td>
                <td style="width: 6.01%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">26</div>
                </td>
              </tr>
              <tr>
                <td style="width: 93.99%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;"><a href="#WHEREYOUCANFINDADDITIONAL">WHERE YOU CAN FIND ADDITIONAL INFORMATION</a></div>
                </td>
                <td style="width: 6.01%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">28</div>
                </td>
              </tr>
              <tr>
                <td style="width: 93.99%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;"><a href="#ENFORCEABILITYOFCIVILLIAB">ENFORCEABILITY OF CIVIL LIABILITIES</a></div>
                </td>
                <td style="width: 6.01%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">28</div>
                </td>
              </tr>
              <tr>
                <td style="width: 93.99%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;"><a href="#INDEMNIFICATIONFORSECURIT">INDEMNIFICATION FOR SECURITIES ACT LIABILITIES</a></div>
                </td>
                <td style="width: 6.01%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">29</div>
                </td>
              </tr>

          </table>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <!--PROfilePageNumberReset%LCR%1%%%-->
          <div style="text-align: center; line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="ABOUTTHISPROSPECTUS"><!--Anchor--></a>ABOUT THIS PROSPECTUS</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, or the SEC, using a &#8220;shelf&#8221; registration process. Under this shelf registration
            process, we may from time to time sell ordinary shares, debt securities, rights, warrants or units comprising any combination of these securities, in one or more offerings up to a total dollar amount of $350,000,000. We have provided to you in
            this prospectus a general description of the securities we may offer. Each time we sell securities, we will, to the extent required by law, provide a prospectus supplement that will contain specific information about the terms of the offering.
            We may also add, update or change in any accompanying prospectus supplement or any free writing prospectus we may authorize to be delivered to you any of the information contained in this prospectus. To the extent there is a conflict between
            the information contained in this prospectus and the prospectus supplement, you should rely on the information in the prospectus supplement, provided that if any statement in one of these documents is inconsistent with a statement in another
            document having a later date-for example, a document incorporated by reference in this prospectus or any prospectus supplement-the statement in the document having the later date modifies or supersedes the earlier statement. This prospectus,
            together with any accompanying prospectus supplement and any free writing prospectus we may authorize to be delivered to you, includes all material information relating to the offering of our securities.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">As permitted by the rules and regulations of the SEC, the registration statement, of which this prospectus forms a part, includes additional information not contained in this prospectus. You may
            read the registration statement and the other reports we file with the SEC at the SEC&#8217;s web site or at the SEC&#8217;s offices described below under the heading &#8220;Where You Can Find Additional Information.&#8221;</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">In this prospectus, unless otherwise stated or the context otherwise requires, references to &#8220;Compugen,&#8221;&#160;&#8220;the Company,&#8221;&#160;&#8220;we,&#8221;&#160;&#8220;us,&#8221;&#160;&#8220;our&#8221; and similar references refer to Compugen Ltd. and our
            wholly owned subsidiary, Compugen USA, Inc. except where the context otherwise requires or as otherwise indicated.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25; font-weight: bold;">You should rely only on the information contained or incorporated by reference in this prospectus, any accompanying prospectus supplement or any &#8220;free writing prospectus&#8221; we
            may authorize to be delivered to you. We have not authorized anyone to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. You should assume that the information
            appearing in this prospectus, any prospectus supplement and the documents incorporated by reference herein and therein are accurate only as of their respective dates. Our business, financial condition, results of operations and prospects may
            have changed since those dates.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25; font-weight: bold;">Neither this prospectus nor any accompanying prospectus supplement shall constitute an offer or solicitation by anyone in any jurisdiction in which such offer or solicitation
            is not authorized or in which the person making such offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make such offer or solicitation.</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">i</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <!--PROfilePageNumberReset%Num%1%%%-->
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">
            <div style="border: #000000 2px solid; padding: 5px; width: 99%;">
              <div>
                <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><a name="PROSPECTUSSUMMARY"><!--Anchor--></a>PROSPECTUS SUMMARY</div>
                <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: normal;">&#160;</div>
                <div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-style: italic; font-weight: normal;">This summary highlights only some of the information included or incorporated by
                  reference in this prospectus. You should carefully read this prospectus together with the additional information about us described in the sections entitled &#8220;Where You Can Find Additional Information&#8221; and &#8220;Incorporation of Certain
                  Information by Reference&#8221; before purchasing our securities.</div>
                <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: normal;">&#160;</div>
                <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Compugen Ltd.</div>
                <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: normal;">&#160;</div>
                <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Overview</div>
                <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: normal;">&#160;</div>
                <div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: normal;">We are a clinical-stage therapeutic discovery and development company utilizing our broadly applicable,
                  predictive computational discovery platforms to identify novel drug targets and develop therapeutics in the field of cancer immunotherapy. Our innovative immuno-oncology pipeline consists of three clinical stage programs, COM701, COM902
                  and BAY 1905254, targeting immune checkpoints we discovered computationally. Our lead product candidate, COM701, a first-in-class anti-PVRIG antibody, for the treatment of solid tumors, is undergoing a Phase 1 clinical study and is under
                  clinical collaboration with Bristol-Myers Squibb. COM902, our therapeutic antibody targeting TIGIT, is in a Phase 1 clinical study and BAY 1905254 a first-in-class therapeutic antibody targeting ILDR2, is licensed to Bayer under a
                  research and discovery collaboration and license agreement and is also in Phase 1 studies in patients with advanced solid tumors. Our therapeutic pipeline further includes early-stage immuno-oncology programs focused largely on myeloid
                  targets. Our innovative immuno-oncology pipeline, strategic collaborations and computational discovery engine serve as the Company&#8217;s three key building blocks. Our business model is to selectively enter into collaborations for our novel
                  targets and related drug product candidates at various stages of research and development.</div>
                <div style="line-height: 1.25; font-weight: normal;"><br style="line-height: 1.25;">
                </div>
                <div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: normal;">In 2018, we entered into two agreements with leading pharmaceutical companies-a clinical collaboration
                  agreement with Bristol-Myers Squibb in connection with our lead immuno-oncology program, COM701, and an exclusive license agreement with AstraZeneca for the development of bi-specific and multi-specific antibody products derived from one
                  of our immuno-oncology programs. The first pipeline agreement we entered into was with Bayer in 2013 for the research, development, and commercialization of immuno-oncology therapeutics against novel targets identified by us. Under this
                  agreement, we collaborate with Bayer on BAY 1905254 targeting ILDR2. We are also engaged in collaboration with Johns Hopkins School of Medicine, a leading academic research center in the United States to advance research and development
                  efforts relating to our pipeline programs.</div>
                <div style="line-height: 1.25; font-weight: normal;"><br style="line-height: 1.25;">
                </div>
                <div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: normal;">We are headquartered in Holon, Israel. Our clinical development activities operate from our U.S. site in
                  South San Francisco, California.&#160;</div>
                <div style="line-height: 1.25; font-weight: normal;"><br style="line-height: 1.25;">
                </div>
                <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;">Corporate Information</div>
                <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: normal;">&#160;</div>
                <div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: normal;">Our legal and commercial name is Compugen Ltd. We were incorporated on February 10, 1993 as an Israeli
                  corporation and operate under the Israel Companies Law, 5759-1999, as amended, or the Companies Law. Our principal offices are located at 26 Harokmim Street, Holon 5885849, Israel, and our telephone number is +972-3-765-8585. Our web
                  address is <font style="font-family: 'Times New Roman', Times, serif; font-style: italic;">www.cgen.com</font>. The information on our website is not incorporated by reference into this prospectus, is not considered a part of this
                  prospectus and should not be relied upon with respect to any offering.</div>
                <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: normal;">&#160;</div>
                <div style="text-align: left; text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: normal;">Compugen USA, Inc., our wholly owned subsidiary, was incorporated in Delaware in March 1997 and is
                  qualified to do business in California.&#160;This subsidiary did not have any significant operations from 2008 to March 2012.</div>
                <div style="text-align: left; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: normal;">&#160;&#160; </div>
              </div>
            </div>
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"> <br>
          </div>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">1</font></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div>
          <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: bold;"><a name="RISKFACTORS"><!--Anchor--></a>RISK FACTORS</div>
          <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: normal;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-weight: normal;">Investing in our securities may involve a high degree of risk. Before making an investment decision, you should carefully consider
            the risks described under <font style="font-family: 'Times New Roman', Times, serif;">&#8220;</font>Risk Factors<font style="font-family: 'Times New Roman', Times, serif;">&#8221;</font> in the applicable prospectus supplement and in our most recent
            Annual Report on Form 20-F, or any updates in our Reports on Form 6-K, together with all of the other information appearing in this prospectus or incorporated by reference into this prospectus and any applicable prospectus supplement, in light
            of your particular investment objectives and financial circumstances. The risks so described are not the only risks facing our company. Additional risks not presently known to us or that we currently deem immaterial may also impair our business
            operations. Our business, financial condition and results of operations could be materially adversely affected by any of these risks. The trading price of our securities could decline due to any of these risks, and you may lose all or part of
            your investment.</div>
          <div style="line-height: 1.25; font-weight: normal;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;"><font style="font-family: 'Times New Roman',Times,serif; font-weight: bold;">The COVID-19 pandemic may adversely affect our business and operations</font><font style="font-family: 'Times New Roman',Times,serif; font-weight: normal;"><br>
            </font><br>
            <div style="line-height: 1.25;">The recent outbreak of COVID-19 has been declared by the World Health Organization to be a &#8220;pandemic,&#8221; and has spread across the globe to many countries, including the United States and Israel and is impacting
              worldwide economic activity. The current COVID-19 pandemic may disrupt or prevent us, our suppliers and other business partners from conducting business activities as usual (including, without limitation, the availability and pricing of
              materials, manufacturing and delivery efforts, clinical trials and other aspects of our business) for a period of time, the duration of which is uncertain. In addition, we, our suppliers and other business partners may also experience
              significant impairments of business activities due to operational shutdowns or suspensions that may be requested or mandated by national or local governmental authorities or self-imposed by us, our suppliers or other business partners.<br style="line-height: 1.25;">
            </div>
            <font style="font-weight: normal;"> <br>
              While it is not possible at this time to estimate the future impact that COVID-19 could have on our business, suppliers or other business partners, the continued spread of COVID-19, the measures taken in Israel and the United States by
              federal and local governments, actions taken to protect employees, and the impact of the pandemic on various business activities could adversely affect our business, results of operations and financial condition.<br>
              <br>
              The capital markets have experienced significant volatility due to the ongoing spread of COVID-19. As a result, the price of our shares may be negatively impacted and affect our ability to raise additional capital.</font></div>
          <br>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">2</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <br>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="NOTEREGARDINGFORWARD-LOOK"><!--Anchor--></a>NOTE REGARDING FORWARD-LOOKING STATEMENTS</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">This prospectus contains, and any accompanying prospectus supplement will contain, forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the
            Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and the Private Securities Litigation Reform Act of 1995. Also, documents that we incorporate by reference into this prospectus, including
            documents that we subsequently file with the SEC, will contain forward-looking statements. Forward-looking statements are those that predict or describe future events or trends and that do not relate solely to historical matters. You can
            generally identify forward-looking statements as statements containing the words &#8220;may,&#8221;&#160;&#8220;will,&#8221;&#160;&#8220;could,&#8221;&#160;&#8220;should,&#8221;&#160;&#8220;expect,&#8221;&#160;&#8220;anticipate&#8220;&#160;&#8220;objective,&#8221;&#160;&#8220;goal,&#8221;&#160;&#8220;intend,&#8221;&#160;&#8220;estimate,&#8221;&#160;&#8220;believe,&#8221;&#160;&#8220;project,&#8221;&#160;&#8220;plan,&#8221;&#160;&#8220;assume,&#8221; &#8220;potential,&#8221; &#8220;likely,&#8221;
            &#8220;confident&#8221; or other similar expressions, or negatives of those expressions, although not all forward-looking statements contain these identifying words. All statements contained or incorporated by reference in this prospectus and any
            prospectus supplement regarding our future strategy, future operations, projected financial position, the timing, progress, and results of preclinical studies and clinical trials,&#160;the timing, scope, or likelihood of regulatory filings and
            approvals, proposed products, anticipated collaborations, our ability to identify, develop and advance any future product candidates into, and successfully complete, clinical studies, estimated future revenues, projected costs, future
            prospects, the future of our industry and results that might be obtained by pursuing management&#8217;s current plans and objectives are forward-looking statements.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">You should not place undue reliance on our forward-looking statements because the matters they describe are subject to certain risks, uncertainties and assumptions, including in many cases
            decisions or actions by third parties that are difficult to predict. Our forward-looking statements are based on the information currently available to us and speak only as of the date on the cover of this prospectus, the date of any prospectus
            supplement, or, in the case of forward-looking statements incorporated by reference, the date of the filing that includes the statement. Over time, our actual results, performance or achievements may differ from those expressed or implied by
            our forward-looking statements, and such difference might be significant and materially adverse to our security holders. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information,
            future events or otherwise.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">We have identified some of the important factors that could cause future events to differ from our current expectations and they are described in this prospectus and supplements to this
            prospectus under the caption &#8220;Risk Factors,&#8221; as well as in our most recent Annual Report on Form 20-F, including without limitation under the captions &#8220;Risk Factors&#8221; and &#8220;Operating and Financial Review and Prospects,&#8221; and in other documents
            that we may file with the SEC, all of which you should review carefully. Please consider our forward-looking statements in light of those risks as you read this prospectus and any prospectus supplement.</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">3</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <br>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="OFFERSTATISTICSANDEXPECTE"><!--Anchor--></a>OFFER STATISTICS AND EXPECTED TIMETABLE</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">We may sell from time to time pursuant to this prospectus (as may be detailed in prospectus supplements) an indeterminate number of securities as shall have a maximum aggregate offering price of
            $350,000,000. The actual number of securities and price of the securities that we will offer pursuant hereto will depend on a number of factors that may be relevant as of the time of offer (see &#8220;Plan of Distribution&#8221; below).</div>
          <div style="line-height: 1.25;">&#160;</div>
        </div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">4</font></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="CAPITALIZATION"><!--Anchor--></a>CAPITALIZATION</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">The table below sets forth our cash and cash equivalents, restricted cash, short-term bank deposits, and capitalization as of June 30, 2020. The information set forth in the following table
            should be read in conjunction with, and is qualified in its entirety by, reference to our audited and unaudited financial statements and the notes thereto incorporated by reference into this prospectus.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z9b67f5241af44930aa2073b6f19cf0dd" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000; width: 100%;">

              <tr>
                <td valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF; padding-bottom: 2px;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
                <td valign="bottom" colspan="2" style="vertical-align: bottom; background-color: #FFFFFF; border-bottom: #000000 solid 2px;">
                  <div style="text-align: center; line-height: 1.25; font-weight: bold;">As of June 30, 2020</div>
                </td>
                <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: #FFFFFF; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>
                <td valign="bottom" colspan="2" style="vertical-align: bottom; background-color: #FFFFFF;">
                  <div style="text-align: center; line-height: 1.25; font-weight: bold;">(in thousands, except share and per share data)</div>
                </td>
                <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: #FFFFFF; vertical-align: bottom;">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 88%; padding-bottom: 2px;">
                  <div style="line-height: 1.25;">Cash and cash equivalents, restricted cash and short-term bank deposits</div>
                </td>
                <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
                  <div style="line-height: 1.25;">136,066</div>
                </td>
                <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 88%;">
                  <div style="line-height: 1.25;">Shareholder&#8217;s equity:</div>
                </td>
                <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
                <td valign="bottom" colspan="1" style="background-color: rgb(255, 255, 255); vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" colspan="1" style="background-color: rgb(255, 255, 255); vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>
                <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(255, 255, 255); vertical-align: bottom; width: 1%;">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 88%;">
                  <div style="line-height: 1.25;">Ordinary shares, NIS 0.01 nominal value: 200,000,000 shares authorized and 82,694,209 shares issued and outstanding</div>
                </td>
                <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">227</div>
                </td>
                <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 88%;">
                  <div style="line-height: 1.25;">Additional paid-in capital</div>
                </td>
                <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
                <td valign="bottom" colspan="1" style="background-color: rgb(255, 255, 255); vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" colspan="1" style="background-color: rgb(255, 255, 255); vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">500,792</div>
                </td>
                <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(255, 255, 255); vertical-align: bottom; width: 1%;">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 88%; padding-bottom: 2px;">
                  <div style="line-height: 1.25;">Accumulated deficit</div>
                </td>
                <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>
                <td valign="bottom" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
                  <div style="line-height: 1.25;">(371,552</div>
                </td>
                <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 2px;">
                  <div style="line-height: 1.25;">)</div>
                </td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; background-color: rgb(255, 255, 255); width: 88%; padding-bottom: 2px;">
                  <div style="line-height: 1.25;">Total shareholders&#8217; equity</div>
                </td>
                <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(255, 255, 255);">&#160;</td>
                <td valign="bottom" colspan="1" style="background-color: rgb(255, 255, 255); vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
                <td valign="bottom" colspan="1" style="background-color: rgb(255, 255, 255); vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">
                  <div style="line-height: 1.25;">129,467</div>
                </td>
                <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: rgb(255, 255, 255); vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" style="vertical-align: bottom; background-color: #CCEEFF; width: 88%; padding-bottom: 4px;">
                  <div style="line-height: 1.25;">Total capitalization</div>
                </td>
                <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">
                  <div style="line-height: 1.25;">129,467</div>
                </td>
                <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">The number of outstanding ordinary shares set forth above excludes, as of June 30, 2020:</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div>
            <table cellspacing="0" cellpadding="0" id="zdb16584b32a444a1b50bbd832e250684" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 90pt; vertical-align: top; align: right;">
                    <div style="margin-left: 72pt; line-height: 1.25;">&#8226;</div>
                  </td>
                  <td style="width: auto; vertical-align: top;">
                    <div style="line-height: 1.25;">5,481,735 ordinary shares issuable upon the exercise of outstanding options to purchase ordinary shares granted under our 2010 Share Incentive Plan, having a weighted average exercise price of $4.33 per
                      share;</div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div>
            <table cellspacing="0" cellpadding="0" id="z4e6b22c69441408091c63c174de5e20c" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 90pt; vertical-align: top; align: right;">
                    <div style="margin-left: 72pt; line-height: 1.25;">&#8226;</div>
                  </td>
                  <td style="width: auto; vertical-align: top;">
                    <div style="line-height: 1.25;">an aggregate 3,464,441 ordinary shares issuable and reserved for future grants under our 2010 Share Incentive Plan; and</div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div>
            <table cellspacing="0" cellpadding="0" id="zdc96b09f9cb1404bbebc516014e88202" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 90pt; vertical-align: top; align: right;">
                    <div style="margin-left: 72pt; line-height: 1.25;">&#8226;</div>
                  </td>
                  <td style="width: auto; vertical-align: top;">
                    <div style="line-height: 1.25;">749,104 ordinary shares issuable upon the exercise of warrants issued to certain institutional investors in a registered direct offering completed in June 2018, with an exercise price of $4.74 per share.</div>
                  </td>
                </tr>

            </table>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">5</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="REASONSFORTHEOFFERANDUSEO"><!--Anchor--></a>REASONS FOR THE OFFER AND USE OF PROCEEDS</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">We cannot assure you that we will receive any proceeds in connection with securities offered pursuant to this prospectus. Unless otherwise indicated in the applicable prospectus supplement, we
            intend to use any net proceeds from the sale of securities under this prospectus for our operations and for other general corporate purposes, which may include working capital, intellectual property protection and enforcement, capital
            expenditures, investments, acquisitions or collaborations, pre-clinical and clinical development of our product candidates, research and development and product development and repayment or refinancing of indebtedness or other corporate
            borrowings. We may set forth additional information on the use of proceeds from the sale of securities we offer under this prospectus in a prospectus supplement relating to the specific offering. We have not determined the amount of net
            proceeds to be used specifically for the foregoing purposes. As a result, our management will have broad discretion in the allocation of the net proceeds. Pending use of the net proceeds, we would expect to invest any proceeds in a variety of
            capital preservation instruments, including short-term and long-term, investment&#8209;grade, interest&#8209;bearing instruments.</div>
          <div style="line-height: 1.25;">&#160;&#160;</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">6</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="DESCRIPTIONOFSECURITIES"><!--Anchor--></a>DESCRIPTION OF SECURITIES</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">The descriptions of the securities contained in this prospectus, together with the applicable prospectus supplements, summarize the material terms and provisions of the various types of
            securities that we may offer. We will describe in the applicable prospectus supplement relating to any securities the particular terms of the securities offered by that prospectus supplement. If we so indicate in the applicable prospectus
            supplement, the terms of the securities may differ from the terms we have summarized below.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">We may sell from time to time, in one or more offerings, ordinary shares, debt securities, rights, warrants to purchase ordinary shares and units comprising any combination of these securities.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">In this prospectus, we refer to the ordinary shares, debt securities, rights, warrants and units that may be offered by us collectively as &#8220;securities.&#8221; The total dollar amount of all securities
            that we may issue under this prospectus will not exceed $350,000,000.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">This prospectus may not be used to consummate a sale of securities unless it is accompanied by a prospectus supplement.</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">7</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="DESCRIPTIONOFORDINARYSHAR"><!--Anchor--></a>DESCRIPTION OF ORDINARY SHARES</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 35pt; line-height: 1.25;">Our authorized share capital consists of 200,000,000 ordinary shares, nominal (par) value NIS 0.01 per share. As of June 30, 2020, 82,694,209 ordinary shares were issued and outstanding. Subject
            to our amended and restated articles of association, or our Articles, fully paid ordinary shares of the Company confer on the holders thereof rights to attend and to vote at general meetings of the shareholders. Subject to the rights of holders
            of shares with limited or preferred rights which may be issued in the future, the ordinary shares of the Company confer upon the holders thereof equal rights to vote, to receive dividends and to participate in the distribution of the assets of
            the Company upon its winding-up, in proportion to the amount paid up or credited as paid up on account of the nominal value of the shares held by them respectively and in respect of which such dividends are being paid or such distribution is
            being made, without regard to any premium paid in excess of the nominal value, if any. All outstanding ordinary shares are validly issued and fully paid.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25; font-weight: bold;">Registration Number and Purpose of the Company</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-indent: 36pt; line-height: 1.25;">Our registration number with the Israeli Registrar of Companies is 51-177-963-9. Our purpose as set forth in our Articles is to engage in any lawful act or activity for which companies may be
            organized under the Companies Law.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25; font-weight: bold;">Rights Attached to Our Shares</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-indent: 36pt; line-height: 1.25;">Subject to our Articles, fully paid ordinary shares confer on the holders thereof rights to attend and to vote at general meetings of the shareholders. Subject to the rights of holders of shares
            with limited or preferred rights which may be issued in the future, our ordinary shares confer upon the holders thereof equal rights to receive dividends and to participate in the distribution of our assets upon our winding-up, in proportion to
            the amount paid up or credited as paid up on account of the nominal value of the shares held by them respectively and in respect of which such dividends are being paid or such distribution is being made, without regard to any premium paid in
            excess of the nominal value, if any. No preferred shares are currently authorized. All outstanding ordinary shares are validly issued and fully paid.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Voting Rights</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-indent: 36pt; line-height: 1.25;">Subject to the provisions of our Articles, holders of ordinary shares have one vote for each ordinary share held by such shareholder of record, on all matters submitted to a vote of shareholders.
            Shareholders may vote in person, by proxy or by proxy card. Alternatively, shareholders who hold shares through members of the Tel Aviv Stock Exchange may vote electronically via the electronic voting system of the Israel Securities Authority,
            or Electronic Vote. These voting rights may be affected by the grant of any special voting rights to the holders of a class of shares with preferential rights that may be authorized in the future. As our ordinary shares do not have cumulative
            voting rights in the election of directors, the holders of the majority of the shares present and voting at a shareholders meeting have the power to elect all of our directors.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Transfer of Shares</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">Our ordinary shares which have been fully paid-up are transferable by submission of a proper instrument of transfer together with the certificate of the shares to be transferred and such other
            evidence of title, as our Board of Directors may require, unless such transfer is prohibited by another instrument or by applicable securities laws.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Dividends</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">Under the Companies Law, dividends may be distributed only out of profits available for dividends as determined by the Companies Law, provided that there is no reasonable concern that the
            distribution will prevent the Company from being able to meet its existing and anticipated obligations when they become due. If the company does not meet the profit requirement, a court may nevertheless allow the company to distribute a
            dividend, as long as the court is convinced that there is no reasonable concern that such distribution will prevent the company from being able to meet its existing and anticipated obligations when they become due. Pursuant to our Articles, no
            dividend shall be paid other than out of the profits of the Company. Generally, under the Companies Law, the decision to distribute dividends and the amount to be distributed is made by a company&#8217;s board of directors.</div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">Our Articles provide that our Board of Directors, may, subject to the Companies Law, from time to time, declare and cause the Company to pay such dividends as may appear to the Board of Directors
            to be justified by the profits of our Company. Subject to the rights of the holders of shares with preferential, special or deferred rights that may be authorized in the future, our profits which shall be declared as dividends shall be
            distributed according to the proportion of the nominal (par) value paid up or credited as paid up on account of the shares held at the date so appointed by the Company and in respect of which such dividend is being paid, without regard to the
            premium paid in excess of the nominal (par) value, if any. The declaration of dividends does not require shareholders&#8217; approval.</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">8</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-indent: 36pt; line-height: 1.25;">To date, we have not declared or distributed any dividend and we do not intend to pay cash dividends on our ordinary shares in the foreseeable future.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Liquidation Rights</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">In the event of our winding up on liquidation or dissolution, subject to applicable law and after satisfaction of liabilities to creditors, our assets available for distribution among the
            shareholders shall be distributed to the holders of ordinary shares in proportion to the amount paid up or credited as paid up on account of the nominal value of the shares held by them respectively and in respect of which such distribution is
            being made, without regard to any premium paid in excess of the nominal value, if any. This liquidation right may be affected by the grant of limited or preferential rights as to liquidation to the holders of a class of shares that may be
            authorized in the future.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Redemption Provisions</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">We may, subject to applicable law and to our Articles, issue redeemable shares and redeem the same upon such terms and conditions as determined by our Board of Directors.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Limitation of Liability</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">Under our Articles, the liability of each shareholder for the Company&#8217;s obligations is limited to the unpaid sum, if any, owing to the Company in consideration for the issuance of the shares held
            by such shareholder.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Modification of Class Rights</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">Our amended and restated Memorandum of Association, or Memorandum, provides that we may amend the Memorandum in order to increase, consolidate or divide or otherwise amend our share capital by a
            simple majority of the voting power present at a shareholders meeting as currently provided in our Articles or by such other majority as shall be set forth in our Articles from time to time.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">Pursuant to our Articles, if at any time our share capital is divided into different classes of shares, the rights attached to any class, unless otherwise provided by our Articles, may be
            modified or abrogated by the Company, subject to the consent in writing of, or sanction of a resolution passed by, the holders of a majority of the issued shares of such class at a separate general meeting of the holders of the shares of such
            class.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25; font-weight: bold;">Limitations on the Rights to Own Securities</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">Our Articles and Israeli law do not restrict the ownership or voting of ordinary shares by non-residents or persons who are not citizens of Israel, though such ownership is prohibited under
            applicable law with respect to subjects of nations which are in a state of war with Israel.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25; font-weight: bold;">Changes in Authorized Share Capital</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">Our Articles enable us, among others, to increase or reduce our authorized share capital. Any such changes are subject to the provisions of the Companies Law and our Articles and must be approved
            by a resolution duly passed by a simple majority of our shareholders at a general meeting by voting on such change in capital.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25; font-weight: bold;">Shareholders&#8217; Meetings and Resolutions</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">Our Articles provide that our annual general meeting shall be held once in every calendar year at such time (within a period of not more than fifteen months after the last preceding annual
            general meeting), and place determined by our Board of Directors. Our Board of Directors may, in its discretion, convene additional special shareholders meetings and, pursuant to the Companies Law, must convene a meeting upon the demand of: (a)
            two directors or one quarter of the directors in office; or (b) the holder or holders of (i) 5% or more of our issued share capital and one percent or more of our voting rights; or (ii) 5% or more of our voting rights. All demands for
            shareholders meetings must set forth the items to be considered at that meeting.</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">9</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">The chairman of the Board of Directors, or any other director or office holder of the Company which may be designated for this purpose by the Board of Directors, shall preside as chairman at each
            of our general meetings. If there is no such chairman, or if the appointed chairman is unwilling to take the chair, or if he shall have indicated in advance that he will not be attending, or if at any meeting such chairman is not present within
            thirty (30) minutes after the time fixed for holding the meeting, then those present at the meeting shall choose someone present to be chairman of the meeting. The office of chairman shall not, by itself, entitle the holder thereof to vote at
            any general meeting nor shall it entitle a second or casting vote.</div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">According to regulations promulgated pursuant to the Companies Law and governing the terms of notice and publication of shareholder meetings of public companies, or the General Meeting
            Regulations, holder(s) of one percent or more of the Company&#8217;s voting rights may propose any matter appropriate for deliberation at a shareholder meeting to be included on the agenda of a shareholder meeting, generally by submitting a proposal
            within seven days of publicizing the convening of a shareholder meeting, or within fourteen days, if the Company publishes at least 21 days prior to publicizing the proxy materials for a shareholder meeting, a preliminary notice stating its
            intention to convene such meeting, the agenda thereof, shareholder&#8217;s right to propose a matter to be included on the agenda of such meeting and company&#8217;s right not to examine such proposals received upon termination of 14 day period from the
            publication of such notice. Any such proposal must further comply with the information requirements under applicable law and our Articles. The agenda for a shareholder meeting is determined by the Board of Directors and must include matters in
            respect of which the convening of a shareholder meeting was demanded and any matter requested to be included by holder(s) of one percent of the Company&#8217;s voting rights, as detailed above.</div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">Pursuant to the Companies Law and the General Meeting Regulations shareholder meetings generally require prior notice of not less than 21 days, and not less than 35 days in certain cases.
            Pursuant to our Articles, we are not required to deliver or serve notice of a general meeting or of any adjournments thereof to any shareholder. However, subject to applicable law and stock exchange rules and regulations, we will publicize the
            convening of a general meeting in any manner reasonably determined by us, and any such publication shall be deemed duly made, given and delivered to all shareholders on the date on which it is first made, posted, filed or published in the
            manner so determined by us in our sole discretion.</div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">The function of the annual general meeting is to elect directors, receive and consider the profit and loss account, the balance sheet and the ordinary reports and accounts of the directors and
            auditors, appoint auditors and transact any other business which under our Articles or applicable law may be transacted by the shareholders of the Company in a general meeting.</div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">Pursuant to our Articles, the quorum required for a meeting of shareholders consists of at least two shareholders, present in person, by proxy, by proxy card or by Electronic Vote and holding
            shares conferring in the aggregate twenty-five percent (25%) or more of the voting power of the Company. If within half an hour from the time appointed for the meeting a quorum is not present, the meeting shall stand adjourned to the same day
            in the following week at the same time and place or to such other later day, time and place as the Board of Directors may determine and specify in the publication with respect to the Meeting. At the adjourned meeting, any number of participants
            will constitute a quorum present, in person, by proxy, by proxy card or by Electronic Vote; provided, however, that special general meeting which was convened by the Board upon the demand of shareholders or directors then in office, as detailed
            above, or directly by such shareholders or directors, in accordance the terms of the Companies Law, shall be cancelled.</div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">Generally, under the Companies Law and our Articles, shareholder resolutions are deemed adopted if approved by the holders of a simple majority of the voting rights represented at the meeting, in
            person, by proxy, by proxy card or by Electronic Vote, and voting on the matter, unless a different majority is required by law or pursuant to our Articles such as a resolution for the voluntary winding up of our Company which requires the
            approval of holders of 75% of the voting power presented and voting at the meeting, or resolutions concerting certain related party transactions as set forth in Sections 267 and 270-275 of the Companies Law.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25; font-weight: bold;">Change of Control</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Merger</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">Under the Companies Law, a merger is generally required to be approved by the shareholders and board of directors of each of the merging companies. If the share capital of the company that will
            not be the surviving company is divided into different classes of shares, the approval of each class is also required, unless determined otherwise by the court. Similarly, unless an Israeli court determines otherwise, a merger will not be
            approved if it is objected to by shareholders holding a majority of the voting rights participating and voting at the meeting (abstentions are disregarded), after excluding the shares held by the other party to the merger, by any person who
            holds 25% or more of the other party to the merger or by anyone on their behalf, including by the relatives of, or corporations controlled by, these persons. In approving a merger, the board of directors of both merging companies must determine
            that there is no reasonable concern that, as a result of the merger, the surviving company will not be able to satisfy its obligations to its creditors. Similarly, upon the request of a creditor of either party to the proposed merger, an
            Israeli court may prevent or delay the merger if it concludes that there exists a reasonable concern that, as a result of the merger, the surviving company will not be able to satisfy the obligations of the merging parties. A court may also
            issue other instructions for the protection of the creditors&#8217; rights in connection with a merger. Further, a merger may not be completed unless at least (i) 50 days have passed from the time that the requisite proposals for the approval of the
            merger were filed with the Israeli registrar of companies; and (ii) 30 days have passed since the merger was approved by the shareholders of each party.</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">10</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Special Tender Offer</div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">The Companies Law provides that an acquisition of shares of an Israeli public company must be made by means of a special tender offer if as a result of the acquisition the purchaser would become
            a holder of 25% or more of the voting rights in the company. This rule does not apply if there is already another holder of 25% or more of the voting rights in the company. Similarly, the Companies Law provides that an acquisition of shares in
            a public company must be made by means of a special tender offer if as a result of the acquisition the purchaser would become a holder of more than 45% of the voting rights in the company, if there is no other shareholder of the company who
            holds more than 45% of the voting rights in the company. These requirements do not apply if the acquisition (i) occurs in the context of a private placement by the company that received shareholder approval for the purpose of allowing the
            purchaser to hold more than 25% of 45% of the voting rights in the company, as the case may be, (ii) was from a shareholder holding 25% or more of the voting rights in the company and resulted in the acquirer becoming a holder of 25% or more of
            the voting rights in the company, or (iii) was from a holder of more than 45% of the voting rights in the company and resulted in the acquirer becoming a holder of more than 45% of the voting rights in the company. A special tender offer may be
            consummated only if (i) at least 5% of the voting power attached to the company&#8217;s outstanding shares will be acquired by the offeror and (ii) the number of shares tendered in the offer exceeds the number of shares whose holders objected to the
            offer (excluding controlling shareholders, holders of 25% or more of the voting rights in the company and any person having a personal interest in the acceptance of the tender offer).</div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">In the event that a special tender offer is made, a company&#8217;s board of directors is required to express its opinion on the advisability of the offer, or shall abstain from expressing any opinion
            if it is unable to do so, provided that it gives the reasons for its abstention. An office holder in a target company who, in his or her capacity as an office holder, performs an action the purpose of which is to cause the failure of an
            existing or foreseeable special tender offer or is to impair the chances of its acceptance, is liable to the potential purchaser and shareholders for damages, unless such office holder acted in good faith and had reasonable grounds to believe
            he or she was acting for the benefit of the company. However, office holders of the target company may negotiate with the potential purchaser in order to improve the terms of the special tender offer and may further negotiate with third parties
            in order to obtain a competing offer. Shares purchased in contradiction to the tender offer rules under the Companies Law will have no rights and will become dormant shares.</div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">If a special tender offer is accepted, then shareholders who did not respond to or that had objected the offer may accept the offer within four days of the last day set for the acceptance of the
            offer. In the event that a special tender offer is accepted, then the purchaser or any person or entity controlling it or under common control with the purchaser or such controlling person or entity may not make a subsequent tender offer for
            the purchase of shares of the target company and may not enter into a merger with the target company for a period of one year from the date of the offer, unless the purchaser or such person or entity undertook to effect such an offer or merger
            in the initial special tender offer.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Full Tender Offer</div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">Under the Companies Law, a person may not acquire shares in a public company if, after the acquisition, the acquirer will hold more than 90% of the shares or more than 90% of any class of shares
            of that company, unless a tender offer is made to purchase all of the shares or all of the shares of the particular class. The Companies Law also generally provides that as long as a shareholder in a public company holds more than 90% of the
            company&#8217;s shares or of a class of shares, that shareholder shall be precluded from purchasing any additional shares. In order for all of the shares that the purchaser offered to purchase be transferred to him by operation of law, one of the
            following needs to have occurred: (i) the shareholders who declined or do not respond to the tender offer hold less than 5% of the company&#8217;s outstanding share capital or of the relevant class of shares and the majority of offerees who do not
            have a personal interest in accepting the tender offer accepted the offer, or (ii) the shareholders who declined or do not respond to the tender offer hold less than 2% of the company&#8217;s outstanding share capital or of the relevant class of
            shares.</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">11</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-indent: 36pt; line-height: 1.25;">A shareholder that had his or her shares so transferred, whether he or she accepted the tender offer or not, has the right, within six months from the date of acceptance of the tender offer, to
            petition the court to determine that the tender offer was for less than fair value and that the fair value should be paid as determined by the court. However, the purchaser may provide in its offer that shareholders who accept the tender offer
            will not be entitled to such rights.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">If the conditions set forth above are not met, the purchaser may not acquire additional shares of the company from shareholders who accepted the tender offer to the extent that following such
            acquisition, the purchaser would own more than 90% of the company&#8217;s issued and outstanding share capital. The above restrictions apply, in addition to the acquisition of shares, to the acquisition of voting power.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25; font-weight: bold;">Transfer Agent and Registrar</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 35pt; line-height: 1.25;">The transfer agent and registrar for our ordinary shares is American Stock Transfer &amp; Trust Company, LLC.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25; font-weight: bold;">The Nasdaq Global Market and the Tel Aviv Stock Exchange</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 35pt; line-height: 1.25;">Our ordinary shares are listed on The Nasdaq Global Market and the Tel Aviv Stock Exchange under the symbol &#8220;CGEN.&#8221;</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25; font-weight: bold;">Warrants</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 35pt; line-height: 1.25;">As of June 30, 2020, we had warrants outstanding to purchase an aggregate 749,104 ordinary shares. See &#8220;Description of Warrants&#8212;Outstanding Warrants.&#8221;</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25; font-weight: bold;">Share History</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">The following is a summary of the history of our share capital for the last three years.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Ordinary Share Issuances</div>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z067024fec2bf4274a255891883ce7597" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 9.82%; vertical-align: middle; background-color: #FFFFFF;">&#160;</td>
                <td style="width: 4.46%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 85.71%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;"><font style="font-style: italic;">Share Options.</font> Since January 1, 2017 and through June 30, 2020, we have issued a total of 4,256,307 ordinary shares upon the exercise of share options.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z733c9152ed6b4000bea5220c5df63c33" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 9.85%; vertical-align: middle; background-color: #FFFFFF;">&#160;</td>
                <td style="width: 4.43%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 85.71%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;"><font style="font-style: italic;">ATM Sales Agreement</font>. In May 2018, we entered into a Controlled Equity Offering<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">SM</sup>
                    Sales Agreement, or the ATM Sales Agreement, with Cantor Fitzgerald &amp; Co., or Cantor, as sales agent, pursuant to which we may offer and sell, from time to time through Cantor, our ordinary shares having an aggregate offering price
                    of up to $25 million. Under the ATM Sales Agreement, Cantor may sell Shares by any method permitted by law and deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) promulgated under the Securities Act, including sales
                    made directly on the Nasdaq Global Market, or on any other existing trading market for the ordinary shares. As of December 31, 2019, we sold 7,245,268 shares through the ATM Sales Agreement for an aggregate purchase price of
                    approximately $23.7 million. The program was terminated in 2019.</div>
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
              </tr>
              <tr>
                <td style="width: 9.85%; vertical-align: middle; background-color: #FFFFFF;">&#160;</td>
                <td style="width: 4.43%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 85.71%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;"><font style="font-style: italic;">Registered Direct Offering</font>. In June 2018, we entered into a definitive securities purchase agreement with certain institutional investors and a placement agency
                    agreement with JMP Securities LLC, in connection with a registered direct offering which resulted in the issuance of 5,316,457 of our ordinary shares at a purchase price of $3.95 per share. In connection with the issuance of the
                    ordinary shares, we also issued warrants to purchase up to 4,253,165 additional ordinary shares. The warrants have an exercise price of $4.74 per share and have a term of five years from the date of issuance. Gross proceeds from this
                    offering were approximately $21 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by us. As of June 30, 2020, warrants to purchase up to 749,104 ordinary shares remained
                    outstanding (warrants to purchase 3,504,061 ordinary shares were exercised as of such date).</div>
                  <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
                </td>
              </tr>
              <tr>
                <td style="width: 9.85%; vertical-align: middle; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 4.43%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 85.71%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="background-color: #FFFFFF; line-height: 1.25;">
                    <div style="line-height: 1.25;"><font style="background-color: #FFFFFF; font-style: italic;">Bristol-Myers Squibb Securities Purchase Agreement. </font><font style="background-color: #FFFFFF;">In October 2018, we and Bristol-Myers
                        Squibb entered into a Securities Purchase Agreement pursuant to which Bristol-Myers&#160;Squibb purchased 2,424,243 ordinary shares at a purchase price of $4.95 per share, which represented a 33% premium over the average closing price on
                        the last 20 Nasdaq trading days. Gross proceeds from this private placement were approximately $12 million.</font></div>
                  </div>
                  <div style="background-color: #FFFFFF; line-height: 1.25;"> <br>
                  </div>
                </td>
              </tr>

          </table>
          <div> <br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">12</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div>
            <div style="line-height: 1.25;">
              <div style="line-height: 1.25;"> </div>
              <table cellspacing="0" cellpadding="0" id="z44bae48d11c444bc99a7bb8aece81872" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                  <tr>
                    <td style="width: 9.82%; vertical-align: middle; background-color: #FFFFFF;">&#160;</td>
                    <td style="width: 4.46%; vertical-align: top; background-color: #FFFFFF;">
                      <div style="line-height: 1.25;">&#8226;</div>
                    </td>
                    <td style="width: 85.71%; vertical-align: top; background-color: #FFFFFF;">
                      <div style="line-height: 1.25;">
                        <div style="line-height: 1.25;"><font style="background-color: #FFFFFF; font-style: italic;">Public Offering.</font><font style="background-color: #FFFFFF;"> In March 2020, we entered into an underwriting agreement with SVB Leerink
                            LLC and Stifel,&#160;Nicolaus &amp; Company, Incorporated, as representatives of several underwriters relating to the issuance and sale in a public offering of 8,333,334 of our ordinary shares at a price to the public of $9.00 per
                            share (and a price of $8.46 per share to the underwriters). In addition, we granted the underwriters a 30-day option to purchase additional ordinary shares at the price set forth above. On April 14, 2020, we issued and sold,
                            pursuant to that underwriting agreement an additional 483,005 ordinary shares pursuant to the underwriters&#8217; option specified above.&#160;We sold a total of 8,816,339 ordinary shares in the offering with gross proceeds of
                            approximately $79.3 million.</font></div>
                      </div>
                    </td>
                  </tr>

              </table>
              <div style="line-height: 1.25;">&#160;</div>
            </div>
          </div>
          <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Authorized Share Capital</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">Our authorized share capital is equal to NIS2,000,000 divided into 200,000,000 ordinary shares nominal (par) value NIS 0.01 per share.</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">13</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="DESCRIPTIONOFDEBTSECURITI"><!--Anchor--></a>DESCRIPTION OF DEBT SECURITIES</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">The following description, together with the additional information we include in any applicable prospectus supplements, summarizes the material terms and provisions of the debt securities that
            we may offer under this prospectus. While the terms we have summarized below will apply generally to any future debt securities we may offer pursuant to this prospectus, we will describe the particular terms of any debt securities that we may
            offer in more detail in the applicable prospectus supplement. If we so indicate in a prospectus supplement, the terms of any debt securities offered under such prospectus supplement may differ from the terms we describe below, and to the extent
            the terms set forth in a prospectus supplement differ from the terms described below, the terms set forth in the prospectus supplement shall control.</div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">We may sell from time to time, in one or more offerings under this prospectus, debt securities, which may be senior or subordinated. We will issue any such senior debt securities or subordinated
            debt securities under an indenture that we will enter into with a trustee to be named in the indenture. We have filed a form of this document as an exhibit to the registration statement, of which this prospectus is a part. The indenture will be
            qualified under the Trust Indenture Act of 1939, as in effect on the date of the indenture. We use the term &#8220;debenture trustee&#8221; to refer to the trustee under the indenture.</div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">The following summaries of material provisions of the senior debt securities, the subordinated debt securities and the indenture are subject to, and qualified in their entirety by reference to,
            all the provisions of the indenture applicable to a particular series of debt securities.</div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25; font-weight: bold;">General</div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">The indenture provides that debt securities may be issued from time to time in one or more series and may be denominated and payable in foreign currencies or units based on or relating to foreign
            currencies. The indenture does not limit the amount of debt securities that may be issued thereunder, and it provides that the specific terms of any series of debt securities shall be set forth in, or determined pursuant to, an authorizing
            resolution and/or a supplemental indenture, if any, relating to such series.</div>
          <div style="text-indent: 36pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">We will describe in each prospectus supplement the following terms relating to a series of debt securities:</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" id="z5ebf10669d08485f82e079ea5c1d3286" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 10.71%; vertical-align: middle; background-color: #FFFFFF;">&#160;</td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 85.71%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">title or designation;</div>
                  <div style="line-height: 1.25;"> <br>
                  </div>
                </td>
              </tr>
              <tr>
                <td style="width: 10.71%; vertical-align: middle; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 85.71%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">the aggregate principal amount and any limit on the amount that may be issued;</div>
                  <div style="line-height: 1.25;"> <br>
                  </div>
                </td>
              </tr>
              <tr>
                <td style="width: 10.71%; vertical-align: middle; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 85.71%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">the currency or units based on or relating to currencies in which debt securities of such series are denominated and the currency or units in which principal or interest or both will or may be payable;</div>
                  <div style="line-height: 1.25;"> <br>
                  </div>
                </td>
              </tr>
              <tr>
                <td style="width: 10.71%; vertical-align: middle; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 85.71%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">the maturity date and the date or dates on which principal will be payable;</div>
                  <div style="line-height: 1.25;"> <br>
                  </div>
                </td>
              </tr>
              <tr>
                <td style="width: 10.71%; vertical-align: middle; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 85.71%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">the interest rate, which may be fixed or variable, or the method for determining the rate and the date interest will begin to accrue, the date or dates interest will be payable and the record dates for
                    interest payment dates or the method for determining such dates;</div>
                  <div style="line-height: 1.25;"> <br>
                  </div>
                </td>
              </tr>
              <tr>
                <td style="width: 10.71%; vertical-align: middle; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 85.71%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">whether or not the debt securities will be secured or unsecured, and the terms of any secured debt;</div>
                  <div style="line-height: 1.25;"> <br>
                  </div>
                </td>
              </tr>
              <tr>
                <td style="width: 10.71%; vertical-align: middle; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 85.71%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">the terms of the subordination of any series of subordinated debt;<br>
                    <br>
                  </div>
                </td>
              </tr>
              <tr>
                <td style="width: 10.71%; vertical-align: middle; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 85.71%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">the place or places where payments will be payable;</div>
                  <div style="line-height: 1.25;"> <br>
                  </div>
                </td>
              </tr>
              <tr>
                <td style="width: 10.71%; vertical-align: middle; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 85.71%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">our right, if any, to defer payment of interest and the maximum length of any such deferral period;</div>
                  <div style="line-height: 1.25;"> <br>
                  </div>
                </td>
              </tr>
              <tr>
                <td style="width: 10.71%; vertical-align: middle; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 85.71%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">the date, if any, after which, and the price at which, we may, at our option, redeem the series of debt securities pursuant to any optional redemption provisions;</div>
                  <div style="line-height: 1.25;"> <br>
                  </div>
                </td>
              </tr>
              <tr>
                <td style="width: 10.71%; vertical-align: middle; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 85.71%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">the date, if any, on which, and the price at which we are obligated, pursuant to any mandatory sinking fund provisions or otherwise, to redeem, or at the holder&#8217;s option to purchase, any series of debt
                    securities;</div>
                  <div style="line-height: 1.25;"> <br>
                  </div>
                </td>
              </tr>
              <tr>
                <td style="width: 10.71%; vertical-align: middle; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 85.71%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">whether the indenture will restrict our ability to pay dividends, or will require us to maintain any asset ratios or reserves;</div>
                </td>
              </tr>

          </table>
          <div><br>
          </div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">14</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <table cellspacing="0" cellpadding="0" id="zdddb896c856d42cf92f5bfd3f1a22c77" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 10.71%; vertical-align: middle; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 85.71%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">whether we will be restricted from incurring any additional indebtedness;</div>
                  <div style="line-height: 1.25;"> <br>
                  </div>
                </td>
              </tr>
              <tr>
                <td style="width: 10.71%; vertical-align: middle; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 85.71%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">a discussion of any material or special U.S. federal income tax considerations applicable to a series of debt securities;</div>
                  <div style="line-height: 1.25;"> <br>
                  </div>
                </td>
              </tr>
              <tr>
                <td style="width: 10.71%; vertical-align: middle; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 85.71%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">the denominations in which we will issue the series of notes, if other than denominations of $1,000 and any integral multiple thereof; and</div>
                  <div style="line-height: 1.25;"> <br>
                  </div>
                </td>
              </tr>
              <tr>
                <td style="width: 10.71%; vertical-align: middle; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 85.71%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">any other specific terms, preferences, rights or limitations of, or restrictions on, the debt securities.</div>
                </td>
              </tr>

          </table>
          <div> <br>
          </div>
          <div style="line-height: 1.25;">We may issue debt securities that provide for an amount less than their stated principal amount to be due and payable upon declaration of acceleration of their maturity pursuant to the terms of the indenture. We
            will provide you with information on the federal income tax considerations and other special considerations applicable to any of these debt securities in the applicable prospectus supplement.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25; font-weight: bold;">Conversion or Exchange Rights</div>
          <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
          <div style="line-height: 1.25;">We will set forth in the prospectus supplement the terms, if any, on which a series of debt securities may be convertible into or exchangeable for our ordinary shares or our other securities. We will include
            provisions as to whether conversion or exchange is mandatory, at the option of the holder or at our option. We may include provisions pursuant to which the number of ordinary shares or our other securities that the holders of the series of debt
            securities receive would be subject to adjustment.</div>
          <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
          <div style="line-height: 1.25; font-weight: bold;">Consolidation, Merger or Sale; No Protection in Event of a Change of Control or Highly Leveraged Transaction</div>
          <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
          <div style="line-height: 1.25;">The indenture does not contain any covenant that restricts our ability to merge or consolidate, or sell, convey, transfer or otherwise dispose of all or substantially all of our assets. However, any successor to or
            acquirer of such assets must assume all of our obligations under the indenture or the debt securities, as appropriate.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25;">Unless we state otherwise in the applicable prospectus supplement, the debt securities will not contain any provisions that may afford holders of the debt securities protection in the event we have a change of
            control or in the event of a highly leveraged transaction (whether or not such transaction results in a change of control), which could adversely affect holders of debt securities.</div>
          <div style="line-height: 1.25; font-weight: bold;">&#160;</div>
          <div style="line-height: 1.25; font-weight: bold;">Events of Default Under the Indenture</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25;">The following are events of default under the indenture with respect to any series of debt securities that we may issue:</div>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z7190ccd6651a48da97a6b540913f8530" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 10.71%; vertical-align: middle; background-color: #FFFFFF;">&#160;</td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 85.71%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">if we fail to pay interest when due and our failure continues for 90 days and the time for payment has not been extended or deferred;<br>
                    <br>
                  </div>
                </td>
              </tr>
              <tr>
                <td style="width: 10.71%; vertical-align: middle; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 85.71%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">if we fail to pay the principal, or premium, if any, when due and the time for payment has not been extended or delayed;</div>
                  <div style="line-height: 1.25;"> <br>
                  </div>
                </td>
              </tr>
              <tr>
                <td style="width: 10.71%; vertical-align: middle; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 85.71%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">if we fail to observe or perform any other covenant set forth in the debt securities of such series or the indenture, other than a covenant specifically relating to and for the benefit of holders of another
                    series of debt securities, and our failure continues for 90 days after we receive written notice from the debenture trustee or holders of not less than a majority in aggregate principal amount of the outstanding debt securities of the
                    applicable series; and<br>
                    <br>
                  </div>
                </td>
              </tr>
              <tr>
                <td style="width: 10.71%; vertical-align: middle; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 85.71%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">if we experience specified events of bankruptcy, insolvency or reorganization.</div>
                  <div style="line-height: 1.25;"> <br>
                  </div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;No event of default with respect to a particular series of debt securities (except as to certain events of bankruptcy, insolvency or reorganization) necessarily constitutes an event of default with respect to any
            other series of debt securities. The occurrence of an event of default may constitute an event of default under any bank credit agreements we may have in existence from time to time. In addition, the occurrence of certain events of default or
            an acceleration under the indenture may constitute an event of default under certain of our other indebtedness outstanding from time to time.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25;">If an event of default with respect to debt securities of any series at the time outstanding occurs and is continuing, then the trustee or the holders of not less than a majority in principal amount of the
            outstanding debt securities of that series may, by a notice in writing to us (and to the debenture trustee if given by the holders), declare to be due and payable immediately the principal (or, if the debt securities of that series are discount
            securities, that portion of the principal amount as may be specified in the terms of that series) of and premium and accrued and unpaid interest, if any, on all debt securities of that series. Before a judgment or decree for payment of the
            money due has been obtained with respect to debt securities of any series, the holders of a majority in principal amount of the outstanding debt securities of that series (or, at a meeting of holders of such series at which a quorum is present,
            the holders of a majority in principal amount of the debt securities of such series represented at such meeting) may rescind and annul the acceleration if all events of default, other than the non-payment of accelerated principal, premium, if
            any, and interest, if any, with respect to debt securities of that series, have been cured or waived as provided in the indenture (including payments or deposits in respect of principal, premium or interest that had become due other than as a
            result of such acceleration). We refer you to the applicable prospectus supplement(s) relating to any series of debt securities that are discount securities for the particular provisions relating to acceleration of a portion of the principal
            amount of such discount securities upon the occurrence of an event of default.</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">15</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;">Subject to the terms of the indenture, if an event of default under an indenture shall occur and be continuing, the debenture trustee will be under no obligation to exercise any of its rights or powers under such
            indenture at the request or direction of any of the holders of the applicable series of debt securities, unless such holders have offered the debenture trustee reasonable indemnity. The holders of a majority in principal amount of the
            outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the debenture trustee, or exercising any trust or power conferred on the debenture
            trustee, with respect to the debt securities of that series, provided that:</div>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z7705c50e747e4533854e4b328e4e9e75" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 10.71%; vertical-align: middle; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 85.71%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">the direction so given by the holder is not in conflict with any law or the indenture; and</div>
                  <div style="line-height: 1.25;"> <br>
                  </div>
                </td>
              </tr>
              <tr>
                <td style="width: 10.71%; vertical-align: middle; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 85.71%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">subject to its duties under the Trust Indenture Act, the debenture trustee need not take any action that might involve it in personal liability or might be unduly prejudicial to the holders not involved in
                    the proceeding.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;">A holder of the debt securities of any series will only have the right to institute a proceeding under the indenture or to appoint a receiver or trustee, or to seek other remedies if:</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <table cellspacing="0" cellpadding="0" id="z2ccdc8afe7e04808af1a81eb9fa092a1" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 10.71%; vertical-align: middle; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 85.71%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">the holder previously has given written notice to the debenture trustee of a continuing event of default with respect to that series;</div>
                  <div style="line-height: 1.25;"> <br>
                  </div>
                </td>
              </tr>
              <tr>
                <td style="width: 10.71%; vertical-align: middle; background-color: #FFFFFF;">&#160;</td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 85.71%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">the holders of at least a majority in aggregate principal amount of the outstanding debt securities of that series have made written request, and such holders have offered reasonable indemnity to the
                    debenture trustee to institute the proceeding as trustee; and</div>
                  <div style="line-height: 1.25;"> <br>
                  </div>
                </td>
              </tr>
              <tr>
                <td style="width: 10.71%; vertical-align: middle; background-color: #FFFFFF;">&#160;</td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 85.71%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">the debenture trustee does not institute the proceeding, and does not receive from the holders of a majority in aggregate principal amount of the outstanding debt securities of that series (or at a meeting
                    of holders of such series at which a quorum is present, the holders of a majority in principal amount of the debt securities of such series represented at such meeting) other conflicting directions within 60 days after the notice,
                    request and offer.</div>
                  <div style="line-height: 1.25;"> <br>
                  </div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">These limitations do not apply to a suit instituted by a holder of debt securities if we default in the payment of the principal, premium, if any, or interest on, the debt securities.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25;">We will periodically file statements with the applicable debenture trustee regarding our compliance with specified covenants in the indenture.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25; font-weight: bold;">Modification of Indenture; Waiver</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25;">The debenture trustee and we may change the indenture without the consent of any holders with respect to specific matters, including:</div>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="zfab4deaa63b2440888414d9aaad967b4" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 10.71%; vertical-align: top;">&#160;</td>
                <td style="width: 3.57%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 85.71%; vertical-align: top;">
                  <div style="line-height: 1.25;">to fix any ambiguity, defect or inconsistency in the indenture; and</div>
                  <div style="line-height: 1.25;"> <br>
                  </div>
                </td>
              </tr>
              <tr>
                <td style="width: 10.71%; vertical-align: top;">&#160;</td>
                <td style="width: 3.57%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 85.71%; vertical-align: top;">
                  <div style="line-height: 1.25;">to change anything that does not materially adversely affect the interests of any holder of debt securities of any series issued pursuant to such indenture.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">16</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25;">In addition, under the indenture, the rights of holders of a series of debt securities may be changed by us and the debenture trustee with the written consent of the holders of at least a majority in aggregate
            principal amount of the outstanding debt securities of each series (or, at a meeting of holders of such series at which a quorum is present, the holders of a majority in principal amount of the debt securities of such series represented at such
            meeting) that is affected. However, the debenture trustee and we may make the following changes only with the consent of each holder of any outstanding debt securities affected:</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25;">
            <table cellspacing="0" cellpadding="0" id="zdf9afa67eff340ec8024d79d637d3690" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                <tr>
                  <td style="width: 10.71%; vertical-align: top;">&#160;</td>
                  <td style="width: 3.57%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#8226;</div>
                  </td>
                  <td style="width: 85.71%; vertical-align: top;">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">extending the fixed maturity of the series of debt securities;</div>
                      <div style="line-height: 1.25;"> <br>
                      </div>
                    </div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 10.71%; vertical-align: top;">&#160;</td>
                  <td style="width: 3.57%; vertical-align: top;">
                    <div style="line-height: 1.25;">&#8226;</div>
                  </td>
                  <td style="width: 85.71%; vertical-align: top;">
                    <div style="line-height: 1.25;">
                      <div style="line-height: 1.25;">reducing the principal amount, reducing the rate of or extending the time of payment of interest, or any premium payable upon the redemption of any debt securities;</div>
                    </div>
                  </td>
                </tr>

            </table>
            <div style="line-height: 1.25;">&#160;
              <table cellspacing="0" cellpadding="0" id="z780bb14567cd406cb42506b30448997c" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                  <tr>
                    <td style="width: 10.71%; vertical-align: top;">&#160;</td>
                    <td style="width: 3.57%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#8226;</div>
                    </td>
                    <td style="width: 85.71%; vertical-align: top;">
                      <div style="line-height: 1.25;">
                        <div style="line-height: 1.25;">reducing the principal amount of discount securities payable upon acceleration of maturity;</div>
                        <div style="line-height: 1.25;"> <br>
                        </div>
                      </div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 10.71%; vertical-align: top;">&#160;</td>
                    <td style="width: 3.57%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#8226;</div>
                    </td>
                    <td style="width: 85.71%; vertical-align: top;">
                      <div style="line-height: 1.25;">
                        <div style="line-height: 1.25;">making the principal of or premium or interest on any debt security payable in currency other than that stated in the debt security; or</div>
                      </div>
                    </td>
                  </tr>

              </table>
              <div style="line-height: 1.25;">&#160;
                <table cellspacing="0" cellpadding="0" id="z037233eec19f4c99a2d300eba5f6faed" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                    <tr>
                      <td style="width: 10.71%; vertical-align: top;">&#160;</td>
                      <td style="width: 3.57%; vertical-align: top;">
                        <div style="line-height: 1.25;">&#8226;</div>
                      </td>
                      <td style="width: 85.71%; vertical-align: top;">
                        <div style="line-height: 1.25;">
                          <div style="line-height: 1.25;">reducing the percentage of debt securities, the holders of which are required to consent to any amendment or waiver.</div>
                        </div>
                      </td>
                    </tr>

                </table>
                <div style="line-height: 1.25;">&#160;</div>
              </div>
            </div>
          </div>
          <div style="line-height: 1.25;">Except for certain specified provisions, the holders of at least a majority in principal amount of the outstanding debt securities of any series (or, at a meeting of holders of such series at which a quorum is
            present, the holders of a majority in principal amount of the debt securities of such series represented at such meeting) may on behalf of the holders of all debt securities of that series waive our compliance with provisions of the indenture.
            The holders of a majority in principal amount of the outstanding debt securities of any series may on behalf of the holders of all the debt securities of such series waive any past default under the indenture with respect to that series and its
            consequences, except a default in the payment of the principal of, premium or any interest on any debt security of that series or in respect of a covenant or provision, which cannot be modified or amended without the consent of the holder of
            each outstanding debt security of the series affected; <font style="font-style: italic;">provided</font>, <font style="font-style: italic;">however</font>, that the holders of a majority in principal amount of the outstanding debt securities
            of any series may rescind an acceleration and its consequences, including any related payment default that resulted from the acceleration.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25; font-weight: bold;">Discharge</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25;">Each indenture provides that we can elect to be discharged from our obligations with respect to one or more series of debt securities, except for obligations to:</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25;">
            <div style="line-height: 1.25;">
              <table cellspacing="0" cellpadding="0" id="z00e5784abb8b4c03b0f94a5aaa9ee07d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                  <tr>
                    <td style="width: 10.71%; vertical-align: top;">&#160;</td>
                    <td style="width: 3.57%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#8226;</div>
                    </td>
                    <td style="width: 85.71%; vertical-align: top;">
                      <div style="line-height: 1.25;">
                        <div style="line-height: 1.25;">
                          <div style="line-height: 1.25;">the transfer or exchange of debt securities of the series;</div>
                          <div style="line-height: 1.25;"> <br>
                          </div>
                        </div>
                      </div>
                    </td>
                  </tr>
                  <tr>
                    <td style="width: 10.71%; vertical-align: top;">&#160;</td>
                    <td style="width: 3.57%; vertical-align: top;">
                      <div style="line-height: 1.25;">&#8226;</div>
                    </td>
                    <td style="width: 85.71%; vertical-align: top;">
                      <div style="line-height: 1.25;">
                        <div style="line-height: 1.25;">
                          <div style="line-height: 1.25;">replace stolen, lost or mutilated debt securities of the series;</div>
                        </div>
                      </div>
                    </td>
                  </tr>

              </table>
              <div style="line-height: 1.25;">&#160;
                <table cellspacing="0" cellpadding="0" id="z3f826af667fb407994d00b7eea1f9fd8" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                    <tr>
                      <td style="width: 10.71%; vertical-align: top;">&#160;</td>
                      <td style="width: 3.57%; vertical-align: top;">
                        <div style="line-height: 1.25;">&#8226;</div>
                      </td>
                      <td style="width: 85.71%; vertical-align: top;">
                        <div style="line-height: 1.25;">
                          <div style="line-height: 1.25;">
                            <div style="line-height: 1.25;">maintain paying agencies;</div>
                          </div>
                          <div style="line-height: 1.25;"> <br>
                          </div>
                        </div>
                      </td>
                    </tr>
                    <tr>
                      <td style="width: 10.71%; vertical-align: top;">&#160;</td>
                      <td style="width: 3.57%; vertical-align: top;">
                        <div style="line-height: 1.25;">&#8226;</div>
                      </td>
                      <td style="width: 85.71%; vertical-align: top;">
                        <div style="line-height: 1.25;">
                          <div style="line-height: 1.25;">
                            <div style="line-height: 1.25;">hold monies for payment in trust;</div>
                          </div>
                        </div>
                      </td>
                    </tr>

                </table>
                <div style="line-height: 1.25;">&#160;
                  <table cellspacing="0" cellpadding="0" id="zb40a1d4cfbb24c8999ae5a8a30e7ea6e" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                      <tr>
                        <td style="width: 10.71%; vertical-align: top;">&#160;</td>
                        <td style="width: 3.57%; vertical-align: top;">
                          <div style="line-height: 1.25;">&#8226;</div>
                        </td>
                        <td style="width: 85.71%; vertical-align: top;">
                          <div style="line-height: 1.25;">
                            <div style="line-height: 1.25;">
                              <div style="line-height: 1.25;">compensate and indemnify the trustee; and</div>
                            </div>
                          </div>
                        </td>
                      </tr>

                  </table>
                  <div style="line-height: 1.25;">&#160;
                    <table cellspacing="0" cellpadding="0" id="z0a25afbc358848cfadacc4519082ab87" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

                        <tr>
                          <td style="width: 10.71%; vertical-align: top;">&#160;</td>
                          <td style="width: 3.57%; vertical-align: top;">
                            <div style="line-height: 1.25;">&#8226;</div>
                          </td>
                          <td style="width: 85.71%; vertical-align: top;">
                            <div style="line-height: 1.25;">
                              <div style="line-height: 1.25;">
                                <div style="line-height: 1.25;">
                                  <div style="line-height: 1.25;">appoint any successor trustee.</div>
                                </div>
                              </div>
                            </div>
                          </td>
                        </tr>

                    </table>
                    <div style="line-height: 1.25;">&#160;</div>
                  </div>
                </div>
              </div>
            </div>
          </div>
          <div style="line-height: 1.25;"> </div>
          <div style="line-height: 1.25;">In order to exercise our rights to be discharged with respect to a series, we must deposit with the trustee money or government obligations sufficient to pay all the principal of, the premium, if any, and interest
            on, the debt securities of the series on the dates payments are due.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25; font-weight: bold;">Form, Exchange, and Transfer</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25;">We will issue the debt securities of each series only in fully registered form without coupons and, unless we otherwise specify in the applicable prospectus supplement, in denominations of $1,000 and any integral
            multiple thereof. The indenture provides that we may issue debt securities of a series in temporary or permanent global form and as book-entry securities that will be deposited with, or on behalf of, The Depository Trust Company or another
            depositary named by us and identified in a prospectus supplement with respect to that series.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25;">At the option of the holder, subject to the terms of the indenture and the limitations applicable to global securities described in the applicable prospectus supplement, the holder of the debt securities of any
            series can exchange the debt securities for other debt securities of the same series, in any authorized denomination and of like tenor and aggregate principal amount.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25;">Subject to the terms of the indenture and the limitations applicable to global securities set forth in the applicable prospectus supplement, holders of the debt securities may present the debt securities for
            exchange or for registration of transfer, duly endorsed or with the form of transfer endorsed thereon duly executed if so required by us or the security registrar, at the office of the security registrar or at the office of any transfer agent
            designated by us for this purpose. Unless otherwise provided in the debt securities that the holder presents for transfer or exchange or in the indenture, we will make no service charge for any registration of transfer or exchange, but we may
            require payment of any taxes or other governmental charges.</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">17</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25;">We will name in the applicable prospectus supplement the security registrar, and any transfer agent in addition to the security registrar, that we initially designate for any debt securities. We may at any time
            designate additional transfer agents or rescind the designation of any transfer agent or approve a change in the office through which any transfer agent acts, except that we will be required to maintain a transfer agent in each place of payment
            for the debt securities of each series.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25;">If we elect to redeem the debt securities of any series, we will not be required to:</div>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z5352fc61af2b4406871cf5200486a4a7" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 7.14%; vertical-align: top;">&#160;</td>
                <td style="width: 3.57%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 89.29%; vertical-align: top;">
                  <div style="line-height: 1.25;">issue, register the transfer of, or exchange any debt securities of that series during a period beginning at the opening of business 15 days before the day of mailing of a notice of redemption of any debt
                    securities that may be selected for redemption and ending at the close of business on the day of the mailing; or</div>
                  <div style="line-height: 1.25;"> <br>
                  </div>
                </td>
              </tr>
              <tr>
                <td style="width: 7.14%; vertical-align: top;">&#160;</td>
                <td style="width: 3.57%; vertical-align: top;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 89.29%; vertical-align: top;">
                  <div style="line-height: 1.25;">register the transfer of or exchange any debt securities so selected for redemption, in whole or in part, except the unredeemed portion of any debt securities we are redeeming in part.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25; font-weight: bold;">Information Concerning the Debenture Trustee</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25;">The debenture trustee, other than during the occurrence and continuance of an event of default under the indenture, undertakes to perform only those duties as are specifically set forth in the indenture. Upon an
            event of default under an indenture, the debenture trustee under such indenture must use the same degree of care as a prudent person would exercise or use in the conduct of his or her own affairs. Subject to this provision, the debenture
            trustee is under no obligation to exercise any of the powers given it by the indenture at the request of any holder of debt securities unless it is offered reasonable security and indemnity against the costs, expenses and liabilities that it
            might incur.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25; font-weight: bold;">Payment and Paying Agents</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25;">Unless we otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any interest payment date to the person in whose name the debt securities, or one
            or more predecessor securities, are registered at the close of business on the regular record date for the interest.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25;">We will pay the principal of and any premium and interest due on the debt securities of a particular series at the office of the paying agents designated by us, except that unless we otherwise indicate in the
            applicable prospectus supplement, will we make interest payments by check which we will mail to the holder. Unless we otherwise indicate in a prospectus supplement, we will designate the corporate trust office of the debenture trustee in the
            City of New York as our sole paying agent for payments with respect to debt securities of each series. We will name in the applicable prospectus supplement any other paying agents that we initially designate for the debt securities of a
            particular series. We will maintain a paying agent in each place of payment for the debt securities of a particular series.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25;">All money we pay to a paying agent or the debenture trustee for the payment of the principal of or any premium or interest on any debt securities which remains unclaimed at the end of two years after such
            principal, premium or interest has become due and payable will be repaid to us, and the holder of the security thereafter may look only to us for payment thereof.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25; font-weight: bold;">Governing Law</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25;">The indenture and the debt securities will be governed by and construed in accordance with the laws of the State of New York, except to the extent that the Trust Indenture Act is applicable.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25; font-weight: bold;">Subordination of Subordinated Debt Securities</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25;">Our obligations pursuant to any subordinated debt securities will be unsecured and will be subordinate and junior in priority of payment to certain of our other indebtedness to the extent described in a prospectus
            supplement. The subordinated indenture does not limit the amount of senior indebtedness we may incur. It also does not limit us from issuing any other secured or unsecured debt.</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">18</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="DESCRIPTIONOFRIGHTS"><!--Anchor--></a>DESCRIPTION OF RIGHTS</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25; font-weight: bold;">General</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">We may issue rights to purchase any of our securities or any combination thereof. Rights may be issued independently or together with any other offered security and may or may not be transferable
            by the person purchasing or receiving the rights. In connection with any rights offering to our shareholders, we may enter into a standby underwriting arrangement with one or more underwriters pursuant to which such underwriters will purchase
            any offered securities remaining unsubscribed for after such rights offering. We may also appoint a rights agent that may act solely as our agent in connection with the rights that are sold. Any such agent will not assume any obligation or
            relationship of agency or trust with any of the holders of the rights. In connection with a rights offering to our shareholders, we will distribute certificates evidencing the rights and a prospectus supplement to our shareholders on the record
            date that we set for receiving rights in such rights offering.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">The applicable prospectus supplement will describe the following terms of rights in respect of which this prospectus is being delivered:</div>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z5ad3068a095b40218786420f723ff7b5" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 7.14%; vertical-align: middle; background-color: #FFFFFF;">&#160;</td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 89.29%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">the title of such rights;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z608ef4d4d6304f75b591d5a38ee09d27" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 7.14%; vertical-align: middle; background-color: #FFFFFF;">&#160;</td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 89.29%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">the securities for which such rights are exercisable;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z3879a2b4a9674b8283515d685a24e004" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 7.14%; vertical-align: middle; background-color: #FFFFFF;">&#160;</td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 89.29%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">the exercise price for such rights;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="zad9b2a98b7ac45c4a1c2bdeb3d417c26" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 7.14%; vertical-align: middle; background-color: #FFFFFF;">&#160;</td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 89.29%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">the number of such rights issued with respect to each ordinary share;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z8bc05fab90ee4d94b74433b362822144" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 7.14%; vertical-align: middle; background-color: #FFFFFF;">&#160;</td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 89.29%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">the extent to which such rights are transferable;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z1049751e1e7c48bda2a292a497b08178" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 7.14%; vertical-align: middle; background-color: #FFFFFF;">&#160;</td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 89.29%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">if applicable, a discussion of the material Israeli and U.S. income tax considerations applicable to the issuance or exercise of such rights;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z29559f80f9f14582a73c7b271b399c98" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 7.14%; vertical-align: middle; background-color: #FFFFFF;">&#160;</td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 89.29%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">the date on which the right to exercise such rights shall commence, and the date on which such rights shall expire (subject to any extension);</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z07fc8f7c00844bd8a0530aac116894d8" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 7.14%; vertical-align: middle; background-color: #FFFFFF;">&#160;</td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 89.29%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">the extent to which such rights include an over-subscription privilege with respect to unsubscribed securities;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="zc75860a12fa4481196626a5e51572775" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 7.14%; vertical-align: middle; background-color: #FFFFFF;">&#160;</td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 89.29%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">if applicable, the material terms of any standby underwriting or other purchase arrangement, or any agency agreement, that we may enter into in connection with the rights offering; and</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z94d4ecc824af4cbca657797757979521" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 7.14%; vertical-align: middle; background-color: #FFFFFF;">&#160;</td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 89.29%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">any other terms of such rights, including terms, procedures and limitations relating to the exchange and exercise of such rights.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25; font-weight: bold;">Exercise of Rights</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">Each right will entitle the holder of the right to purchase for cash such securities or any combination thereof at such exercise price as shall in each case be set forth in, or be determinable as
            set forth in, the prospectus supplement relating to the rights offered thereby. Rights may be exercised at any time up to the close of business on the expiration date for such rights set forth in the prospectus supplement. After the close of
            business on the expiration date, all unexercised rights will become void.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">Rights may be exercised as set forth in the prospectus supplement relating to the rights offered thereby. Upon receipt of payment and the rights certificate properly completed and duly executed
            at the corporate trust office of the rights agent or any other office indicated in the prospectus supplement, we will forward, as soon as practicable, the securities purchasable upon such exercise. We may determine to offer any unsubscribed
            offered securities directly to persons other than shareholders, to or through agents, underwriters or dealers or through a combination of such methods, including pursuant to standby underwriting arrangements, as set forth in the applicable
            prospectus supplement.</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">19</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="DESCRIPTIONOFWARRANTS"><!--Anchor--></a>DESCRIPTION OF WARRANTS</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">We may issue warrants to purchase ordinary shares. We may issue warrants independently or together with any other securities offered by any prospectus supplement and the warrants may be attached
            to or separate from those securities. Any series of warrants may be issued under a separate warrant agreement, which may be entered into between us and a warrant agent specified in a prospectus supplement. Any such warrant agent will act solely
            as our agent in connection with the warrants of such series and will not assume any obligation or relationship of agency or trust with any of the holders of the warrants. We will set forth further terms of the warrants and any applicable
            warrant agreements in the applicable prospectus supplement relating to the issuance of any warrants, including, where applicable, the following:</div>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z601c85616c50430e8f32e93890c4b8a5" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 7.14%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 89.29%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">the title of the warrants;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="zdb492d1ef57542ad9b52e42fdba32f12" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 7.14%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 89.29%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">the aggregate number of the warrants;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="zd9da1e100d6946439cb6c3c1478b6a93" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 7.14%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 89.29%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">the number of ordinary shares purchasable upon exercise of the warrants;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="zbf2059e71c9b4731b97f47039f7bbecc" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 7.14%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 89.29%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">the designation and terms of the securities, if any, with which the warrants are issued and the number of the warrants issued with each such offered security;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="zdcccc9d8b25e4044846a49117f14b963" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 7.14%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 89.29%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">the date, if any, on and after which the warrants and the related securities will be separately transferable;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z123a058399d14ddd868a296edc6ba9cc" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 7.14%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 89.29%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">the price at which, and form of consideration for which, each security purchasable upon exercise of the warrants may be purchased;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z2293d5d4d2aa4d3ab138b55a02243707" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 7.14%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#160;</div>
                </td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 89.29%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">the date on which the right to exercise the warrants will commence and the date on which the right will expire;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="zcf1a624f5dca428989c77b1954aaa9b2" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 7.14%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 89.29%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">the minimum or maximum amount of the warrants which may be exercised at any one time;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="zbe9892d377cb499da6fd92b857004bb3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 7.14%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 89.29%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">any circumstances that will cause the warrants to be deemed to be automatically exercised; and</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="za013d8cb7f63458791c0562605c63ceb" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 7.14%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 89.29%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">any other material terms of the warrants.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25; font-weight: bold;">Outstanding Warrants</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 35pt; line-height: 1.25;">In connection with the issuance of the ordinary shares in our June 2018 registered direct offering, we also issued to certain institutional investors warrants to purchase up to 4,253,165
            additional ordinary shares, out of which 749,104 were outstanding as of June 30, 2020. The following is a brief summary of certain terms and conditions of the warrants and is subject in all respects to the provisions contained in the warrants.</div>
          <div style="text-indent: 35pt; line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Term</div>
          <div style="text-indent: 35pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 35pt; line-height: 1.25;">The warrants are exercisable during the period beginning six months from the date of issuance and ending at 5:00 P.M. on June 19, 2023.</div>
          <div style="text-indent: 35pt; line-height: 1.25; font-style: italic; font-weight: bold;">&#160;</div>
          <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Exercise Price</div>
          <div style="text-indent: 35pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 35pt; line-height: 1.25;">The exercise price of the warrants is $4.74 per whole ordinary share. The exercise price is subject to appropriate adjustment in the event of certain stock splits, dividends, recapitalizations or
            similar events affecting our ordinary shares.</div>
          <div style="text-indent: 35pt; line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Exercisability</div>
          <div style="text-indent: 35pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 35pt; line-height: 1.25;">Holders may exercise the warrants beginning six months from June 19, 2018, the date of issuance, and at any time during the applicable term of the warrant. The warrants will be exercisable, at
            the option of each holder, in whole or in part, by delivering to us a written notice and, within&#160;one&#160;trading&#160;day&#160;of delivering such notice, payment&#160;shall be made&#160;in full for the number of ordinary shares purchased upon such exercise. If there
            is no effective registration statement registering the issuance and sale of the ordinary shares underlying the warrants, the holder may exercise the warrant through a cashless exercise, in which case the holder would receive upon such exercise
            the net number of ordinary shares determined according to the formula set forth in the warrant.</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">20</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-indent: 35pt; line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Exercise Limitation</div>
          <div style="text-indent: 35pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 35pt; line-height: 1.25;">Holders shall not have the right to exercise the warrant, to the extent that after giving effect to such exercise, such holder, together with such holder&#8217;s affiliates and any other persons acting
            as a group together with the holder or any of the holder&#8217;s affiliates, would beneficially own in excess of 4.99% of the ordinary shares outstanding immediately after giving effect to such exercise which limitation may be increased to 9.99% by
            the holder.</div>
          <div style="text-indent: 35pt; line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25; font-style: italic; font-weight: bold;">No Fractional Shares</div>
          <div style="text-indent: 35pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 35pt; line-height: 1.25;">No fractional ordinary shares will be issued upon exercise of the warrants. If there is a fractional share issuable upon exercise, we will, at our election, either pay a cash adjustment or it
            will be rounded up to the nearest whole share.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Transferability</div>
          <div style="text-indent: 35pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 35pt; line-height: 1.25;">Subject to applicable laws and the restriction on transfer set forth in the warrant, the warrant may be transferred at the option of the holder upon surrender of the warrant to us together with
            the appropriate instruments of transfer.</div>
          <div style="text-indent: 35pt; line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Authorized Shares</div>
          <div style="text-indent: 35pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 35pt; line-height: 1.25;">During the period the warrants are outstanding, we will reserve from our authorized and unissued ordinary shares a sufficient number of shares to provide for the issuance of ordinary shares
            underlying the warrants upon the exercise of the warrants.</div>
          <div style="text-indent: 35pt; line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Exchange Listing</div>
          <div style="text-indent: 35pt; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">We have not and do not plan on applying to list the warrants on Nasdaq, the TASE, any other national securities exchange or any other nationally recognized trading system.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Purchase Rights</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-indent: 36pt; line-height: 1.25;">Subject to certain limitations, if at any time during the period the warrants are outstanding we grant, issue or sell certain of our securities pro rata to the record holders of our ordinary
            shares, the warrant holders shall be entitled to participate upon the same terms in an amount up to the number of ordinary shares acquirable upon complete exercise of the warrant.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Pro Rata Distributions</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-indent: 36pt; line-height: 1.25;">Subject to certain limitations, if at any time during the period the warrants are outstanding we declare or make any dividend or other distribution of assets to our ordinary shareholders, the
            warrant holders shall be entitled to distributions upon the same terms in an amount up to the number of ordinary shares acquirable upon complete exercise of the warrant.</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Fundamental Transactions</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">In the event of any fundamental transaction, as defined in the warrants and generally including any consolidation or merger with or into another entity, the sale of all or substantially all of
            our assets, tender offer or exchange offer, reorganization or recapitalization through which another entity acquires us, or reclassification of our ordinary shares, then the successor entity in such transaction will assume in writing all of our
            obligations under the warrant pursuant to written agreements, including an adjusted exercise price equal to the value for the ordinary shares reflected by the terms of such fundamental transaction, and exercisable for a corresponding number of
            shares equivalent to the ordinary shares acquirable and receivable upon exercise of the warrant prior to such fundamental transaction.</div>
          <div style="line-height: 1.25; font-style: italic; font-weight: bold;">&#160;</div>
          <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Failure to Timely Deliver Securities</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">If we fail for any reason to deliver to a holder the number of shares of ordinary shares due to the holder pursuant to the holder&#8217;s written notice on or before the second
            trading day following receipt of such notice, we will pay to the holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of ordinary shares subject to such exercise, $10 per trading day (increasing to $20 per trading day on
            the fifth trading day after such liquidated damages begin to accrue) for each trading day until such ordinary shares are delivered or the holder rescinds such exercise.</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">21</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Right as a Shareholder</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">Except as otherwise provided in the warrants or by virtue of such holder&#8217;s ownership of our ordinary shares, the holders of the warrants do not have the rights or privileges of holders of our
            ordinary shares, including any voting rights, until they exercise their warrants.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="line-height: 1.25; font-style: italic; font-weight: bold;">Waivers and Amendments</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">Any term of the warrants issued in the offering may be amended or waived with our written consent and the written consent of the holder.</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">22</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="DESCRIPTIONOFUNITS"><!--Anchor--></a>DESCRIPTION OF UNITS</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">As specified in the applicable prospectus supplement, we may issue units consisting of our ordinary shares, debt securities, rights, warrants or any combination of such securities. The applicable
            prospectus supplement will describe:</div>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="ze2e48d5bbe0044c48192922b2bd4b148" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 7.14%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 89.29%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">the terms of the units and of the ordinary shares, debt securities, rights and/or warrants comprising the units, including whether and under what circumstances the securities comprising the units may be
                    traded separately;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="zc9e18c65eba74ed0bb2f75f7eef3f1b3" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 7.14%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 89.29%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">the terms of any unit agreement governing the units or any arrangement with an agent that may act on our behalf in connection with the unit offering; and</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z70462581e10a43e38a43732076463195" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 7.14%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 89.29%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">the provisions for the payment, settlement, transfer or exchange of the units.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">23</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="PLANOFDISTRIBUTION"><!--Anchor--></a>PLAN OF DISTRIBUTION</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">We may sell the offered securities on a negotiated or competitive bid basis to or through underwriters or dealers. We may also sell the securities directly to corporate partners in various
            programs of the Company, institutional investors or other purchasers or through agents. We will identify any underwriter, dealer, or agent involved in the offer and sale of the securities, and any applicable commissions, discounts and other
            terms constituting compensation to such underwriters, dealers or agents, in a prospectus supplement.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">We may distribute our securities from time to time in one or more transactions:</div>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z7485c1315de64386afd4ddbccd07446f" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 7.14%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 89.29%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">at a fixed price or prices, which may be changed;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="zf330e5c44d764d8e9a013e61cb771d17" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 7.14%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 89.29%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">at market prices prevailing at the time of sale;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="zda46e8080a044af5a14efad456064060" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 7.14%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 89.29%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">at prices related to such prevailing market prices; or</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z27c32ad8c0ef48cf9b4013b0291974de" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 7.14%; vertical-align: top; background-color: #FFFFFF;">&#160;</td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 89.29%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">at negotiated prices.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">Only underwriters named in the prospectus supplement are underwriters of our securities offered by the prospectus supplement.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">If underwriters are used in the sale of our securities, such securities will be acquired by the underwriters for their own account and may be resold from time to time in one or more transactions,
            including negotiated transactions, at a fixed public offering price or at varying prices determined at the time of sale. Unless stated otherwise in a prospectus supplement, the obligation of any underwriters to purchase our securities will be
            subject to certain conditions and the underwriters will be obligated to purchase all of the applicable securities if any are purchased. If a dealer is used in a sale, we may sell our securities to the dealer as principal. The dealer may then
            resell the securities to the public at varying prices to be determined by the dealer at the time of resale. In effecting sales, dealers engaged by us may arrange for other dealers to participate in the resales.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">We or our agents may solicit offers to purchase securities from time to time. Unless stated otherwise in a prospectus supplement, any agent will be acting on a best efforts basis for the period
            of its appointment. In addition, we may enter into derivative, sale or forward sale transactions with third parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions. If the applicable
            prospectus supplement indicates, in connection with such transaction, the third parties may, pursuant to this prospectus and the applicable prospectus supplement, sell securities covered by this prospectus and the applicable prospectus
            supplement. If so, the third party may use securities borrowed from us or others to settle such sales and may use securities received from us or others to close out any related short positions. We may also loan or pledge securities covered by
            this prospectus and the applicable prospectus supplement to third parties, who may sell the loaned securities or, in the event of default in the case of a pledge, sell the pledged securities pursuant to this prospectus and the applicable
            prospectus supplement. The third party in such transactions will be an underwriter and will be identified in the applicable prospectus supplement or in a post-effective amendment.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">In connection with the sale of our securities, underwriters or agents may receive compensation (in the form of discounts, concessions or commissions) from us or from purchasers of securities for
            whom they may act as agents. Underwriters may sell securities to or through dealers, and such dealers may receive compensation in the form of discounts, concessions or commissions from the underwriters and/or commissions from the purchasers for
            whom they may act as agents. Underwriters, dealers and agents that participate in the distribution of our securities may be deemed to be &#8220;underwriters&#8221; as that term is defined in the Securities Act, and any discounts or commissions received by
            them from us and any profits on the resale of the shares by them may be deemed to be underwriting discounts and commissions under the Securities Act. Compensation as to a particular underwriter, dealer or agent might be in excess of customary
            commissions and will be in amounts to be negotiated in connection with transactions involving our securities. We will identify any such underwriter or agent, and we will describe any such compensation paid, in the related prospectus supplement.
            Maximum compensation to any underwriters, dealers or agents will not exceed any applicable limitations of the Financial Industry Regulatory Authority, Inc.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">Underwriters, dealers and agents may be entitled, under agreements with us, to indemnification against and contribution toward certain civil liabilities, including liabilities under the
            Securities Act.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">If stated in a prospectus supplement, we will authorize agents and underwriters to solicit offers by certain specified institutions or other persons to purchase our securities at the public
            offering price set forth in the prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specific date in the future. Institutions with whom such contracts may be made include commercial savings
            banks, insurance companies, pension funds, investment companies, educational and charitable institutions, and other institutions, but shall in all cases be subject to our approval. Such contracts will be subject only to those conditions set
            forth in the prospectus supplement, and the prospectus supplement will set forth the commission payable for solicitation of such contracts. The obligations of any purchase under any such contract will be subject to the condition that the
            purchase of the securities shall not be prohibited at the time of delivery under the laws of Israel and of the jurisdiction to which the purchaser is subject. The underwriters and other agents will not have any responsibility in respect of the
            validity or performance of such contracts.</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">24</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">If underwriters or dealers are used in the sale, until the distribution of our securities is completed, SEC rules may limit the ability of any such underwriters and selling group members to bid
            for and purchase the securities. As an exception to these rules, representatives of any underwriters are permitted to engage in certain transactions that stabilize the price of the securities. Such transactions may consist of bids or purchases
            for the purpose of pegging, fixing or maintaining the price of the securities. If the underwriters create a short position in the securities in connection with the offering (in other words, if they sell more shares than are set forth on the
            cover page of the prospectus supplement), the representatives of the underwriters may reduce that short position by purchasing securities in the open market. The representatives of the underwriters also may elect to reduce any short position by
            exercising all or part of any over-allotment option we may grant to the underwriters, as described in the prospectus supplement. In addition, the representatives of the underwriters may impose a penalty bid on certain underwriters and selling
            group members. This means that if the representatives purchase securities in the open market to reduce the underwriters&#8217; short position or to stabilize the price of our securities, they may reclaim the amount of the selling concession from the
            underwriters and selling group members who sold those securities as part of the offering. In general, purchases of a security for the purpose of stabilizing or to reduce a short position could cause the price of the security to be higher than
            it might be in the absence of such purchases. The imposition of a penalty bid might also have the effect of causing the price of the securities to be higher than it would otherwise be. If commenced, the representatives of the underwriters may
            discontinue any of the transactions at any time. These transactions may be affected on any exchange on which our securities are traded, in the over-the-counter market, or otherwise.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">Certain of the underwriters or agents and their associates may engage in transactions with and perform services for us or our affiliates in the ordinary course of their respective businesses.</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">25</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="LEGALMATTERS"><!--Anchor--></a>LEGAL MATTERS</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; margin-right: 4.95pt; line-height: 1.25;">Certain matters of Israeli law with respect to the legality of the issuance of the ordinary shares offered by this prospectus will be passed upon for us by Shibolet &amp;
            Co., Law Firm, Tel Aviv, Israel. Certain matters of U.S. law will be passed upon for us by&#160;Cooley&#160;LLP, New York, New York.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="EXPERTS"><!--Anchor--></a>EXPERTS</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; margin-right: 4.95pt; line-height: 1.25;">The consolidated financial statements of Compugen Ltd. appearing in the Annual Report on Form 20-F for the year ended December 31, 2019 and the effectiveness of Compugen
            Ltd. internal control over financial reporting as of December 31, 2019, as filed with the SEC on&#160; February 24, 2020, have been audited by Kost Forer Gabbay &amp; Kasierer (a Member of Ernst &amp; Young Global), independent registered public
            accounting firm, as set forth in their report thereon, included therein, and incorporated herein by reference. Such consolidated financial statements are incorporated herein by reference in reliance upon such reports pertaining to such
            consolidated financial statements and the effectiveness of Compugen Ltd. internal control over financial reporting as of the respective dates, given on the authority of such firm as experts in accounting and auditing. The address of Kost Forer
            Gabbay &amp; Kasierer is 144 Menachem Begin Road, Building A, Tel-Aviv, Israel 6492102.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="EXPENSES"><!--Anchor--></a>EXPENSES</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">The following are the estimated expenses related to the filing of the registration statement of which this prospectus forms a part, all of which will be paid by us. In addition, we anticipate
            incurring additional expenses in the future in connection with the offering of our securities pursuant to this prospectus. Any such additional expenses will be disclosed in a prospectus supplement.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" border="0" align="right" id="z51caecd546c04145bb110949be0960dd" style="width: 95%; color: #000000; font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left;">

              <tr>
                <td valign="bottom" colspan="1" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 88%;">
                  <div style="text-align: justify; line-height: 1.25;">SEC registration fee&#160;</div>
                </td>
                <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">45,430</div>
                </td>
                <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" colspan="1" style="vertical-align: top; width: 88%; background-color: rgb(255, 255, 255);">
                  <div style="text-align: justify; line-height: 1.25;">Printing expenses*</div>
                </td>
                <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
                <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
                <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255, 255, 255);">
                  <div style="line-height: 1.25;">1,000</div>
                </td>
                <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" colspan="1" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 88%;">
                  <div style="text-align: justify; line-height: 1.25;">Legal fees and expenses*&#160;</div>
                </td>
                <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
                <td valign="bottom" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%;">
                  <div style="line-height: 1.25;">25,000</div>
                </td>
                <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%;">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" colspan="1" style="vertical-align: top; width: 88%; background-color: rgb(255, 255, 255);">
                  <div style="text-align: justify; line-height: 1.25;">Accounting fees and expenses*&#160;</div>
                </td>
                <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
                <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
                <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(255, 255, 255);">
                  <div style="line-height: 1.25;">5,000</div>
                </td>
                <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; background-color: rgb(255, 255, 255);">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" colspan="1" style="vertical-align: top; background-color: rgb(204, 238, 255); width: 88%; padding-bottom: 2px;">
                  <div style="text-align: justify; line-height: 1.25;">Miscellaneous*&#160;</div>
                </td>
                <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255);">&#160;</td>
                <td valign="bottom" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>
                <td valign="bottom" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">
                  <div style="line-height: 1.25;">570</div>
                </td>
                <td valign="bottom" nowrap="nowrap" colspan="1" style="background-color: #CCEEFF; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>
              </tr>
              <tr>
                <td valign="bottom" colspan="1" style="vertical-align: top; width: 88%; padding-bottom: 4px; background-color: rgb(255, 255, 255);">
                  <div style="text-align: justify; line-height: 1.25;">Total*&#160;</div>
                </td>
                <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(255, 255, 255);">&#160;</td>
                <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(255, 255, 255);">
                  <div style="line-height: 1.25;">$</div>
                </td>
                <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(255, 255, 255);">
                  <div style="line-height: 1.25;">77,000</div>
                </td>
                <td valign="bottom" nowrap="nowrap" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(255, 255, 255);">&#160;</td>
              </tr>

          </table>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25; clear: both;">__________</div>
          <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">*Estimated</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="INCORPORATIONOFCERTAININF"><!--Anchor--></a>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">The SEC allows us to &#8220;incorporate by reference&#8221; the information we file with it, which means that we can disclose important information to you by referring you to those documents. The information
            incorporated by reference is considered to be part of this prospectus and information we file later with the SEC will automatically update and supersede this information. The documents we are incorporating by reference as of their respective
            dates of filing are:</div>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z760714538e7f42dca202e545e3f4e3cd" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 7.14%; vertical-align: middle; background-color: #FFFFFF;">&#160;</td>
                <td style="width: 7.14%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 85.71%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">Annual Report on Form 20-F for the year ended December 31, 2019, filed on February 24, 2020 and as amended on February 27, 2020 (File Nos. 000-30902);</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="zb84ccd094c4d42e289c81cd766c6b574" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 7.14%; vertical-align: middle; background-color: #FFFFFF;">&#160;</td>
                <td style="width: 7.14%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 85.71%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">Reports on Form 6-K filed on January 9, 2020, February 20, 2020, February 20, 2020, March 9, 2020, March 11, 2020, March 12, 2020, March 13, 2020, March 17, 2020, April 6, 2020, April 15, 2020, April 27,
                    2020, May 6, 2020, May 27, 2020, June 1, 2020 and July 30, 2020&#160;(File Nos. 000-30902); and</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z1f66e8d220294be7a6d8c22e9469e808" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 7.14%; vertical-align: middle; background-color: #FFFFFF;">&#160;</td>
                <td style="width: 7.14%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#8226;</div>
                </td>
                <td style="width: 85.71%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">the description of our ordinary shares contained in our Form 8-A filed on August 2, 2000 (File No. 000-30902), as updated and amended by the disclosure contained under &#8220;Description of Ordinary Shares&#8221; in
                    this registration statement on Form F-3.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">All subsequent annual reports on Form 20-F, Form 40-F or Form 10-K filed by us, all subsequent reports on Forms 10-Q and 8-K filed by us, and all subsequent reports on Form 6-K filed by us that
            are identified by us as being incorporated by reference shall be deemed to be incorporated by reference into this prospectus and deemed to be a part hereof after the date of this prospectus but before the termination of the offering by this
            prospectus.</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">26</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">Any statement contained in a document incorporated by reference herein shall be deemed to be modified or superseded for all purposes to the extent that a statement contained in this prospectus,
            or in any other subsequently filed document which is also incorporated or deemed to be incorporated by reference, modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or
            superseded, to constitute a part of this prospectus.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">You may request, orally or in writing, a copy of these documents, which will be provided to you at no cost, by contacting:</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: center; line-height: 1.25;"><font style="font-weight: bold;">Ari Krashin</font><br>
            <font style="font-weight: bold;">Chief Financial Officer</font><br>
            <font style="font-weight: bold;">Compugen Ltd.</font><br>
            <font style="font-weight: bold;">26 Harokmim Street</font><br>
            <font style="font-weight: bold;">Holon 5885849, Israel</font><br>
            <font style="font-weight: bold;">Phone: +972-3-765-8585</font><br>
            <font style="font-weight: bold;">Fax: +972-3-765-8555</font><br>
            &#160;</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">27</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <div style="line-height: 1.25">&#160;</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="WHEREYOUCANFINDADDITIONAL"><!--Anchor--></a>WHERE YOU CAN FIND ADDITIONAL INFORMATION</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">This prospectus is part of a registration statement on Form F-3 that we filed with the SEC relating to the securities offered by this prospectus, which includes additional information. You should
            refer to the registration statement and its exhibits for additional information. Whenever we make reference in this prospectus to any of our contracts, agreements or other documents, the references are not necessarily complete, and you should
            refer to the exhibits attached to the registration statement for copies of the actual contract, agreements or other document.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">We are subject to the informational requirements of the Exchange Act applicable to foreign private issuers. We, as a &#8220;foreign private issuer,&#8221; are exempt from the rules under the Exchange Act
            prescribing certain disclosure and procedural requirements for proxy solicitations, and our office holders, directors and principal shareholders are exempt from the reporting and &#8220;short-swing&#8221; profit recovery provisions contained in Section 16
            of the Exchange Act, with respect to their purchases and sales of shares. In addition, we are not required to file annual, quarterly and current reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose
            securities are registered under the Exchange Act. So long as we are a foreign private issuer, we anticipate filing with the SEC, within three months after the end of each fiscal year, an Annual Report on Form 20-F containing financial
            statements audited by an independent accounting firm. We also furnish or file with the SEC Reports of Foreign Private Issuer on Form 6-K and other information with the SEC as required by the Exchange Act. You can review our SEC filings and the
            registration statement by accessing the SEC&#8217;s internet site at <font style="font-style: italic;">http://www.sec.gov</font>.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">We also maintain a website at <font style="font-style: italic;">www.cgen.com</font>, through which you can access certain SEC filings. The information set forth on our website is not part of
            this prospectus.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="ENFORCEABILITYOFCIVILLIAB"><!--Anchor--></a>ENFORCEABILITY OF CIVIL LIABILITIES</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">We are incorporated under the laws of the State of Israel. Service of process upon us and upon our directors and office holders, almost all of whom reside outside the United States, may be
            difficult to obtain within the United States. Furthermore, because the majority of our assets and investments, and almost all of our directors and officer holders are located outside the United States, any judgment obtained in the United States
            against us or any of them may not be collectible within the United States.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">Additionally, it may be difficult to assert U.S. securities law claims in original actions instituted in Israel. Israeli courts may refuse to hear a claim based on an alleged violation of U.S.
            securities laws because Israel is not the most appropriate forum to bring such a claim. In addition, even if an Israeli court agrees to hear such a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S.
            law is found to be applicable, the content of applicable U.S. law must be proved as a fact which can be a time-consuming and costly process. Certain matters of procedure will also be governed by Israeli law. There is little binding case law in
            Israel that addresses the matters described above.</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">Subject to specified time limitations and legal procedures, Israeli courts may enforce a United States judgment in a civil matter which, subject to certain exceptions, is non-appealable,
            including judgments based upon the civil liability provisions of the Securities Act and the Exchange Act and including a monetary or compensatory judgment in a non-civil matter, provided that among other things:</div>
          <div style="text-align: justify; line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z0f4c39f6bae74919b7dcccfe22dbabb8" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 7.14%; vertical-align: middle; background-color: #FFFFFF;">&#160;</td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#160;&#8226;</div>
                </td>
                <td style="width: 89.29%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">the judgments are obtained after due process before a court of competent jurisdiction, according to the laws of the state in which the judgment is given and the rules of private international law currently
                    prevailing in Israel;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="zb3aa07a6366b46ec94f79aef3ace1f62" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 7.14%; vertical-align: middle; background-color: #FFFFFF;">&#160;</td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#160;&#8226;</div>
                </td>
                <td style="width: 89.29%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">the prevailing law of the foreign state in which the judgments were rendered allows for the enforcement of judgments of Israeli courts;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z24443a795c974588838c39ae1f65b892" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 7.14%; vertical-align: middle; background-color: #FFFFFF;">&#160;</td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#160;&#8226;</div>
                </td>
                <td style="width: 89.29%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">adequate service of process has been effected and the defendant has had a reasonable opportunity to be heard and to present his or her evidence;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z55bf9f395c734066ba2ccf97da62c201" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 7.14%; vertical-align: middle; background-color: #FFFFFF;">&#160;</td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#160;&#8226;</div>
                </td>
                <td style="width: 89.29%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">the judgments are not contrary to public policy of Israel, and the enforcement of the civil liabilities set forth in the judgment is not likely to impair the security or sovereignty of Israel;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z45db4342add44c3faf5b88a4cbf5bf1d" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 7.14%; vertical-align: middle; background-color: #FFFFFF;">&#160;</td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#160;&#8226;</div>
                </td>
                <td style="width: 89.29%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">the judgments were not obtained by fraud and do not conflict with any other valid judgments in the same matter between the same parties;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">28</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <table cellspacing="0" cellpadding="0" id="za799eb7107f2406dbe249916915755b7" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 7.14%; vertical-align: middle; background-color: #FFFFFF;">&#160;</td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#160;&#8226;</div>
                </td>
                <td style="width: 89.29%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">an action between the same parties in the same matter is not pending in any Israeli court at the time the lawsuit is instituted in the foreign court;</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z2ddf7f96b8d74fbebf43b1ce4463df11" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 7.14%; vertical-align: middle; background-color: #FFFFFF;">&#160;</td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#160;&#8226;</div>
                </td>
                <td style="width: 89.29%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">the judgment is not subject to any further appeal procedures; and</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <table cellspacing="0" cellpadding="0" id="z1883db8eda754df2ae81a9fb06241b96" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 7.14%; vertical-align: middle; background-color: #FFFFFF;">&#160;</td>
                <td style="width: 3.57%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">&#160;&#8226;</div>
                </td>
                <td style="width: 89.29%; vertical-align: top; background-color: #FFFFFF;">
                  <div style="line-height: 1.25;">the judgment is enforceable according to the laws of Israel and according to the law of the foreign state in which the relief was granted.</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">Generally, an Israeli court will not enforce a foreign judgment if the motion for enforcement was filed more than five years after the date of its award in the United States, unless Israel and
            the United States have agreed otherwise on a different period, or if an Israeli court finds exceptional reasons justifying the delay.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">If a foreign judgment is enforced by an Israeli court, it generally will be payable in Israeli currency, which can then be converted into non-Israeli currency and transferred out of Israel. The
            usual practice in an action before an Israeli court to recover an amount in a non-Israeli currency is for the Israeli court to issue a judgment for the equivalent amount in Israeli currency at the rate of exchange in force on the date of the
            judgment, but the judgment debtor may make payment in foreign currency. Pending collection, the amount of the judgment of an Israeli court stated in Israeli currency ordinarily will be linked to the Israeli consumer price index plus interest at
            the annual statutory rate set by Israeli regulations prevailing at the time. Judgment creditors must bear the risk of unfavorable exchange rates.</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;"><a name="INDEMNIFICATIONFORSECURIT"><!--Anchor--></a>INDEMNIFICATION FOR SECURITIES ACT LIABILITIES</div>
          <div style="line-height: 1.25;">&#160;</div>
          <div style="text-indent: 36pt; line-height: 1.25;">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officer holders and controlling persons, we have been informed that in the opinion
            of the SEC such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable.</div>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="text-align: center;" class="BRPFPageNumberArea"><font style="color: #000000; font-weight: normal; font-style: normal;" class="BRPFPageNumber">29</font></div>
            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
          </div>
          <br>
          <div style="text-align: center; line-height: 1.25;"><img width="229" height="74" src="image00001.jpg"></div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

              <tr>
                <td style="width: 100%; vertical-align: top;">
                  <div style="line-height: 1.25;"><font style="line-height: 1.25;">&#160;</font></div>
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Up to $50,000,000</div>
                  <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Ordinary Shares</div>
                </td>
              </tr>

          </table>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25; text-align: center;">
            <hr align="center" style="height: 1px; width: 15%; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;"></div>
          <div style="line-height: 1.25;"><br>
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">PROSPECTUS SUPPLEMENT</div>
          <div style="text-align: center; line-height: 1.25;"><br>
          </div>
          <div style="line-height: 1.25; text-align: center;">
            <hr align="center" style="height: 1px; width: 15%; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;"></div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="line-height: 1.25; background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-style: normal; font-variant: normal; text-transform: none;">
            <div style="text-align: center; line-height: 1.25;">SVB Securities</div>
          </div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
          <div style="text-align: center; line-height: 1.25; font-weight: bold;">January 31, 2023</div>
          <div style="line-height: 1.25;"><br style="line-height: 1.25;">
          </div>
        </div>
        <br>
      </div>
    </div>
  </div>
  <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>image0.jpg
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0J!W@# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$M%%%(04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5-VIO2E%9,!C+DTJC%/Q12 **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **2EI7 ****8!1110 4444 %%%% "$X%5Y+
ME4ZFGW#;8R:Y+5M3,(;FFE<#H'U.)3RU1_VO%_?%>77_ (F,;D;_ -:S6\6M
M_?\ UI\H['L?]KQ?WQ2_VM%_>%>,CQ:W]_\ 6G_\)8V/O_K1RB9[%_:\7]X4
MO]K1?WA7C1\6MG[_ .M.'BQL??\ UI\@KGL7]KQ?WA2_VM%_>KQH^+6S]_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "DI:2DP%J.4X4U)4<PRAIH#G]3N2B-S7
MGVM:RT1;YJ[O6(B8FKRS7[=F=ACO5#1B7?BJ1),;S^=0+XLD_OG\ZS;K199)
M,A34(T.4#[IJHH$;8\629^^?SI__  EDF/\ 6'\ZP?[$E'\)IITB4?PFKLA,
MW#XMDS]\_G3U\52$??/YUSO]CRD_=-3IHTN/NFK41&[_ ,)5)_?/YT[_ (2E
M\??/YUA?V/*/X333I4G3!IJ(T;+>+) ?OG\Z!XMDQ_K#^=89T64G.TTG]BR_
MW34N((W/^$MD_OG\Z7_A+9/^>A_.L#^Q9?[II?[%E_NFCE!&[_PELG]\_G2_
M\);)_P ]#^=87]B2_P!TT?V++_=-'*@1N?\ "6R?WS^=+_PELF/]8?SK _L6
M7^Z:4:-+C[IHY01N_P#"6R9^^?SJ0>+),??/YUSW]BRY^Z:F719<?=-'*A&R
MWBR3^^?SII\6R?WS^=8S:)+_ '341T67^Z:.4;-S_A+9,_ZS]:D7Q7(1]\_G
M7/C1)2?NFK*:'+C[II\J$;0\52?WS^=2?\)5)C[Y_.L,Z)*/X32?V1)TVFG&
M*&C3N/%<A4C>?SK OM<DFS\QJT=!E?\ A-)_PC4K?P'\JZ()1$SEKF=Y6J)8
M6;M77CPK)G[A_*IT\-,H^X?RK6,E<2.+\AAVIC0MZ5W!\.-_<I#X:8C[GZ5I
MS(I'";6!J5-V*[%O"SD_</Y4#PPX_@/Y4.:$<>48]JC,39Z5VX\,MC[A_*FG
MPTV?N4<R*>QQH5@*8R,>U=L/##G^ _E2'PP_]P_E4.2).&,38Z4ZRC;[:G'>
MNX_X19ROW#^51V_AIDNU.P]?2L7,&>I?#V'_ $>/CM7JUJF%%<'X(L3! @([
M5Z%$N!7)5E<9+1117. 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-89
M%.I#0!DZE!NA;BO/-2L/,N2,=Z]0NH]\9%<W<:;NFSCO5(#E(/#ZNF2H_*G-
MX=0?PC\J[:WL@J8Q4C60]*I,:.!?P\N/N_I5.30%S]W]*]&:Q!'2JSZ<"?NU
M7,2<$OA]<_=_2K">'UQ]S]*[5=.'I4JV QTJU)%'#-H"X^[55M"7?]W]*]$:
MP&.E5CIHW?=JN= <='X>4K]T?E36\/+G[OZ5WL=@ O2D:P&>E3S(DX/_ (1Y
M?[OZ4G_"/+G[OZ5WGV >E'V 9Z4<R&SAQX=7'W1^5,;P\N?N_I7?"Q&.E,-@
M,]*2D(X3_A'E_N_I2?\ "/+_ '*[W[ /2D^P#TI\R&SA!X>7^[^E2CP^O]W]
M*[<6 ]*>+$>E)R!G#'P\F/NC\JA/AY<_=_2O0/L(QTJ,V STIJ2$<.GAU/[H
M_*K*>'4Q]T?E79)8@=JF%F,=*.= <*_AY /NC\JJ-H2A_NBO0GLQMZ5GS6@#
M9Q3C+4;V.:M_#\9'*BKR>'8O[HK67$=2"X45J[V$C+_X1R+'W156708P?NBN
MA^U+C%,9U>E"Z8'.C0H_[HJ5=!C/\(K;X%.WJ*V;8S''AZ(C[HIC>'H_[HK<
M^T+3O,4BL];C,#^P(\?=%1'0(\_=%="TBTT,I-6FQ&/'X?CV_=%(= BS]T5N
MB55%1-<+NK-MW&9R^'HBGW16?)H$:S@A1UKJ8[A2M1L%=\UC=W$RSHEF((U
M%= !BLZQ "BM$5C)Z@+1114 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_>-"0'N/_"41_P!\?G2?\).G]\?G7AW_  D,W]XTO_"0S?WC0D![C_PE$?\
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M_A'XO[GZ4?V!%_=_2CF \0/A63^X:7_A%9/[AKV[^P(O[GZ4?\(_%_=_2CF
M\1_X163^X:</"TG]P_E7MG_"/Q?W?TI1H$7]W]*:8'B1\*28^X?RJ!O"\@/W
M#^5>\?\ "/Q;?N_I5*70(]WW?THC+4$CQ5?#$G]RGCPM)_<KV9- C_N_I5A=
M B_N_I3<@/$3X5D_N'\J0>%I,_<->X'P_%C[OZ4S^P(L_=_2A,$>,)X3<C[G
MZ5(/"#D_ZO\ 2O;(] BQ]T?E4O\ 8<(_A'Y5+J68T>+)X0;_ )Y_I3SX0;'^
MK_2O9?[*MU[#\J<-+MSV%"KM SQ-O"#9_P!7^E.'A!O^>?Z5[4=)M_04W^RK
M?T%7]88FCQ7_ (1!L_ZO]*D7P@V/]7^E>SC2K?T%.&E6_H*/K#"QXLWA%O\
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MK#/WJD751CK7GAUH9^]^M2+K8 ^]1[(H[\ZH/6@:B#WK@/[<&?O?K4BZXO\
M>_6G[*Q+9WPU( =::VJ@?Q5PIUQ?[U0OK@S][]:GV07.]_M4?WJD74P>]>>C
M6P?XOUJ9=< _B_6CV0'H/]HC'6JLU\,YS7'KKJX^]^M1R:XI'WOUJ?9@=8=6
M"?Q4L>M9D W5P$^M#/WJB@UG]\OS=_6H<&"9[9I=T)D!S6KFN \/:RFQ06KK
M[>^64#!K)HHT:3%-1]U/J0$%+110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 AZ5$3S4IZ5$1S0
MX"GBD7I2GI0 M%1;^:D!R* (;EML9-<Q=7VR;&>]='?'$!KS[6+GRI2<]ZTB
M(Z*+4!M^]3OMX_O5Y\_B$1'&_P#6F?\ "2C^_P#K6J2&ST7[>,?>I/MXS]ZO
M//\ A)E_O_K1_P )*/[_ .M-10,]%^WC'WJ;]O&>M>>_\),O_/3]:3_A)1_?
M_6GRH&>B_;QC[U--^,_>KSW_ (29?^>GZTG_  DH_O\ ZT<J!GHOV\8^]3?M
MXS]ZO//^$G'_ #T_6C_A)1_?_6CE0,]%^WC'WJ:;\9^]7GO_  DR_P#/3]:3
M_A)1_?\ UHY4#/1?MXQ]ZFF_&?O5YY_PDZ_\]/UH_P"$E']_]:.5 ST47X_O
M4AOQ_>KSS_A)E_O_ *TA\2@C[_ZTU% ST Z@/[U/2_&?O5YR?$@_O_K3E\2@
M?Q_K3Y4(],%ZNWK5:34 #]ZN#'BA=O\ K/UJO)XF!/W_ -:7*BD>A+J S]ZK
M"7P(ZUYB/$PS_K/UJW'XF7'W_P!:KE1+/09;T;>M<WK-Z! _-8<GB52OW_UK
M$U/7A)$PW_K1&.HSE/$FJ%+AL-WK%BUIA_%5;79S/,2#WK'4,*[(03).K763
MC[U!UH_WJYD.13MQ-:."$SH_[8/]ZF-K3#^*L$$TA1C3Y$-,WO[;;^]2?VZP
M_CK *,*A8-FJ]FA,Z?\ MUL?>J,ZXV?O5SZJV*0HV:ATT!T\>M-C[U!UQA_%
M7/HK8IKJU"IH9T0U]O[_ .M(VO,?X_UKESN!I0&-2Z2&= VLLQ^]4D&JG>#N
MKFCN!JS#GK42I*PF>F:)KY1E&^O3M"U;SE7YJ^>;*\,4J\]Z]+\-:QM"#=7#
M.&I70]PLY@ZCFKH.:X_2=4#A?FKI[>;S .:YY1L!:HHHJ "FFG4TTF)BBEI!
M2TQH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ:(I:2C-<XQ:3%+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% "'I4)ZU,:;MYH 5>E.I!2T )MHZ4M(:
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M769T!8U['X<OQ+&N37)-#1UM%-5PPIU9C"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4H!ZFG4Q:?0P"BBBD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ME^SKZ4>>OJ*//7UH 3[.GI1]G7TI?/7UH\]?6@!/LR^E'V=?2E\]?6CSU]:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:2H:&+1115(04444P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MD%+5+8 HHHI@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJP>XQI.*53FHWZT]*D!])FBBDV M%%%4@"BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MD]Z39)[TW30([G_A*F_O_K3?^$J;^_\ K7%"&4^M(8)?>G[-"9V__"5-_?\
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M:[_^Q^/NTUM&_P!FCG1*//3IG/W:D72\C[M=P=%.?NU(NC<?=HYT,X3^RO\
M9IW]D\?=KN_[&_V:=_8_'W:'-"9Y^^EX_AJ+^R^?NUZ"^BY_AJ/^Q#G[M)30
M(XJ/2LC[M2?V1_LUW,>CX'W:D_LC_9JN= <#_9//W:7^R./NUW?]C_[-._LC
MC[M'.@1Y_P#V3\WW:LQ:0,?=KLSH_/W:4:=M'2A23!G(KHXS]VK2:*NW[M=)
M]C /2GB( 8Q3N#.1DT8 _=IO]CC'W:Z\VH;M339CTIH>R./.DC/W:/[%#?PU
MUILN>E2)9CTK6Z XS^P%)^Y4R^'5Q]P5V2V0]*F%J .E-20CACX?4'[E*-"
M_AKMS9@]J8;,#M6T9H#C?["7^[33H"_W*[/[*/2E^R@]J;FBDSBO[!7/W:E7
M0%Q]VNS%B#VIQM !TJ'43).';05S]V@: I'W178/;#/2FB$#M4.: XYM!4'[
MM+_8 VYVUV(M0QZ592P!7I42FAV/.IM$ ;[M+#H 9A\E=[)I6YONU-!I6"/E
MKG<T2SGM-\/J"OR5V6FZ4(P/EJ>TL@F.*V8(@HZ5C.0T+!#Y8JQ117.,****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8L8TT4M%,FP"EHHI%!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M 444E*X!2TE+0@"BD-(#3 =1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !12$TT-S0 ^BBB@ HHHH **** "BBB@ HHHH **** $I:2EI(
MHHI*& 4M)123 6BBBJ **** "BBB@ HHHH ***2@!:*** "BBB@ HHHH ***
M* "BBB@ HHHH **** "H+D9C-3U'(,K36X'*W]MYC'BL9]'5WR5KLIK;<>E1
M"S&>E="FK".:CT*/'W:F_L*/'W/TKIDM@!TI_D#'2FJB&SD_["CS]S]*=_84
M>/NUU/V<9Z4OD#'2FZB$<G_84>?N_I3O["BQ]S]*ZG[.,]*7R!CI2]HALY+^
MPH\_=_2G_P!A1X^[^E=3]G&>E+Y QTH]HA,Y!M#CS]W]*7^PX\?=KJS;#/2C
M[,,=*?M$".3_ +#CS]VE_L*/^[^E=5]F'I2_9AZ4>T0T<G_8<?\ =_2E_L./
M'W?TKJOLP]*7[,,=*/:($<E_8<>?NTO]AQX^[^E=7]F&>E+]F&.E2IH$<=_8
M<>[[OZ5970H]OW?TKI?LHSTJ46XQTH<T#.2.AQY^Y^E2#0H\?=_2NG^SC/2G
MB 8Z57M$2<G_ &%'N^[^E3C0X@OW?TKI/LXSTHDC"QFI<RF<HVDPJWW14Z:;
M;[>@I]]<"-CS6<VJ!3C=6G+=$EQM,@ST%*-,@]!5(:F#WH_M0>M6J38TS0&G
M0>@IXTZWQT%9G]J#UIPU4?WJ'18V:!TZ#/04O]G08Z"J']IC'6D_M4?WJ7LF
M#+_]GP9Z"GC3[?'05G?VF/6D.J@?Q4.DQIEXV$&>@J0:=;E>@K(.JC/6I%U<
M=-U2Z; M2Z=#V J :?%NZ"D_M -WIIO!US6L4TA&A#I\&WD"GOI]OCH*S/[5
M"#K41UC)QNK!Q=QW+4FG0EN *ECTF)A]VH(+OS6'-;EH=P%:MZ"3N9W]B1$_
M=_2K4.B1#^']*V(X@>U6DC [5SSF49\&FHF,"M"*$(.*E Q2UBV)@!2T45(@
MI*6BDP"BBBF@"BBB@ HHHH 2BEI*AC"EI*6FA!1115 %%%% !2&EHH A;K3T
MH(I5% #J*** "BBB@ HHHH 2EHHI=0$HI:::74!U%(#13N M%%%, HHHH 8U
M*M!%*!3'T%HHHI"$H%+12Z@%%%%, HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** $HI:*5M0"BBBF 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 AI!2F@"D+J+1113
M&%)2T4K:@%%%%, I*6BEU ****8!1110 4444 %%%% #&IJ]:>12 <U2V <*
M6BBI *2EI*E[@+1115( HHHH 2BBEJ; %%%%4 UJ:.M/-(!3&APHHHI""BBB
M@ I*6BDP"BBBF 4444 %%%% !112&@!:*;FEI7 6BDI:8#6Z5&.M2D4P+S0
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M 4444 %%%% !1110 449HH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ4?G 55@+%+4*R@U*#2L M%%%38 HHHI@%%%% !3&%/HH 8!3Z,44, HHHH
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MT@"DW"HW?;6?<7PC[T[ :>\>M&]?6N9FUQ4_BJ >(5/\8JE!@=;O%&\5RO\
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MQ ^?O&I3X@;'WC7$)<'UI[71QUKJA30CLQX@;/WC2_\ "0-_>-<2MV<]:?\
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M:L<N-U72CH)Z'.Z]J9D=P&KC9&9Y2<FK%S>F:=AGO1'%NYKOHP!L;$A-6U3
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MIMUVWUK+C3YZNZ@V^Z;ZU&B=Z]2DB43H/EI&6G)3RO%==M!ME0K2H.:>PYI
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MNFQ;M]*\3\>3X=^:]BU"7; WTKPGQ[<9E?FN:BM0.!F?>QJ-12(=YJ0C%>C
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MM77)Q'^%>76?O#.1\52[(VYKQ'Q)-YCN,]Z]B\9R;8GKP[6)=\K_ %KJPST
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M^;I?E[UZGX8TS8B_+VKB>X6.[T5=L(^E;-9UA'Y: 5H"N:6XQ:***D HHHH
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M_.F]C54KLKT84R!S'FK,'2J!;FK=NW%=$8V&0WH.>*CMP<5;F3=3$CVBJD]
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MPH_M&/\ O"BP%_8*-@JA_:47]X4?VC'_ 'A0!?V"C8*H?VC'_>%+_:,?]X4
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MS5T*0K%M4R*B=,&K,&"M17! S5*0R(2A14?FAWQ5>5SG J6RMY)9UX[T3G9
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M>R<5[IH$.Q%KCQ#]T$CJ#_JOPKSOQ<^ ]>AN<1'Z5YEXRE"[^:XJ7Q%'C?B
M&1VKGX(<&NCU1@[M64B@&O;H2T(:$5*4K4G HX-:S8$86ID?:*9P*ADDQ7/(
M&@N'W-71^'(=S+Q7*;]S"N]\)V^]DXK*XCUGPO%M5:[G_EG^%<MH,&Q5XKJ3
M_J_PKSJ_Q%HX/Q9/L5^:\0\1S;V;FO7?&\VP/S7B>K2^8[?6N_#_   S"C7Y
MJN(,5%$G-6,8KKCL(<!FE(Q3DI6K:(A@%.VT+4F14S=@,R[2K>E2&,BH[A<T
MR$[#6$F#1U O3MZU3N+P^M9XN..M03S$U',-#IIC(>M,C;::B3+&GLI%:P8F
MBQ]^@18HM_>K+%0*Z$P*^VF,^VI&<54F))XI2EH-(5D\\UU?AG2"[J=M8FDV
MK3.O%>L>%-* V$K7G5F(ZOPWIWD*GR]J[E!B,?2LVQM5B1<#M6F/NUYDW=E(
MXKQ8V$>O"_$WS._UKW/Q8I*/7B'B*,[WSZUUX=DM')6D69*TWCPM5K0 2<U?
MF9=O6O0BQ6T*&,&E#8I20344F:Z8/0.A<BDS1.<BJL#'-3N<BFWH"*X'-689
M#'WJ$8!I)&XXKEFQV+,]V2,9K.DD+'K0=S&FE".U8-B'1*6-7HTVBH+< 'FK
M;, *U@PMH))R*A'!I^[)IKFNE2!(4C?4$L6WFK,!!/-%WM"TI2&9N,M7;^#H
M<RIQ7%1\O^->B^"XLRI7+4D,]CT2';$GTKJ$^Y6+I46V!..U;:_=KS*SNRK'
M->(X/,B;BO#O&%GL,AQ7T%JD7F(>*\A\;6'R28%:T=A-'B2'R[@_6M:&?*CF
ML^\MVBN'X[T0.0<5WTM";FL1OJ,PT^!@<9JPQ7%=<0*H2E9:DR,TUV&*;#<J
M2+20Y5JD9A30PKGD[#2'3SD)UJDLQ=NM2S@N.*BM[=]^2*S>I++(7(J2)<&I
M/+PM(O!K6"&MB;J*814BTC]*V0DQL8R:?,,+38NM.N3\E3(9G2')Q79^!XLW
M2<=ZXM06D_&O0O L/^D)QWKCK/0$SW;2(]MHGTK71N*H:<N+)/I5M#S7FRU*
M,K7H?-A8>U>*^+K$IYAQ7O%]%OC->6^-+']RY [5OAW9#L>"SC;<L/>KEJ>E
M-O[<I=OQWHM_E-=].8F:+-A*B67+4R:3Y.*K0L?,KH4A;EV=-Z56MX?+ES[U
MH(,KS4<JA1FLYL;1T>B:E]G9?FKN[3Q,$B W_K7C27C1MP:MKJ\H& U<E17%
M<]7O?$P="-_ZUQNKZIYV[#5S+:K*W4U$UVTG4T4O=$5[QBSDU4C!+U;E^89J
M*%1OKH3!$AC.RJ4X*YK8.W96== '.*J^@S*)9FQ5ZQLFF<<5'!;EY.E=EX?T
MS?(N5[UQUE=C1I>&M$;S%;;WKV/0; Q1+Q6-X>T=513MKT"RM%CC'%<50$1W
M)\NV_"O-/&-Q^Y<9[5Z3J[>7;GZ5X_XNNLAQGM6^&8I'D^H'=>M]:>B_+4%R
MVZ\;ZU;3'EUZ,&2D(*'7BE'6G.1MK>Y16 ^:G2#Y*%^_3YL>7428[$5FN^;'
MO7I7A"SQ,AQWKSO2AON@/>O8?"=L!L.*XJKT"QZMHZ[;-1[4[46VQ'Z4_3EV
MVZCVJMK+;8"?:O-7Q#/,O%]QF)QGM7B&I_->M]:]:\67'WQFO)+TAKH_6O1I
ML2'6Z]*N_P -58!Q5G=\M=D6(:/O4]CA:B!YITA^2K;!%6>6FV)WS@>]5[AC
MFI]'!:Z ]ZQFRF>G^$K;]XAQ7N.BKMM%^E>3^$K;A#CTKUW3%VVZUYF(>H%^
MBBBN4 I*6BDP$HHI:E %%%%6 4444 %)2TE2P%HHHJ@"BBB@ I#2TC=* *MS
M)L0FN9U'5/*!YKH+X'RS7!:ZKX;!-:10BE>>)3&Q&ZL]O%A!^_\ K7*ZJ91(
M>36#(\V[J:M10'I"^*S_ '_UJ4>*CC[_ .M>9(\WJ:G$DN.II\J*/1?^$J.?
MO_K2_P#"4G'W_P!:\YWS9ZFG%Y<=35*"$CT$^*SG[_ZTO_"5''W_ -:\X+S9
MZFEWS8^\:'! ST3_ (2LY^_^M._X2HX^_P#K7FVZ;/4T\/-CJ:7*@9Z)_P )
M6<_?_6G?\)4<??\ UKS<O-GJ:=OFQ]XTW! ST0^*SG[_ .M.'BH_W_UKS;=-
MGJ:D5YO4U/*@9Z-_PE1_O_K2_P#"4G'W_P!:\YWS>II?,E]33Y4"/1/^$J/]
M_P#6E_X2D_W_ -:\YWR^II?,E]32Y4"/1/\ A*C_ '_UI?\ A*3_ '_UKSG?
M+ZFE\R7U-'*@1Z)_PE1_O_K2_P#"5''W_P!:\YWR^IH\R7'4T<J!'H8\5$MC
M?^M/N?$)DMC\W;UKS=7FWCDU?$DA@QD]*M00S.\0ZB996Y[UQ=VY<FNBU"VD
MDD/7K68^FN1T-4V)F-:Y^TBO4_").]*X*WTQQ.#@]:]'\+6I1TXK-B/;O#?_
M ![+]*WR>:PO#JXME^E;AZUAU&2"EIJTZDP"BBBD 4444 -<96L#6;3S+9^.
MU=#52]B#P,,=JJ+LP/GCQ=IG[]SM[UPLUN8CTKV[Q/I7F,Y"UYKJNE,I;Y:]
M6C)6).5\_9Q3?M.3UIUW9NC'@U3\ME-:N0S3BG]ZNJ^Y*Q(W(-7XIQMI-Z"8
MV=<M3DC^6HY)06J6.48I7 ADAYH VBIV8$57D<=*5QHADDP::C9--=2QI44@
MT<P&A%)A*JW,IS4\2DC%/_LYYCP#5<PEN9T*F24#UKO/#FA^>R-MK&T[09#.
MI*GKZ5Z_X3T?RT3<OZ5$ZF@V;?AS2O(1?EKM+>/8*K6-LL:CBKX&*\JK+4$/
MI&&5H%+4(9AZG:>9$W':O(O%6C;G<[:]RGC#1GBN'\0::)%?Y:Z:4Q,^?=0M
MC;DC%8[L<UWWB'2&#MA:Y"?3G4]#79"9**\,N*M"3(JF8C&:D5L"NR,M!A(<
MM4T46Y:JL_S5=MY!LIIZ@4KB+#4^&/BGW# M3H6&VF!$XP:FB&:AF<9I\4@
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MY6@BHI364QA:Q[I/QKTSP3!B9#CO7GNF)OD'UKU;P=;[70XKSZST!'KUBO\
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MG':NWMQA!7!7 FHHHKF *2EI*3 **6DI +1115 %%%% !1110 4444 %%%%
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M_A%=#Y7M4BQ@=JMS YS^P8Q_"*D30X\_=%=#L'I3@H]*AR&4;2Q6#H*T .*
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M"BBBD 4444 %%%% !1110 4444 %%%(: #-+46>:D% "T444 %%%% !1110
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MWKGJR&F>A^&+#RPAVUZ9:#;"H]JYW1K#RX$..U='%PH%>;4ES,HGHI!TI:Q
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM-_L3'\->DMHW/W?TIC:+_LTG4$>=+HW^S4HT;'\-=Z-%Y^[4G]C?[/Z5/M
M.'@T7<?NUJ0>'\X^7]*ZVVTC#?=_2MNVTL #Y:ES!G%V_AG=CY/TK:M/# 7!
MV?I79VFG*,?**UXK) /NBLW,5CE;+1!'CY:Z*TM/+ XK06W4=JD" 5+FPL*@
MPM.HHK,84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M44446 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :1
MFH)(=W:K-)BG<"LD(':E:'-6,48I\P%3[/[4]8L58Q1BCF8%=XLU'Y'M5PBD
MQ34V,@6+%3!<4[%+2;N(8QI%-*PI%%'0"2BBBI **** $HI:2IZ@+24M)1U
M6BBBJ **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 2FFG4T
MBLIW  :7K2 4X4X7 0"G445H 444A- $<J;A5-[0$]*O9S3L55V@,EK 'M43
M::#_  UM[12;11S,# .E#^[33I(_NUT.P4;!1S,#G?[(']VG?V2/[M=!L%&P
M4<P&$FEA3]VK:607M6EL%+M%*X%6.';VJR!@4N**+@+1112 **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** $(H I:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *0TM%)H!,4M%%"5@"DS37.*8K9-5
M8":F-3QTIK"A ,7K4@IH'-/H8!1112 **** "DS033-U.P$E%-!IU(!#24IH
MIB>XM%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0!#*>*BC/S5)-TJ*+[U:K81;'2EI!TI:R&)BEHHH **** "BBB@!C5'GFI'J
M+O5K8$2+4E1K4E2QL****0@HHHH *2EI*E[@+1115 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
' 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 0W!W\# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** $(R,52N+(2CIS]*O44[@<[-HBN?N56/AY<_<'Y5U6!Z48'I
M1<#F4T!%_@J==$4?P?I6_@>E+1<#!_L9/[GZ4PZ*N?N#\JZ&DP/2GS 8 T5?
M[E(VBH?X!^5=!@>E&!Z4<P'._P!AK_<I/[#7^Y728'I1@>E/G8'/#1%_N4?V
M(N?N?I70T8HYV!SO]B+_ '?TI#H29^Y^E='28'I1SL#GAHBC^ 4IT1?[GZ5T
M.!Z44K@<^-$7'W!^5)_8B_W*Z&BE<#GAHJ_W!^5*=%7^Y6_@>E+BGS <\-%4
M?PC\J8^DIZ"MJYE$0-<WJ&MI 3EA6D5)@2_V?&IZ"G+8QGL*YYO$R9/SBFCQ
M0@_CK50E89TAL(P.@I5T^,]A7,GQ5&?XZ>GBA/[])PD!TXT^/'04IL8_05SH
M\3*1P]12^*D3^.CDD(ZA;.,=A3C;H.PKDX_%:-QOJ.;Q4B_QT^60'7BV5^@I
M&TH.?NBL+3=?6<X# UU=G<+* :SG<"*VTQ8L?+^5::)L%/HK&X!1112 ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(?[P_.O*SXG'_/8TT^)QC_6T<C&>K?VC!_?%']H0?WA7DQ\4@'_74Y?%&?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/,6T^7'2HO[,E;M7JJ^&0W\%3+X6&/N4_;(1Y =-E4]#5^QTJ5W4X->CS^&
M#]WI[5J:1X7#,"4K*54"WX$TQH]FX>E>P6T01!@=JYS0M'^R!?EP*ZI1A0*X
MJL[C%HHHK$ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7UJR'3IFJN-;&8]@G]T57?3U[**V69<=131L[XHNPN9<6G*.JBK L4 ^Z*T
M4'<4CR)CK4W8C#N;%=W"CI6KHUDHQE137 <\8S6MIL>,5,M@-)(U4# I]%%<
MPPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU#)XL7./,_6O&CKTHS\Q_.H3KLN\?.?SJ73!GT+I.L"[P-WZUW.FGY1BO#?
MU\\[)DU[?IF?+4Y[5A5C:(D:U%%%<904444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %':BD/0T 9U]<F-&[5Q.KZT8BV6Z>]=5JP;RVQGI7EGB/?EP":H:
M(KOQ>8FQYGZU OC4G_EI^M</J-M</)P6ZU2%G<CJ3510'HX\:'/^L_6I!XT;
M'^L_6O-?LMR.YI?(N?4U?*A,]%;QJ<_ZS]:5?&1/_+3]:\U,%P3U-31VUQCJ
M:I1$>C?\)B?[_P"M*/&!Q_K?UKSO[/<>IH,-P.-QIJ T>@MXT9?^6GZT#QHW
M]_\ 6O.7MKDGJU-^S7'JU2X@>C_\)J?^>GZT?\)H?[_ZUYO]GN?4T?9[GU:C
ME ](_P"$U/\ ST_6C_A-3_ST_6O./LMSZM1]FN?5J.0#T?\ X34_\]/UI?\
MA-#C[_ZUYM]GN?4T"WN?5J.4#TC_ (34\?O/UJ1?&C8QYGZUYG]FN/5JE2UN
M,=31RH1Z*WC5A_RT_6FGQJ<?ZS]:\[:UN?5JC-M<^K4<HST?_A-6S_K*5?&9
M/_+3]:\U^RW.>K?G5B.TN<=6I\B$>BCQDW_/3]:D'C(X_P!9^M><_9+D=VIW
MV>X'\1IJ"&CO9_&9VM^\[>M<SJ?B8S C=G\:PY+.Y?NU0-I=P_8UT4X)"91O
M]0,Q)R:S<L_%;AT*9CRIJ:/0)01\IK=-7$CG1&1VI&4BNH.A2?W333H3D?=-
M:712.7RP-2I(?>MU_#\O9335T"4'[II\R$8K,6J)@<UT8T&7^Z:&T&3^Z:5T
M5T.?C+"B1B:Z#^P9?[II#H$O]TU+:).9.:B.=X^M=4/#\I_A-0/X?E$@RIK&
M4D#._P#AM'N*9]J]]T]-L:\5XY\/-.:$IN%>V6R[8Q]*Y:T[H:)Z***Y "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHI"<"@!3R,52FLP[9P*L&3% DJDF!'';!1TIYASZ4_?1YE&H$?V<>@J,V
MBGJM6-]'F4:@5A:*.@IPME':I]XH\RB[ A^SKCI3#9J3G%6=]&\>E.[ A2V
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MZD6M1DM%%%9 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ-3ET.?T-/F0C6/B$#O^M \0#N?UK(.ASYZ&G#0Y_0T<R&:AU\#O^M'_  D
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M^M>B:7=>:HZ'BO+-"T^5"O6O2M%B9%7.>E<\TK"U.AHH'2BN884444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MP.BHJ""<2*,&IZEJP!1112 **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***9(
M^T4(!Q8#J::94'<5EW-\$)YK&N-9VMC?5<H'6><GK2^8OK7'IK.3]_\ 6K4>
MJ[A]_P#6FH =-YB^M'F+ZUSO]IC^]33JG/W_ -:KV8'2>8OK1YB^M<V-5_VO
MUI#JHS][]:'38'2^8OK1YB^M<Z-4!&=U,?50/X_UH]DP.E\U?6CS5]:Y<:N/
M[].&K#^]^M'LF)'3>8OK1YB^M<Z-4!'WOUIIU4?W_P!:/9,9TGFK1YB^M<Z-
M4!'WOUIIU0#^+]:?LF(Z3S%]:/,6N<&J C[U(=4Q_'^M'LF!TGF+ZT>:OK7.
M#5!C.ZD.JC^]^M'LF,Z3S5]:/,7UKF/[5'][]:D75 ?XJ/8L#HS(H'6LV\N@
MJGFJ!U,;3E^WK6-?:E\I^;]:N-)H5RKJ^I;2<-^M<I<ZRP)^:FZQJ.<_-7$7
M^IE2?FK=4P;U.O\ [=;/W_UJU!KA(Y?]:\S_ +7.?O5-'K)'\7ZT>S$>CRZW
M_M_K4UMKG^W^M>:/K1./F/YT^'6BO\7ZU:I#/1[G6R/X_P!:BAUH_P!\_G7
M2:QN'WJ8NL%0?F-5[(1WUSKAQ]_K[U6CUUL_?Z^]<'/K!/\ %4":N0?O9JE!
M"1Z5_;A/\?ZU+'K9Q]_]:\Y75B1]ZG_VP5'WOUH]FBKGH;ZV<??_ %J ZT3_
M !_K7 MK)(^\?SI!JQ_O?K5<B0,]#36C_>_6GG6SC&_]:\\75R/XC0VL?[1K
M.424=O/KK9^_W]:V-%UO>PR_ZUY/)JI/\57K#7?)(^8_G6+B,^C-+U-' R_Z
MUT,<BR+D'->&Z'XFW%1O_6O3]#U/[2J_-UKEFAHZ:B@<C-%9#"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P!T4?V''_=I>U&>.MX:?^Y^E(/#3_W/TKV(Z%'C[HH&A)_=%2Z@'D(\-O\
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 TL
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MOFME10'LT7BP'C?^M2GQ6!_'^M>.0:K)C[YJ635I /O&J=% >M'Q6/[_ .M
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@@3TXJ:_N!&#S7'ZIK*Q _,?SK2$6P-^2>V7N*KM=6WJ*\\O?$Z*2/,(_&J
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MW8_4?G7C'_"3M_STI/\ A*'_ +]/V(SV?^W8_7]:/[=C]?UKQC_A*'_OT?\
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M:!!Q3ZQ;NQA0.E%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_*NZ-K'_ '12?9(_[HI>U XR/1L?P_I4O]D?[-=>+5/04&W3T%/VH''G1O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $9<YIX.143*=
MU2*.*; =114$MP(^IQ2 GHK'GU=(^I%4)?$2+_$*=@.FW#UI<UQI\3Q@_>%.
M7Q3'_>%/E8'845R7_"41_P!X4G_"4QY^^M'*P.NHKD?^$IC_ +ZTG_"51_WQ
M1RL1U]%<C_PE$?\ ?6D_X2F/^\*.1C.OHKD/^$IC_OBC_A*8_P"^*.1@=?17
M(_\ "41_WUI#XIC_ +XHY6!U]%<B/%,?]\4[_A)X_P"^*.1@=917)?\ "41_
MWUIA\51YY=:.1@=A17(+XIC_ +XH_P"$IC_OBCE8'7T5R'_"4Q_WQ2_\)1'_
M 'UHY6!UN1ZT;AZUR)\2I_>%+_PDJ?WZ?(P.MW#UHR/6N1_X25/[XH_X2>/^
M^*.1@SKZAFE"J>:Y8^*(\?>%4KKQ0FUL..:J--L#3U/4A%NYKD;_ ,0F//SU
MF:OXA63=AA7"ZIJ^[=AJZ%3).HO?%Q4D;ZRI?%Q8_?KS^]OW))W&LXW;^I_.
MK5.Q1Z;_ ,)46_CIX\1%AD-7F*7;YZG\ZNPWC;.II\K)ZG?-XF*'[]"^*2?X
MZ\[GN7)X)J);IQ_$:=BCTH^*?]L4#Q4<_?KS5KI_[Q_.D%T_J?SIV ]*;Q61
M_'3?^$L)/WZ\W:Y?^\::+A_4_G182/2QXM('WZ</%9/\=>9&Y?\ O&E6[<=S
M2:%<]-_X2@_WZ:WBHC^.O.DNG/<TV2Y<=S04CT3_ (2XK_'43^,&/\=><&>1
MN,FIX(I9".M8S$=T?%;DCY^M:-GX@:0@;C7$VNDSRD<-73Z9H4P*DJU1S#W/
M2-#U R[>:[_3&W*#[5Y[H.F/'MR#7HFFQ%$%$GH!KCI2T=J*Y@"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** &2':AKG=4NC&#@UMW,F(SS7+ZI\RMDU<4-'*:KJ[QD_,:X^^\02*3\
MQS70ZM;[R>:Y&]T[<YIV$RI+XDE#?>-(OB67^\:A?2"3TH&C_P"S71""L(M?
M\)+-_?-,/B67/WC48T<XZ4AT?VK3D&R4^)9?[YJ,^)I<_>-1G2#Z4W^QN^VA
M4Q(MKXEEQ]\TC>)9<?>-0KHW'2AM'/I0X#8X^)I>FXT@\33?WC4#:.<]*5=&
M]J.0$7%\22X^\:8WB:7/WC3%T?CI2?V)DYQ24!DZ^))<?>-/_P"$DF_O'\ZK
MC1L=J7^QCZ4^0"<^)9<?>-59/$TN[[QIQT<^E0OHF3G%#BA%F/Q-+M^^::WB
M:7/WC4"Z00,8IW]BY/2DH#)E\32_WC4H\22_WC4":)[5.FA].*.1"1,GB&4_
MQ&G_ /"02_WC48T7';]*7^QCZ4^1 *?$$O\ >-0OXBE!^\:F&BDC&*8VA9/2
MJY4)D?\ PD<N/OG\ZJ3>(I23\QJX="]JA;0>>E7&"0S(GU:67/)K,GN'D/>N
MI'A_/\-._P"$<!_A_2G8#A7C=_6H_L[5Z /#@_N_I3AX;7^[^E/0#SY;=AVJ
M58W'&#7>GPVH&=OZ4W_A&US]W]*>EA6.&\AV[?I4;6[CM7H2^'5]/TI'\-C^
M[^E(9YW]G?T_2CR']/TKT ^&UYX_2C_A&QG[OZ4: <&MLS=JD^RMZ5W2^'E'
M\/Z4[^P!_=_2F*QP1M6]*KR0,#TKT,Z",?=_2JTOA\'/'Z5+0'&6T3=P:DFM
MSZ5U:Z*L?:I5T42=A68SD(+,N1\OZ5U.D:-YA7*?I6U9>'%XR/TKL=)T%8RO
MRC\JQFQ$6A^&%=0"GZ5V=MX61-IV?I6EHU@D:@[1D5T00#M7/)C,:UT=8N=H
M&*U(XO+QBIZ*GF 0=*6BBI **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ IK]*=2$9&* ,VY8\UBW<>X'BNB
MDAS522TSVJ[@V<1>6(<GBLN31PS_ ':[Z33\MTJ'^S/F^[33&<0N@J?X?TIX
MT!?[OZ5W*Z=_LT_^SA_=KIC-(1PG]A+_ '?TI#H"X^[^E=Y_9W^S2_V>,?=I
M^T0'GS:"N?N_I3ET%<?=_2NZ.F#/W:>NFC'W:KVJ X/^P5_N_I2_V"N/N_I7
M=_V:/2E.G\?=I>T0CSQ] 7=]W]*D30%_N_I7=MIO/W:>FFX'W:/:(+'"_P!@
MK_=_2I5T!<?=_2NV_L\9^[4@L!CI2]HAG!-H*@_=_2F_V$O]W]*[UM/']VF_
MV</[M'M4%SA?[!7^[^E._P"$?7;]T?E7<#3QGI3Q8#'2CVB \\?0%#?=_2IH
M] 5A]W]*[A].!(^6GQZ>!VQ0JB XQ?#Z?W?TJ9=!0#[HKLOL0 Z56FC"9]J:
MFA,Y&314!Z"HQH\?H*Z&<BJA< UJF/H9R:/&>PJ==$C(^Z*O1R#K5I)!^%,E
M.YC-H4?]T5'_ &#'_=%=!N%1LX%5<HP_["C_ +HJ5="B]!6H91FG+.O>A@9@
MT&+/W14R:#%Z"M)9EJ59QV[5#3 QGT&+GY13/["B]!6TTRU$9UIJ]@,O^PXO
M04G]A1'L*U/M*T?:%]*+,#+_ +"B]!1_847H*U?M*TTW-%F!DMHD8X %1G1H
M_05JM<@FA90:+V"YCG1$/\(I#H",/NBNBB4.?K5V.W#+TS42E8#SV\T-4/"T
M^RT0,P!7]*[BXTWS.U/M-,"'.*R=1 9FG^'TX.W]*Z"WT>.,#BK]O $ JU7-
M.=V*Q#%;K$!CBIJ**S&%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJN>M:%O=!\8.:\ML-8>0CYJ[/2+II2OO64F!WMA\V.];T$0XK#T=<[:Z:),
M5S5)%(!"IZTY8E4<"GT5SW ****0!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQR( HXI]%%9""BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6,Y:#8MK8I !@5=Z445@W<04444@"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHI"P% "T4@.12T %%
M%% !1110 4444 %%%% !1110 4444 %%%% !11128!1244)@+1113 **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** $'2EHHH *BGB$D9!%2T4 <W<:0DDN2E*NAPX'R?I6Z8P3TJ0(,=*TY@,%
M=#A_N_I4O]A0X^Y^E;044M)R Y]M#AS]W]*3^PH?[@_*N@VCTHVCTI\X'/\
M]B0_W/TIW]A0X^[^E;VT>E&!Z4G,#GSH4/\ =H_L*'^Z/RKH-HI-HHYP, :%
M#_=_2G?V%#C[OZ5O;1Z48'I1SC.?_L.'^YW]*=_84/\ <'Y5O;1Z48'I1SB,
M#^PH<_=J1=#AQ]S]*V]H]*6CG8&"^A0Y^Y^E)_84/]P?E6\0#1@>E'.!S_\
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MX\3/S\]46\2N?XS6L:=A,]=D\1IS\X_.H&\1*3]X?G7CTOB1_P"_4:>(G/\
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M/OBD_P"$D0'[P_.O(G\0MM^_5*7Q*X;&\_G6J@![=#XD0OC</SK>L=<63 W
M_C7SM;>)7,@^>NPT7Q"S.HWU$H!<]VM[L2@=ZM Y&:XO1-4$BKEJZZVE$D?!
MKEG"P7N3T445F,*C>4(,T]CA2:QM3N?+1N:J*N!//JB19Y&1[U3?7HP?O ?C
M7$:OK>PMANGO7)7/B5A)]\_G6\:5R;GL8UZ/'WA3AKD?]X5XY%XE;'WZL#Q$
M2/O_ *UI[ I'K1UV,?Q"C^WH_P"\*\@;Q(P_Y:?K3?\ A)&[R4O8 >P_V]&>
MX_.E37$+8##\Z\?_ .$D/]_]:GM?$+-.OSGDUFZ0KGM]M<"=0>*L5S7AF[-Q
M I)SFNE/2L&M1B,=JYK,NM42'@D<5:NI=L+'VKS+Q+K1@D8!L<U<8W [<Z]'
M_>'YTO\ ;L?9A^=>-MXE;=]^I4\2,1R_ZUK&E<5SV#^W$_O#\Z/[<3^\/SKR
M ^)#_?\ UI1XD;^_5NA8+GKQUR/U'YTW^WHQW'/O7D1\2''W_P!:A/B9MV-Y
M_.LW3"Y[5'K"/C!_6M"&Z64<&O(=+UYG*C=W]:[W1[PRA3G-9-(+G5 Y%%1Q
M'*U)4#"BBH990JGG&*:5P"6=4!YZ5G3ZND?<5GZEJ(C5OF_6N#UG7RF[YOUK
MHC1N3<[2Z\0HN?F''H:RY_$B?WZ\LOO$K<C?6/)XE<G[YKIC3L.YZS+KZL?O
MY_&I[?Q BC[PKQ]-?=OXJD_X2!U_C-:\HT>T)XB3(&\?G6[I^LH^!N!_&OGV
M+Q(_F+\]=EH.O%RN7K"I"X7/;(KM9!D&FS7BQ@\XKF],U(/&/F[54U;5-@/S
M"N9TA)F_+K2+_$/SJ(:^G]X?G7F&H^("C$;_ -:RQXE.?OTN09[*-=3^\/SH
M.NI_>'YUY$GB0D??IK^)&_OU:HW ]?\ [=3U'YTUM?C'<?G7D8\1DC[_ .M5
MI_$K!OOT_8@>T)KD;$?,/SK2M[Q9NA!KQ"R\1LY7+5Z'X;U!I]O/!J)T[ =O
M12#[HI:P **** "F/($ZTI<#O61J5ZL8/.*J,;L"S+J*1]ZHRZXB9^8?G7(Z
MEK13.&X^M<EJ'B)EW8;]:V]D!Z=+XCC[,/SK/G\1Q\_,/SKR&?Q,^?O_ *U2
MD\2N3_K#^=:1@!ZQ/KZMGYZJG75!^]7EG_"0.Q^_2/KK8^]6\8B9ZS'KRY^^
M/SJ]#X@08^<?G7C":^XYW5+_ ,)&R_QT2B-'N<'B-./F'YUHPZ\C8^85X'!X
MF?\ YZ'\ZW[#Q&Q(R^:QE2 ]Q@U!)>XJ\K!A7G.B:QYFW+?K7<6=TKJ.0>*P
MG3L%R_12 Y&:6L0"BBB@"*698QSQ6?-JR1\9%5]9NO*0\UYYJVO&(L-U:1A<
M#T'^WDSU'YT?V['_ 'A^=>.'Q*=Q^>I8_$C?WZW5"X'L']NIC[PIPUM#_$*\
MB_X2)L??J5/$3'^+]:KV 'JS:Y&!U'YU&NOQD_>'YUY-=^(V4<.:J6_B5F?[
M_>I= #W2WU-9SP15]6!%>8^'M8,S+EJ] @N08P=W:LI4[#6I;EF$8-95QK*1
M9!(_.JVKZ@(P?F'3UKS77O$!B9@&_6G&G=".]G\2Q\C=6=<>(%/1Q^=>/2^*
M7,S#>>M(?$3%?OUT1IV07/4GU]=WWQ3X?$2*?OBO(G\0-UW5"/$3 \.:' FY
M[S:^(T;^,?G6U::NDI'S _C7SY8>)7WCY_UKN=$UTN5R_P"M0Z87/8H9Q(,Y
MJ:N:TG4!(J_,*Z-#N0&N64;,H=1114@%%%% !1110 4444 %%%% !61K,WEV
MS&M8\"N>\1[OLC8]*J('E^N:QY=PPW=ZQ/\ A(<-]^L_Q+YWVEL ]:Y5S<[^
MC5NF(]$C\0#^^/SJP/$''W_UKSF,W/H:M*]SCH:NX6.X.O#=][]:=_;_ /M?
MK7#[KCT- :X]#1<#MSKH_O?K2?V\/[WZUQG^D>AIA-QGH:+H#MO[>'][]:7^
MWA_>_6N(S<>AI-UQZ&I;&=M_;H_O?K2_V\/[WZUQ?^D>AIA-SGH:28,[<:\/
M[WZT_P#X2 ?W_P!:X;=<8Z&C=<?W30V([<Z\,_>_6C^WA_>_6N)S<8Z&FEKC
M'0T7&=O_ &\/[WZT]?$ Q][]:X;-QCH:-UQ_=-#8CN#KHZ[OUI/[>'][]:XK
M-QCH::6N/0TTQG9-KO/WJ<-? _BKBB;C^Z:A+W.[H:JX'?IKNX_>_6K2:Z /
MO5P,!N#C@U8W3XZ&M$Q(Z^\U\&%EW5YSKLQN9VYJ[,]PW&#53[#--)DH:TT!
MF9#:DKT-1S6I!Z5U5MI3[/N<_2FSZ2W]P_E36@T<D+<YZ59CM"5Z5M+I+[_N
M&M&#2'V?<_2FJMB&<D]H0>E1_9CZ5ULVD-G[A_*H/[)?'W#3]N,Y<VY]*3[.
M:Z1])?/W#^5*-(?^X?RH]LP.:^SMZ5'Y)+@8-=2=(;;]P_E4"Z4_G ;#UXXJ
M75*L&C:,T\J-M/6O9/">D&$)E?TK"\*:+N5"R?I7J^D:<L*# Z>U8U*KL(TK
M"+RXAQ5RD50HP*6N%N[&%%%%( HHHH ****  \"LV]OA"I^;I5N>=(XV)/:N
M%U[50D;8;H:UIQNP+EWX@"9&^N-UGQ(#GY_UKG]3UI\G#5Q.J:O(Q;D_G7;3
MIV Z&_U;SF.&_6L*:Z)S@UDQ7COU-2ER:ZN70+$KLS\YJI*2N:N18V\U!<!3
M2Y4)E%MS>M.CC85-$GK5D1KBIY013*-Z4 ,M7=@J-HZ.74!8G((J]#<LA'-4
ME&.U#OMIN '<:-K7D%26_6O0])\1AMHW_K7@(OWB/!KI=$UM]RY;]:Y:L4(^
MD=,U#[2.N:UJ\Z\)ZGYFS+5Z%&X91@C\*XI1L4/HHIDAXJ$ X'-+4:-QS2O(
MJ#)-.P$%U<"%<YKF]0\0"'/SXI^N:DB*WS=J\H\1ZVRE@K?K713I7 Z34O$Z
MON&^N.U'6?,9L-7(SZS*['+?K55[YW/7-=D(6 T;V]+'[V:RGD9CU--9RQYI
M4&3R*OE C*L333N7K5Y%7UJ&X4 '%)K4"MN)-&#2I]ZK 3(K:$= *$NX4MN6
M#9Z59DBIJQX-6XZ 7[:Y,?4UT-AJNP#YNE<BS%*1;MDZ5A*!+/8-*\0A=OS_
M )FNZT?7!/M&X5\ZVFJR*PY_6N^\+:RS2*":Y9Q&CWN"821@U/7/Z1?+)"@W
M=16^IR :XYQLQBT445 &#XBE\N _2O'O$&IX=\-7JGB]RELQ]J^?_$-XWGN!
MZUV4%<"A<Z@6E89IL-TP.<UA><S39/2K8<@<9KMC!"-B:_.W&?UJ&VO29.36
M1),W2EMW(:M.09OW5X?+ZUC_ &L^:<&G7$A,59F3NR!64H =_P"%[HM,N37K
M5E?^3;*V['%>'^&IBDZYXYKT*XU,1V0VMCBLI0!&YK/B$&-AOKS76-7\UV&Z
MJNJZR[LP#?K7,3W;O(<G/-$*>HF333%Y&YZ^E0,233%.XYJ<+D5TJ ,JNK-4
M/D/GI6DL8J41*:U4+(1GP!XSGI70:5J9A89;I63/'M4XYXK/\]XVXK&<!GM_
MAO7-[*N_OZUZ;9WP\A6)[5\W>%-2?[2F6[U[':ZJHLERW.*Y)P&;VL:P(XCA
MNU><ZOKXD=EW_K3_ !%K6(V ;]:\RN]5>2Y8;L\TZ<+ :6K7IDW<]:Y&=F:4
MUJRRETY[UGLF6SBNE1 @16/&*G\EPN<5/;Q9/3-7I(AY72JY1F7&6W5=CD9.
M:K!/WF*FD&U 14. KFYHFIF*Y7+=Z]I\,:^'B5-_IWKYPAN6CG_&O0?"6KL9
MT7<>M<E:('T;:2^=$&S5BL?0)O,LE/J*V*XGN C?=-<KX@?RX'-=1(<(37%^
M*YL6DG/8UK15V)L\D\1ZKMG8;JY)[\M+UIOB>\?[<P![UA1S.37="%@.G2](
M3DTG]HG/+&LA9&V?A4/FMOKIC$#H&O25ZU0>Z;=UJ!9"5JO*QSQ1*(&U97Q$
MHYKMM)U,H%.[\Z\RMG82 \UT-K>LD?7&/6L)1N&QZ;_PD(6#&_'UKF=9UKS5
M8!JY:?5W"XSUK+N-1>0G)K/D&-U"8R3DU77.*3)=LFK"IQ6T(IDE>0MMP*H2
MJ^[-:C)GI4;0@]:TY!W*$ 99 :Z;2KLQLI)QBL3RL'I4RR&,<5,H T>JZ'KX
M0J-_ZUZ1HVM"15^;.:^;[+4I$F7!KTWPOJC.4&?2N:K3N@2/;K>3S8@U2UFZ
M/+YEJ/I6E7GR5F,9)Q&U<AK]QLC8YKK9SB%J\\\4S[8I.:UHQNQ-GFOB+5-L
MS -BN1FO&=\YI_B2Z;[6P]ZQTD)Y]:]"G$:1L17A'>K0O#MZU@"0AJG$IVUO
M8#0>\.[K0+IL=:R7D);O4N\B,U$E83+WV\[L9_6M?293).G7K7%/.?,X/>NO
M\- O,G?FN:9)[YX-S]G3Z5V!^Z:Y+P@NVW6NL?[A^E<,]RT86KW8CA<9[5XA
MXOU ^<W/>O5?$MSLCD^E>#^*[DM.W-=,(A8H"\8GK4Z7; =:PX)":M;SBNJG
M$3-%KPYZTJWA]:R'D-.1SCO6THZ"-8WAQUJLUX?-Z]ZILY(-4WE/F <]:Y9Q
M'8[[0KO+I7L7ACYT7BO"_#I8S)]:]X\()F)<]:Y)JP([*)=J4^CI378*I)-8
M[C*UU<B)"<]*Y75-=6(,-]6]9OQ&C_-7D_B/62I;#'\ZZJ=,#4U;Q*I#?/\
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MV)YJW:R;^N:MQ ;< BJ3;L]ZU+H#;^%9^!DU:@ Q"?>I/F/K2@"I$Q6BB(B
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M:C9YG%H&U<>50^@;O^6==]<0PQ-T IB_9N^*OG=@. _X1WG_ %0JW%H(5?\
M5UVV+;T%/S;A>M1=B.!FT'GB.F#P_P ?ZK]*[IS;[NHI4-MGM3U X)O#O/\
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M,A.8E/M3Z\Q[C"BBB@ HHHH **** "BBB@ HHHH **CDE"+U%49=35#C(IV
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MBPF>:E'/6H\4X' ZUU="NA((QGI4LBCR\#TJ$2=J>9,KUK&I)6)L5+:W\R[
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M^4]:]&C\.A<?**LP^'PL@.T=:S=0KH/\+:8J1H2*[J",(N!6=I=E]GC' K6
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MQ$M"HFF.!1117 ,**** "BBB@ HHHH **** "BBB@!",C!J%[=&.2H-3T47
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M@'M7G_CNX'V=\'M7>2MLMZ\M\>7/[E^:X:2UN!XS?2[[M^>]0A>*BE??>O\
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M5F<H?I7E>CKNU!1ZFO=O"-GF*-L>E<%;1,;/1-)7;:J/:G:FVVU;Z5-:)LA
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MIJ[1W!&XUK&('H U[/>G?V[[UY<-=?/WC3AKKX^\:KV8'IO]O>]+_;IKR_\
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M]*]"\.Z<(U4[>E<<MPL=/I$7E1CM6M5>W38!@58KEEN 4445(!1110 4444
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MXUNJ=D*QU!UG'&\U)!J7F,,-7"27D@/>MK1GDFD7O6,E8:/=/!+EBO->G_\
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MC-]]38CK5&><R]ZK-D4Y!FLW -!T<?/-6 F *8HQ2F3%:0=@L6(H]U).NT5
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M'9C%L@]JGJ. 8A4>U25YCW ****0!1110 4444 %%%% !1110 4444 %%%%
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MI6%2I="L7+&Q2&-< =*T>@I%&% I:XF[EA7.>)I-L!^E='7(^+9,0-CTIQW
M\3\6W!9Y![UYTA)N6R.]=QXC<O+(/4UQZ0XG)QWKKC(DLDX0?2FQ,2U2E/DQ
MBF)'AJZ(3#0E<G957/-7BF5Z56DC(.:Z%/0"E<N<5M^$T\VZ7([UCO%O.#74
M^$+7%PI [UR5W<#V_P +VH6*,X[5WL0Q&OTKDO#L>V"/CM77)]T5PU'=E(Y'
MQK*8[1B/2OG;7+UGNY!GO7T!X[8_9)/I7SGJBEKUQCO75AW9$O<R)V)8FFPN
M=V?>KK6V1TIL=L5;I76I#9,"2M1/D5=BA)'2EFMCMSBFYDLSTD.:;<LS)BI1
M$=_2GM;EEZ5FY#2-'P;$3?KD=Z^D?#<(6T3CM7@O@RS(O%..]?16A1;;-..U
M<]6>@(V0<1UQ?C2;%H_TKLI2$CQ7GGC:8_9G'M7-3W&>$:U<$WDF/6LM9,FK
M6K9-XXQWJK&OM7ITI")'8[:KHY,E6F3*]*C2'Y^E;.6@,F)^2J<[&M#R_EX%
M5I8>.E8N0(HQY+UW'A&+=+TS7)009?H:[[PA!B7IBLI/09[CX7M@+%3CH!71
M@8&!6/X<&+!?I6P3@9KSYMMC,/Q/)MTY_H:^:O%$^=2<=.:^A?%EQML)![&O
MFSQ&^_4FY_BKMPT;$LKQC<,U+MIEO]RI6Z5Z$$! >M.IA^]3NU=4=@&L:A+'
MTJ1C3(T#/BLJ@#XT+'I5AK5BA)!K0TZQ\UQD5T3:,3;%MM<TF"9YS,I5J:C<
M\UL:G9&*1@!^E8S@HW2L.8"_%@U<7;CM6(+@J:E%[BJ4@3-.7"C-9<\A!XJ0
M76_BG>3Y@R!6L)B,W>Q;'-7+.)Y'7BIX; O*!BNKT?0O,9?E_2M7/0+C]!TQ
MI)5)'>O8O#FF!(D)6L30?#VS:=GZ5Z'IMEY,:\5Y]:H-(T+6/RX\8Q4O>E48
M&*,5Y[=V-HCG&8B*\_\ $UGNC<XKT1AE2*YW6[,26[\=JTINS!GS;XDMBEPQ
M [UR<CNA(Z5ZMXHTK]Z_R]_2O.M0L3&[<5Z,&*Q0AE+,.:UX#E*QU38WI6E"
M^V.NA2"VI:.!46_!JM)<]J8)<FJ<AV+S$%36<5=IL <5:B?>V,5L:?I1N)%)
M6L)NX#--LWD(&*Z!--_=Y([5N:5H73Y*VGTC9 ?E[5ES"M<\GU2#RW/%8,CD
M&NT\26I1VXKD98#GO24K,$0)(<U;C)Q5=8L'I5V*/CI71&86&DFH))"O2K$B
MX-,\DL.!4U)V0-&8S%I:Z308BT\?'>L8VQ\Y>*['PY9$R1\=#7-*IH)'M'@F
M'$">PKO ,#%<EX1B\N%:ZZN*;NRPJ&XB$D3#VJ:D/(Q4IV8'G/B72A()/EKQ
M[Q!I+([%4_2OH[4K'SU8%>M<'K'AKSMQV9_"NVG5L!X,UI(@Y6J<@D5NAKT_
M4O#?E@_)^E<S=:*5?[M=].I?4EHYF/S#ZU+M?'0UN1:2?[M3?V4<=*IS Y61
M7':H/+D)Z?I75/I7/W:M6N@>81\O7VK&4Q]#E[6TE:51M->B:!I!>(%D[>E6
MM,\*;G7Y/TKO=+T#[-;_ '>@K-5$GJ2>=ZM8+ &X%<7?C:Y]J])\6QB'=@"O
M,[UMS&NZGKJ*Q#$<U-FJ\0J<5O%#"C)QTIP6F/Q4S @D^9JW=&@W2+QWK ;[
M_P"-=CX;@+NO'>N*J%CV'P5#MC2N^(R*X_PK#Y<:\5V->15^(I" 8&*1UW#%
M.HK,9P'BVP\Q6PM>.:SIC1NQ"D?A7T3J]EYZGC-><ZUH);=\E=5.8CPR[A9"
M2?6F6ZD]:[+5]$,9;Y:YJ2W,)/%=E.0#U 4"AGXJI)/BD24M6[8#+ECWJM'U
M-3W"FJR9!.:PDQ7-:V4$#-+= *O:JT4VT5'=7&16=P0(V6JP,D50A?<:TX%W
M#Z5I%ZCN5)=R] <U3?S">AK>^QE^U7;31#*?NUM<1DZ79R2,,J>M>B:#I!.S
M*_I4NB>&B2/D_2O0=+T'R@ORBN:I4MH.Q:T/3%C"<5V4,011Q5*QLQ$!QC%:
M7:N&I*[&%<#XXEV1M@UWU><>/3^[<U,-P/"M>G+S-]:YZ _.2.U;&J\S-]:S
MH(OGKTX/0AEE3E136)'M4WEX'2FM&:W3!%<DTJ'VIYC-/2//:FY:%%2Z)XKK
M/!2;YUX[US%U$?QKN/ %OOG7/K7/-Z">Y[?H$&V*/Z5U0Z"LK2;;;;H2.U:I
MX%>;4=V4CBO&4FV)OI7@'B.4O*_UKW;QJY\IZ\%UM=\K\=36M/03.:A'[PUH
M](ZKPQ;7)Q5ME_=XKLC(17#Y-2C.,U&%^;I4P0XK?FT&-)R*@E3-6=II#&3V
MJ92&:_A*'=>+D=Z^A/#=N!;1G'85X=X1M\72''>O?= 0"U3Z"N6I*Z"YT:<(
M*=2+]T4M>>P"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 1QE2*P
M]2M0Z'CK6[5:XAW@\=:J+L-'FNI:5O<D+6%+HYW?=_2O3[C3BQ/RCGVJBVCD
MG.W]*M2!GGO]CG'W?TI!HYS]W]*]"_L8_P!W]*/[&.>GZ4<P,X1=(./N4O\
M9!_N5WPTDC^$?E1_91_NC\J.8DX Z.?[E,_LAL_<_2O0CI)(^Z/RIO\ 8Y/.
M/TI\PT<"-&/]VG?V0?[GZ5WO]DG^Z/RI?[).?N_I2YA' '1S_=_2F?V.<_<_
M2O0O[)/I3?['.>GZ4U(9P(T<_P!VG?V0?[GZ5WO]DG^Z/RI?[).?N_I2YA'
M'2#_ '?TJ,Z.<_=/Y5Z$=()[?I33HYS]W]*.89P0T@D?=_2FG2#_ '?TKT$:
M0?[OZ4AT@_W?THYAHX$:0<?=_2FG1SG[M>@#1S_=_2@Z0>FW]*.8#@%T@_W/
MTH.CG/W:] &D,!]W]*/['.>@_*FI".!&CG'W*8VDMG&VO0O[)(&-H_*F'1R3
MT_2JYP.%CT8D\I5I=%&/N#\J[1-)(/0?E4PTL@?='Y4N<#@FT0;_ +@_*M"Q
MTPHZ\=_2NL.F'.=OZ5+%II#=/TI.5QEO1X3'&.,5K57MHPB =Q5BL6(****
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MQ"Q]J!G.:MJ8@8_-C\:Y]]?0-]\5C>,]6-O(V&KSV?Q"P;[]=$($V/9X/$:
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M#/W:F_LI?2NH6Q4?PTOV,>E)3!(P[/3%'!7K6G]A0=JO);A:E*"DZ@T5(;1
M?NBK0C4#&!3@,4M0Y-C$  Z4CC(IU%2!&G6I***; *C>,/UJ2BD!5^QI_=%.
M^R1CL*L44^9@5_LR?W11]DC_ +HJQ11S,"O]DC_NBE%K&.PJ>BCF8$/V>/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!KMM4FN/\6W(^
MQN,]JZNZ?9"37F_BR] A<9]>]:TXW8'A_B+G47.>]48GXJSKLH:\8Y[UGQN.
M.:[(,FY='K2@]J9N 6H_,&:ZX,99/2H)#CO4GF K5.:09K>+ EB.YZ[#PO!N
MNT/O7$VC;YP,UZ5X3@S+&<>E<V(>@(]O\-IML%^E;=96A+MLE'M6K7CRW&%%
M%%2 4444 %%%% !1110 4444 %%%% !1110 4TKS3J* "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@"CJK;+1C[5XMXMO6W2+D]Z]IU1"]HP'I7D
M7B71VEE<XK6F[ >+:H[/<$\]:JQ%SV-=E=^'':8_)WHC\,.!PIKIC(E[G,'=
MMJ %M^.:[%O#K ?<J)?#;;_NFNB#&CG1NV=#5*8MSUKNQX:?9]PU2F\-/_<K
M92 Y;3 QNE&.]>R>$;4_NR1Z5Q6F^&V2Y4[#7K/AG3#"J?+6%>6@'H.DIMM%
MJ_5:R39 !5FO+EN,****0!1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !0>E-SBG4 9&IV*SHWR
MUYOXAT($L0GZ5ZZX#*0:YS5K 2!N*Z*52S ^>=7TKRI&PO2L!XC&<8KV+6=
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MT(>B[5IU%%<H!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 -V"EP*6B@!"HI-HIU%%P$P/2DV"G447 :$ IU%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !24M%)@-I:*6HBG<84445H(**** "D*ANM+10!&
M85/:F&V4U/13NP*QM$)IOV&/TJW11=@5/L$>>@H^PQ^@JW11=@5?L,?I3UM4
M7M4]%%P&")13@,"EHI %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1136;'% #J*13D4M !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5#(>:**J.X#X^E/HHI/< HHHI %%%% !1110 4AZ444 (#3J**& 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
A110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
